



Uganda
Country Operational Plan
FY 2015



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source	Applied Pipeline
	GAP	GHP-State	GHP-USAID	Total	
DOD		12,488,721		12,488,721	900,000
HHS/CDC	3,212,500	171,743,580		174,956,080	6,978,709
PC		1,615,140		1,615,140	274,780
State		412,570		412,570	272,623
State/AF		542,400		542,400	157,600
State/PRM		324,721		324,721	0
USAID		147,242,189		147,242,189	7,222,839
Total	3,212,500	334,369,321	0	337,581,821	15,806,551

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency							On Hold Amount	Total
	State	DOD	HHS/CDC	PC	State/AF	State/PRM	USAID		
CIRC		838,318	9,594,258				7,432,487	0	17,865,063
HBHC	12,814	2,072,242	28,364,706	0	8,614	75,025	19,667,211	0	50,200,612
HKID	76,881	900,485	3,500,033	284,972	25,173	46,972	20,088,050	0	24,922,566
HLAB		106,951	6,549,547		500,000		851,762	0	8,008,260
HMBL			935,228					0	935,228
HMIN		80,000	163,705				1,003,275	0	1,246,980
HTXD		6,951	38,153,007				25,741,007	0	63,900,965
HTXS	12,814	2,451,788	32,497,653		8,613	102,799	25,978,790	0	61,052,457
HVAB		83,063	94,128			0	967,945	0	1,145,136
HVCT		465,061	8,769,668			18,782	4,346,349	0	13,599,860
HVMS	310,061	424,290	10,154,961	358,574			6,563,413	0	17,811,299
HVOP		796,921	4,027,899	971,594		0	4,193,974	0	9,990,388
HVSI		2,029,941	7,225,272				5,881,369	0	15,136,582
HVTB		1,021,041	3,257,568			14,615	3,460,624	0	7,753,848



IDUP			0					0	0
MTCT		380,325	8,951,261			33,332	5,495,749	0	14,860,667
OHSS			4,167,021				8,253,182	0	12,420,203
PDCS		586,690	6,536,663			26,361	5,222,904	0	12,372,618
PDTX		244,654	2,013,502			6,835	2,094,098	0	4,359,089
	412,570	12,488,721	174,956,080	1,615,140	542,400	324,721	147,242,189	0	337,581,821



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	49,712,706	0
HKID	24,157,299	0
HVTB	7,513,179	0
PDCS	12,289,662	0
Total Technical Area Planned Funding:	93,672,846	0

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	7,457,077	0
HVSI	13,520,430	0
OHSS	11,048,876	0
Total Technical Area Planned Funding:	32,026,383	0

Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
CIRC	17,520,817	0
HMBL	927,809	0
HMIN	1,243,275	0
HVAB	1,000,000	0
HVCT	13,304,917	0
HVOP	8,968,089	0
IDUP	0	0
MTCT	14,334,772	0



Total Technical Area Planned Funding:	57,299,679	0
--	-------------------	----------

Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
HTXD	63,499,714	0
HTXS	60,478,681	0
PDTX	4,141,201	0
Total Technical Area Planned Funding:	128,119,596	0

Technical Area Summary Indicators and Targets

Indicator Number	Label	2015	2016
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	95 %	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,167,834	734,388
	Number of new ANC and L&D clients	1,229,299	795,852
	By: Known positives at entry	31,064	45,366
	By: Number of new positives identified	50,684	9,132
	Sum of Positives Status disaggregates	81,748	54,498
	Required only for DREAMS Countries - By Number of new positives: <15		
	Required only for DREAMS Countries - By Number of new positives: 15-19		
	Required only for DREAMS Countries - By Number of new positives: 20-24		
	Required only for DREAMS Countries - By Number of new positives: 25+		

	Required only for DREAMS Countries - By Number of known positives: <15		
	Required only for DREAMS Countries - By Number of known positives: 15-19		
	Required only for DREAMS Countries - By Number of known positives: 20-24		
	Required only for DREAMS Countries - By Number of known positives: 25+		
	Required only for DREAMS Countries - Denominator: <15		
	Required only for DREAMS Countries - Denominator: <15-19		
	Required only for DREAMS Countries - Denominator: 20-24		
	Required only for DREAMS Countries - Denominator: 25+		
PMTCT_STAT_TA	PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (TA)	95 %	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	518,940	797,486

	Number of new ANC and L&D clients	546,253	854,949
	By: Known positives at entry	13,803	48,615
	By: Number of new positives identified	22,522	7,824
	Sum of Positives Status disaggregates	36,325	56,439
	Required only for DREAMS countries - By known positives: <15		
	Required only for DREAMS countries - By known positives: 15-19		
	Required only for DREAMS countries - By known positives: 20-24		
	Required only for DREAMS countries - By known positives: 25+		
	Required only for DREAMS countries - By new positives: <15		
	Required only for DREAMS countries - By new positives: 15-19		
	Required only for DREAMS countries - By new positives: 20-24		
	Required only for DREAMS countries - By new positives: 25+		
	Required only for DREAMS countries - Denominator: <15		
	Required only for DREAMS countries - Denominator:		

	15-19		
	Required only for DREAMS countries - Denominator: 20-24		
	Required only for DREAMS countries - Denominator: 25+		
PMTCT_ARV_DSD	PMTCT_ARV_DSD Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (DSD)	90 %	
	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	78,831	54,498
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	87,591	54,498
	Life-long ART (including Option B+)	78,831	
	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	52,817	9,124
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	26,014	45,374

	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	
	Single-dose nevirapine (with or without tail)	0	
	Sum of Regimen Type disaggregates	78,831	
	Sum of New and Current disaggregates	78,831	54,498
PMTCT_ARV_TA	PMTCT_ARV_TA Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (TA)	90 %	
	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	27,435	56,439
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	30,484	56,439

	Life-long ART (including Option B+)	27,435	
	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	18,381	7,913
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	9,054	48,526
	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	
	Single-dose nevirapine (with or without tail)	0	
	Sum of Regimen Type disaggregates	27,435	
	Sum of New and Current disaggregates	27,435	56,439
PMTCT_FO_DSD	PMTCT_FO_DSD Final outcomes among HIV exposed infants registered in the birth cohort	n/a	
	Number of HIV-exposed infants with a documented outcome by 18 months of age disaggregated by outcome type.		43,887
	Number of HIV-exposed infants registered in the birth		43,903

	cohort at any time between 0 and 18 months of age (including transfer-ins)		
	HIV-infected: Linked to ART		1,990
	HIV-infected: Not linked to ART		239
	HIV-infected: Unknown link		
	HIV-uninfected: Not breastfeeding		11,091
	HIV-uninfected: Still breastfeeding		887
	HIV-uninfected: Breastfeeding status unknown		5,322
	Other: In care but no test done		934
	Other: Lost to follow-up		22,492
	Other: Died		932
	Other: Transferred out		
PMTCT_FO_TA	PMTCT_FO_TA Final outcomes among HIV exposed infants registered in the birth cohort	n/a	
	Number of HIV-exposed infants with a documented outcome by 18 months of age disaggregated by outcome type.		44,856
	Number of HIV-exposed infants registered in the birth cohort at any time between 0 and 18 months of age (including transfer-ins)		45,001
	HIV-infected: Linked to ART		2,006

	HIV-infected: Not linked to ART		203
	HIV-infected: Unknown link		
	HIV-uninfected: Breastfeeding status unknown		5,415
	HIV-uninfected: Not breastfeeding		11,188
	HIV-uninfected: Still breastfeeding		915
	Other: Died		1,005
	Other: In care but no test done		965
	Other: Lost to follow-up		23,159
	Other: Transferred out		
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	812	3,486
	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	22	
	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	22	
	Sub-Disag: Surgical intra-operative AE(s) by	1	

	maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)		
	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	730	
	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	664	
	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	66	
	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	172	
	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)	172	
	Sub-Disag: By Medical device-based AE(s) by	1	

	maximum severity category: Number of clients with one or more severe medical device-related AE(s)		
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	245,772	234,707
	By Age: <1	0	
	By Age: 1-9	0	
	By Age: 10-14	44,239	
	By Age: 15-19	48,565	
	By Age: 20-24	40,700	
	By Age: 25-29		
	By Age: 30-49		
	By Age: 50+	4,915	
	Sum of age disaggregates	245,772	
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	5,751	6,722
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	185,951	189,375
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	54,070	42,486
	By circumcision technique: Surgical VMMC	221,195	223,259
By circumcision technique:	24,577	6,457	

	Device-based VMMC		
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	221,195	225,959
	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	6
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	
	By Age: <1	0	
	By Age: 1-9	0	
	By Age: 10-14	0	
	By Age: 15-19	0	
	By Age: 20-24	0	
	By Age: 25-29		
	By Age: 30-49		
	By Age: 50+	0	
	Sum of Age disaggregations	0	
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	0	
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	0	

	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	
	By circumcision technique: Surgical VMMC	0	
	By circumcision technique: Device-based VMMC	0	
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	0	
	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	
PrEP_NEW_DSD	PrEP_NEW_DSD Number of adult women and adolescent girls newly enrolled on oral or topical PrEP	n/a	
	Number of adult women and adolescent giRls newly enrolled on oral or topical PrEP		
	Estimated number of adolescent girls and young women (ages 15-24) in a district who are HIV uninfected and at elevated risk of HIV infection, as evidence by program or other data		

	Numerator: Female 15-19		60
	Numerator: Female 20-24		340
	Denominator: Female 15-19		569
	Denominator: Female 20-24		2,277
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a	
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	2,744,542	361,655
	Total number of people in the target population		1,834,923
	Age/sex: 10-14 Male	142,469	95,714
	Age/sex: 15-19 Male	279,875	30,347
	Age/sex: 20-24 Male	156,475	22,681
	Age/sex: 25-49 Male	394,356	35,034
	Age/sex: 50+ Male	8,579	3,344
	Age/sex: 10-14 Female	150,883	100,081
	Age/sex: 15-19 Female	517,503	25,448
	Age/sex: 20-24 Female	302,611	20,399
	Age/sex: 25-49 Female	782,667	26,599
	Age/sex: 50+ Female	9,124	2,007
	Sum of Age/Sex disaggregates	2,744,542	361,654
PP_PREV_TA	PP_PREV_TA Percentage of the target population who completed a standardized	n/a	

	HIV prevention intervention including the minimum components during the reporting period (TA-only)		
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.		2,253,998
	Total number of people in the target population	0	5,679,955
	Age/sex: 10-14 Male		94,161
	Age/sex: 15-19 Male		207,582
	Age/sex: 20-24 Male		237,774
	Age/sex: 25-49 Male		396,850
	Age/sex: 50+ Male		32,183
	Age/sex: 10-14 Female		123,289
	Age/sex: 15-19 Female		244,412
	Age/sex: 20-24 Female		362,166
	Age/sex: 25-49 Female		521,427
	Age/sex: 50+ Female		34,154
	Sum of Age/Sex disaggregates		2,253,998
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a	
	Number of key populations reached with individual	20,861	68,689

	and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required		
	Total estimated number of key population in the catchment area		62,170
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	12,217	55,855
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	626
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum	0	7,830

	standards required)		
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	8,644	4,395
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)		57,455
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Females who inject drugs (Female PWID)		

	(Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,823,785	3,322,252
	By Test Result: Negative	1,769,071	3,087,031
	By Test Result: Positive	54,714	235,221
	Sum of Test Result disaggregates	1,823,785	3,322,252
	Test Result by Age and Sex: Positive: <1 Male		
	Test Result by Age and Sex: Positive: 1-4 Male		
	Test Result by Age and Sex: Positive: 5-9 Male		
	Test Result by Age and Sex: Positive: 10-14 Male		



	Test Result by Age and Sex: Positive: 15-19 Male		
	Test Result by Age and Sex: Positive: 20-24 Male		
	Test Result by Age and Sex: Positive: 25-49 Male		
	Test Result by Age and Sex: Positive: 50+ Male		
	Test Result by Age and Sex: Positive: <1 Female		
	Test Result by Age and Sex: Positive: 1-4 Female		
	Test Result by Age and Sex: Positive: 5-9 Female		
	Test Result by Age and Sex: Positive: 10-14 Female		
	Test Result by Age and Sex: Positive: 15-19 Female		
	Test Result by Age and Sex: Positive: 20-24 Female		
	Test Result by Age and Sex: Positive: 25-49 Female		
	Test Result by Age and Sex: Positive: 50+ Female		
	Test Result by Age and Sex: Negative: <1 Male		
	Test Result by Age and Sex: Negative: 1-4 Male		
	Test Result by Age and Sex: Negative: 5-9 Male		
	Test Result by Age and Sex: Negative: 10-14 Male		
	Test Result by Age and Sex: Negative: 15-19 Male		

	Test Result by Age and Sex: Negative: 20-24 Male		
	Test Result by Age and Sex: Negative: 25-49 Male		
	Test Result by Age and Sex: Negative: 50+ Male		
	Test Result by Age and Sex: Negative: <1 Female		
	Test Result by Age and Sex: Negative: 1-4 Female		
	Test Result by Age and Sex: Negative: 5-9 Female		
	Test Result by Age and Sex: Negative: 10-14 Female		
	Test Result by Age and Sex: Negative: 15-19 Female		
	Test Result by Age and Sex: Negative: 20-24 Female		
	Test Result by Age and Sex: Negative: 25-49 Female		
	Test Result by Age and Sex: Negative: 50+ Female		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	42,646	165,355
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	194,274	1,227,206
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	219,215
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,586,865	1,710,476

	Sum of Aggregated Age/Sex <15	42,646	384,570
	Sum of Aggregated Age/Sex 15+	1,781,139	2,937,682
	Sum of Aggregated Age/Sex disaggregates	1,823,785	3,322,252
	Service Delivery Point by Result: Antenatal Clinic - All results		
	Service Delivery Point by Result: Antenatal Clinic - Positive		
	Service Delivery Point by Result: Antenatal Clinic - Negative		
	Service Delivery Point by Result: Labor & delivery - All results		
	Service Delivery Point by Result: Labor & delivery - Positive		
	Service Delivery Point by Result: Labor & delivery - Negative		
	Service Delivery Point by Result: Under 5 Clinic – All results		
	Service Delivery Point by Result: Under 5 Clinic - Positive		
	Service Delivery Point by Result: Under 5 Clinic - Negative		
	Service Delivery Point by Result: Maternal and Child		

	Health Clinic – All Results		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Positive		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Negative		
	Service Delivery Point by Result: Tuberculosis – All results		
	Service Delivery Point by Result: Tuberculosis - Positive		
	Service Delivery Point by Result: Tuberculosis - Negative		
	Service Delivery Point by Result: Sexually Transmitted Infections – All Results		
	Service Delivery Point by Result: Sexually Transmitted Infections - Positive		
	Service Delivery Point by Result: Sexually Transmitted Infections - Negative		
	Service Delivery Point by Result: Outpatient Department – All Results		
	Service Delivery Point by Result: Outpatient Department - Positive		
	Service Delivery Point by Result: Outpatient Department - Negative		
	Service Delivery Point by		

	Result: Inpatient – All Results		
	Service Delivery Point by Result: Inpatient - Positive		
	Service Delivery Point by Result: Inpatient - Negative		
	Service Delivery Point by Result: HIV care and treatment clinic – All Results		
	Service Delivery Point by Result: HIV care and treatment clinic - Positive		
	Service Delivery Point by Result: HIV care and treatment clinic - Negative		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision – All Results		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Positive		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Negative		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Positive		
	Service Delivery Point by Result: Voluntary Counseling		

	& Testing (co-located) - Negative		
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – Positive		
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – Negative		
	Service Delivery Point by Result: Mobile – All Results		
	Service Delivery Point by Result: Mobile - Positive		
	Service Delivery Point by Result: Mobile - Negative		
	Service Delivery Point by Result: Home-based – All Results		
	Service Delivery Point by Result: Home-based - Positive		
	Service Delivery Point by Result: Home-based - Negative		
	Service Delivery Point by Result: Other – All Results		
	Service Delivery Point by Result: Other - Positive		
	Service Delivery Point by Result: Other - Negative		

HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,367,320	2,631,297
	By Test Result: Negative	1,257,914	2,487,059
	By Test Result: Positive	109,406	144,238
	Sum of Test Result disaggregates	1,367,320	2,631,297
	Test Result by Age and Sex: Positive: <1 Male		
	Test Result by Age and Sex: Positive: 1-4 Male		
	Test Result by Age and Sex: Positive: 5-9 Male		
	Test Result by Age and Sex: Positive: 10-14 Male		
	Test Result by Age and Sex: Positive: 15-19 Male		
	Test Result by Age and Sex: Positive: 20-24 Male		
	Test Result by Age and Sex: Positive: 25-49 Male		
	Test Result by Age and Sex: Positive: 50+ Male		
	Test Result by Age and Sex: Positive: <1 Female		
	Test Result by Age and Sex: Positive: 1-4 Female		
	Test Result by Age and Sex: Positive: 5-9 Female		
	Test Result by Age and Sex: Positive: 10-14 Female		
	Test Result by Age and Sex:		

	Positive: 15-19 Female		
	Test Result by Age and Sex: Positive: 20-24 Female		
	Test Result by Age and Sex: Positive: 25-49 Female		
	Test Result by Age and Sex: Positive: 50+ Female		
	Test Result by Age and Sex: Negative: <1 Male		
	Test Result by Age and Sex: Negative: 1-4 Male		
	Test Result by Age and Sex: Negative: 5-9 Male		
	Test Result by Age and Sex: Negative: 10-14 Male		
	Test Result by Age and Sex: Negative: 15-19 Male		
	Test Result by Age and Sex: Negative: 20-24 Male		
	Test Result by Age and Sex: Negative: 25-49 Male		
	Test Result by Age and Sex: Negative: 50+ Male		
	Test Result by Age and Sex: Negative: <1 Female		
	Test Result by Age and Sex: Negative: 1-4 Female		
	Test Result by Age and Sex: Negative: 5-9 Female		
	Test Result by Age and Sex: Negative: 10-14 Female		
	Test Result by Age and Sex: Negative: 15-19 Female		
	Test Result by Age and Sex:		

	Negative: 20-24 Female		
	Test Result by Age and Sex: Negative: 25-49 Female		
	Test Result by Age and Sex: Negative: 50+ Female		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	225,001	132,060
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	445,197	972,099
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	275,001	175,051
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	422,121	1,352,087
	Sum of Aggregated Age/Sex <15	500,002	307,111
	Sum of Aggregated Age/Sex 15+	867,318	2,324,186
	Sum of Aggregated Age/Sex disaggregates	1,367,320	2,631,297
	Service Delivery Point by Result: Antenatal Clinic - All results		
	Service Delivery Point by Result: Antenatal Clinic - Positive		
	Service Delivery Point by Result: Antenatal Clinic - Negative		
	Service Delivery Point by Result: Labor & delivery - All results		

	Service Delivery Point by Result: Labor & delivery - Positive		
	Service Delivery Point by Result: Labor & delivery - Negative		
	Service Delivery Point by Result: Under 5 Clinic – All results		
	Service Delivery Point by Result: Under 5 Clinic - Positive		
	Service Delivery Point by Result: Under 5 Clinic - Negative		
	Service Delivery Point by Result: Maternal and Child Health Clinic – All Results		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Positive		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Negative		
	Service Delivery Point by Result: Tuberculosis – All results		
	Service Delivery Point by Result: Tuberculosis - Positive		
	Service Delivery Point by Result: Tuberculosis - Negative		
	Service Delivery Point by Result: Sexually Transmitted		

	Infections – All Results		
	Service Delivery Point by Result: Sexually Transmitted Infections - Positive		
	Service Delivery Point by Result: Sexually Transmitted Infections - Negative		
	Service Delivery Point by Result: Outpatient Department – All Results		
	Service Delivery Point by Result: Outpatient Department - Positive		
	Service Delivery Point by Result: Outpatient Department - Negative		
	Service Delivery Point by Result: Inpatient – All Results		
	Service Delivery Point by Result: Inpatient - Positive		
	Service Delivery Point by Result: Inpatient - Negative		
	Service Delivery Point by Result: HIV care and treatment clinic – All Results		
	Service Delivery Point by Result: HIV care and treatment clinic - Positive		
	Service Delivery Point by Result: HIV care and treatment clinic - Negative		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision – All		

	Results		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Positive		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Negative		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Positive		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Negative		
	Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) - All		
	Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) - Positive		
	Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) - Negative		
	Service Delivery Point by Result: Mobile – All Results		
	Service Delivery Point by Result: Mobile - Positive		
	Service Delivery Point by		

	Result: Mobile - Negative		
	Service Delivery Point by Result: Home-based – All Results		
	Service Delivery Point by Result: Home-based - Positive		
	Service Delivery Point by Result: Home-based - Negative		
	Service Delivery Point by Result: Other – All Results		
	Service Delivery Point by Result: Other - Positive		
	Service Delivery Point by Result: Other - Negative		
	Test Result by Aggregated Age and Sex: Negative <15 Male		
	Test Result by Aggregated Age and Sex: Negative 15+ Male		919,227
	Test Result by Aggregated Age and Sex: Negative <15 Female		170,111
	Test Result by Aggregated Age and Sex: Negative 15+ Female		1,269,399
	Test Result by Aggregated Age and Sex: Positive <15 Male		3,684
	Test Result by Aggregated Age and Sex: Positive 15+ Male		52,866
	Test Result by Aggregated		4,915

	Age and Sex: Positive <15 Female		
	Test Result by Aggregated Age and Sex: Positive 15+ Female		82,773
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	n/a	
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.		29,730
	Total number of registered new and relapsed TB cases, during the reporting period.		29,730
	Sex: Male		20,469
	Sex: Female		9,261
	Age: <1		
	Age: 1-4		
	Age: 5-9		
	Age: 10-14		
	Age 15-19		
	Age: 20+		
	Status: Positive		12,797
	Status: Negative		16,933
TB_STAT_TA	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	n/a	
	Number of registered new and relapsed TB cases with		18,944

	documented HIV status, during the reporting period.		
	Total number of registered new and relapsed TB cases, during the reporting period.		18,944
	Age 15-19		
	Age: <1		
	Age: 1-4		
	Age: 10-14		
	Age: 20+		
	Age: 5-9		
	Sex: Female		5,974
	Sex: Male		12,970
	Status: Negative		10,811
	Status: Positive		8,133
GEND_GBV_DSD	Number of people receiving post-GBV care	576,673	87,411
	Age/Sex: <10 Male		2,919
	Age/Sex: 10-14 Male		2,662
	Age/Sex: 15-17 Male		3,606
	Age/Sex: 18-24 Male		5,438
	Age/Sex: 25+ Male		11,694
	Age/Sex: <10 Female		
	Age/Sex: 10-14 Female		5,982
	Age/Sex: 15-17 Female		8,889
	Age/Sex: 18-24 Female		14,253
	Age/Sex: 25+ Female		31,968
	Sum of Age/Sex Disaggregates		87,411
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	0	75,788
	By type of service: Sexual	0	25,126

	Violence (Post-Rape Care)		
	By PEP service provision (related to sexual violence services provided)	0	
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	840,386	35,977
	Age/Sex: <10 Male		729
	Age/Sex: 10-14 Male		1,846
	Age/Sex: 15-19 Male		1,622
	Age/Sex: 20-24 Male		4,981
	Age/Sex: 25+ Male		7,301
	Age/Sex: <10 Female		431
	Age/Sex: 10-14 Female		1,935
	Age/Sex: 15-19 Female		2,078
	Age/Sex: 20-24 Female		5,733
	Age/Sex: 25+ Female		9,321
	By Age: 0-9	0	
	By Age: 10-14	74,078	
	By Age: 15-19	174,289	
	By Age: 20-24	148,469	
	By Age: 25+	443,550	
	Sum of Age disaggregates	840,386	
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	50,117	178,187
	Age/Sex: <1 Male		3,766
	Age/Sex: 1-4 Male		13,852
	Age/Sex: 5-9 Male		24,281
	Age/Sex: 10-14 Male		24,657

	Age/Sex: 15-17 Male		15,870
	Age/Sex: 18-24 Male		5,403
	Age/Sex: 25+ Male		0
	Age/Sex: <1 Female		3,898
	Age/Sex: 1-4 Female		14,463
	Age/Sex: 5-9 Female		25,286
	Age/Sex: 10-14 Female		25,696
	Age/Sex: 15-17 Female		16,441
	Age/Sex: 18+ Female		
	Age/Sex: 18-24 Female		4,574
	Age/Sex: 25+ Female		0
	Sum of Age/Sex disaggregates		178,187
OVC_ACC_TA	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services		982
	Age/Sex: <1 Male		21
	Age/Sex: 1-4 Male		78
	Age/Sex: 5-9 Male		137
	Age/Sex: 10-14 Male		140
	Age/Sex: 15-17 Male		90
	Age/Sex: 18-24 Male		25
	Age/Sex: 25+ Male		0
	Age/Sex: <1 Female		21
	Age/Sex: 1-4 Female		78
	Age/Sex: 5-9 Female		137
	Age/Sex: 10-14 Female		140
	Age/Sex: 15-17 Female		90
	Age/Sex: 18-24 Female		25
	Age/Sex: 25+ Female		0

	Sum of Age/Sex disaggregates		982
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	269,635	346,043
	Age/Sex: <1 Male		7,704
	Age/Sex: 1-4 Male		28,335
	Age/Sex: 5-9 Male		44,169
	Age/Sex: 10-14 Male		40,077
	Age/Sex: 15-17 Male		32,330
	By: Age/sex: Male 18-24		18,393
	By: Age/sex: Male 25+		0
	Age/Sex: <1 Female		7,522
	Age/Sex: 1-4 Female		27,876
	Age/Sex: 5-9 Female		45,540
	Age/Sex: 10-14 Female		47,515
	Age/Sex: 15-17 Female		29,316
	By: Age/sex: 18-24 Female		16,850
	By: Age/sex: 25+ Female		0
	Sum of Age/Sex disaggregates		310,384
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Education Support		

	Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+		
	Required only for DREAMS countries - By service, age and sex: Education Support Male <1		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14		
	Required only for DREAMS countries - By service, age		



	and sex: Education Support Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24		
	Required only for DREAMS		



	countries - By service, age and sex: Parenting/Caregiver Programs Female 25+		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1		

	Required only for DREAMS countries - By service, age and sex: Social Protection Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Social Protection		

	Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14		
	Required only for DREAMS countries - By service, age		

	and sex: Economic Strengthening Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24		
	Required only for DREAMS		

	countries - By service, age and sex: Economic Strengthening Male 25+		
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	59,446	45,306
	Age/Sex: <1 Male		949
	Age/Sex: 1-4 Male		3,584
	Age/Sex: 5-9 Male		6,355
	Age/Sex: 10-14 Male		6,484
	Age/Sex: 15-17 Male		4,171
	By age/sex: 18-24 Male		1,135
	By age/sex: 25+ Male		0
	Age/Sex: <1 Female		949
	Age/Sex: 1-4 Female		3,584
	Age/Sex: 5-9 Female		6,355
	Age/Sex: 10-14 Female		6,484
	Age/Sex: 15-17 Female		4,171
	By age/sex: 18-24 Female		1,135
	By age/sex: 25+ Female		0
	Sum of Age/Sex disaggregates		36,731
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 1-4		
Required only for DREAMS countries: By Service Area,			



	age and sex: Education Support Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male <1		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 10-14		
	Required only for DREAMS		



	countries: By Service Area, age and sex: Education Support Male 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 15-17		



	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male <1		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 15-17		
	Required only for DREAMS		



	countries: By Service Area, age and sex: Parenting/Caregiver Program Male 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 18-24		
	Required only for DREAMS countries: By Service Area,		



	age and sex: Social Protection Female 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male <1		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female <1		
	Required only for DREAMS		

	countries: By Service Area, age and sex: Economic Strengthening Female 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male <1		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 5-9		



	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service		

	Areas Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 25+		
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	828,370	737,292
	Age/sex: <1 Male	0	
	Age/sex: 1-4 Male	0	
	Age/sex: 5-9 Male	0	
	Age/sex: 10-14 Male	0	
	Age/sex: 15-19 Male	0	
	Age/sex: 20-24 Male	0	
	Age/sex: 25-49 Male	0	
	Age/sex: 50+ Male	0	
	Age/sex: <1 Female	0	
	Age/sex: 1-4 Female	0	
	Age/sex: 5-9 Female	0	
	Age/sex: 10-14 Female	0	
	Age/sex: 15-19 Female	0	
	Age/sex: 20-24 Female	0	
	Age/sex: 25-49 Female	0	
	Age/sex: 50+ Female	0	
	Sun of Age/Sex disaggregates	0	

	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	27,336	23,563
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	264,250	28,032
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	37,277	232,265
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	499,507	453,432
	Sum of Aggregated Age/Sex disaggregates	828,370	737,292
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	201,867	349,339
	Age/sex: <1 Male	0	
	Age/sex: 1-4 Male	0	
	Age/sex: 5-9 Male	0	
	Age/sex: 10-14 Male	0	
	Age/sex: 15-19 Male	0	
	Age/sex: 20-24 Male	0	
	Age/sex: 25-49 Male	0	
	Age/sex: 50+ Male	0	
	Age/sex: <1 Female	0	
	Age/sex: 1-4 Female	0	
	Age/sex: 5-9 Female	0	
	Age/sex: 10-14 Female	0	
	Age/sex: 15-19 Female	0	

	Age/sex: 20-24 Female	0	
	Age/sex: 25-49 Female	0	
	Age/sex: 50+ Female	0	
	Sum of Age/Sex disaggregates	0	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	6,662	11,207
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	64,395	13,258
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	9,084	110,023
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	121,726	214,851
	Sum of Aggregated Age/Sex disaggregates	201,867	349,339
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	199,413	107,667
	Age/sex: <1 Male	0	
	Age/sex: 1-4 Male	0	
	Age/sex: 5-9 Male	0	
	Age/sex: 10-14 Male	0	
	Age/sex: 15-19 Male	0	
	Age/sex: 20-24 Male	0	

	Age/sex: 25-49 Male	0	
	Age/sex: 50+ Male	0	
	Age/sex: <1 Female	0	
	Age/sex: 1-4 Female	0	
	Age/sex: 5-9 Female	0	
	Age/sex: 10-14 Female	0	
	Age/sex: 15-19 Female	0	
	Age/sex: 20-24 Female	0	
	Age/sex: 25-49 Female	0	
	Age/sex: 50+ Female	0	
	Sum of Age/sex disaggregates	0	
	Aggregated Age/sex: <15 Male	8,774	3,318
	Aggregated Age/sex: 15+ Male	61,220	35,540
	Aggregated Age/sex: <15 Female	8,176	3,793
	Aggregated Age/sex: 15+ Female	121,243	65,016
	Sum of Aggregated Age/sex disaggregates	199,413	107,667
CARE_NEW_TA	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load		73,534
	Age/sex: <1 Female		
	Age/sex: 1-4 Female		
	Age/sex: 5-9 Female		

	Age/sex: 10-14 Female		
	Age/sex: 15-19 Female		
	Age/sex: 20-24 Female		
	Age/sex: 25-49 Female		
	Age/sex: 50+ Female		
	Age/sex: <1 Male		
	Age/sex: 1-4 Male		
	Age/sex: 5-9 Male		
	Age/sex: 10-14 Male		
	Age/sex: 15-19 Male		
	Age/sex: 20-24 Male		
	Age/sex: 25-49 Male		
	Age/sex: 50+ Male		
	Aggregated Age/sex: <15 Female		2,548
	Aggregated Age/sex: <15 Male		2,298
	Aggregated Age/sex: 15+ Female		44,616
	Aggregated Age/sex: 15+ Male		24,072
	Sum of Aggregated Age/sex disaggregates	199,413	107,667
	Sum of age/sex disaggregates		
FN_THER_DSD	FN_THER_DSD Proportion of clinically undernourished PLHIV who received therapeutic or supplementary food	8 %	
	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during	24,726	17,685

	the reporting period.		
	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	309,773	221,435
	Age: <1	0	
	Age: 1-4	0	
	Age: 5-14	0	
	Age: 15-17	0	
	Age: 18+	0	
	Sum of Age disaggregates	0	
	Aggregated Age: <18	15,207	6,830
	Aggregated Age: 18+	9,519	10,855
	Sum of Aggregated Age disaggregates	24,726	17,685
	By Pregnancy/Postpartum Status: Pregnant		1,285
	By Pregnancy/Postpartum Status: Postpartum		577
FN_THER_TA	FN_THER_TA Proportion of clinically undernourished PLHIV who received therapeutic or supplementary food	n/a	
	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.		8,394
	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.		104,554
	Age: <1		

	Age: 1-4		
	Age: 5-14		
	Age: 15-17		
	Age: 18+		
	Sum of Age disaggregates		
	Aggregated Age - USE WITH HQ PERMISSION ONLY: <18		3,210
	Aggregated Age - USE WITH HQ PERMISSION ONLY: 18+		5,184
	By Pregnancy/Postpartum Status: Pregnant		570
	By Pregnancy/Postpartum Status: Postpartum		230
	Sum of Aggregated Age disaggregates		8,394
TB_IPT_DSD	TB_IPT_DSD Proportion of PLHIV newly enrolled in HIV clinical care who start isoniazid preventive therapy (IPT)	n/a	
	The number of PLHIV newly enrolled in HIV care who start IPT during the reporting period		73,747
	Number of HIV-positive adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load		

	Age: <1			
	Age: 1-4			
	Age: 5-9			
	Age: 10-14			
	Age: 15-19			
	Age: 20+			
	Sum of Age disaggregates			
	Age (Aggregated)- USE WITH HQ PERMISSION ONLY: <15		4,879	
	Age (Aggregated)- USE WITH HQ PERMISSION ONLY: 15+		68,868	
	Sex: Male		26,599	
	Sex: Female		47,148	
	TB_IPT_TA	TB_IPT_TA Proportion of PLHIV newly enrolled in HIV clinical care who start isoniazid preventive therapy (IPT)	n/a	
		The number of PLHIV newly enrolled in HIV care who start IPT during the reporting period		49,288
Number of HIV-positive adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load				
Age: <1				

	Age: 1-4		
	Age: 5-9		
	Age: 10-14		
	Age: 15-19		
	Age: 20+		
	Sum of Age disaggregates		
	Age (Aggregated)- USE WITH HQ PERMISSION ONLY: <15		3,241
	Age (Aggregated)- USE WITH HQ PERMISSION ONLY: 15+		46,047
	Sex: Male		17,695
	Sex: Female		31,593
FN_ASSESS_DSD	FN_ASSESS_DSD Proportion of PLHIV who were nutritionally assessed via anthropometric measurement	n/a	
	The number of PLHIV who were nutritionally assessed via anthropometric measurement		590,108
	Number of HIV positive adults and children who received care and treatment services		737,339
	Age: <1		
	Age: 1-4		
	Age: 5-14		
	Age: 15-17		
	Age: 18+ years		
	Sum of Age disaggregates		
	Age (Aggregated) - USE		227,172

	WITH HQ PERMISSION ONLY <18		
	Age (Aggregated) - USE WITH HQ PERMISSION ONLY 18+		362,936
	By Pregnancy/Postpartum Status: Pregnant		58,788
	By Pregnancy/Postpartum Status: Postpartum		58,761
FN_ASSESS_TA	FN_ASSESS_TA Proportion of PLHIV who were nutritionally assessed via anthropometric measurement	n/a	
	The number of PLHIV who were nutritionally assessed via anthropometric measurement		279,197
	Number of HIV positive adults and children who received care and treatment services		349,316
	Age: <1		
	Age: 1-4		
	Age: 5-14		
	Age: 15-17		
	Age: 18+ years		
	Sum of Age disaggregates		
	Age (Aggregated) - USE WITH HQ PERMISSION ONLY <18		107,507
	Age (Aggregated) - USE WITH HQ PERMISSION ONLY 18+		171,690

	By Pregnancy/Postpartum Status: Pregnant		28,093
	By Pregnancy/Postpartum Status: Postpartum		28,141
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a	
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	30,598	10,189
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period		12,747
	Age: <1		
	Age: 1-4		
	Age: 5-9		
	Age: 10-14		
	Age: 15-19		
	Age: 20+		
	Sum of Age disaggregates		
	Male	19,889	3,634
	Female	10,709	6,555
	Sum of Sex disaggregates	30,598	10,189
	Newly tested	0	
	Known HIV-positive	0	4,593
	Sum of Test Status disaggregates	0	4,593

	Aggregated Age: <15	765	745
	Aggregated Age: 15+	29,833	9,444
	Sum of Aggregated Age disaggregates	30,598	10,189
	Timeliness: Art initiation <8 weeks of start of TB treatment		
	Timeliness: Art initiation >8 weeks of start of TB treatment		
TB_ART_TA	TB_ART_TA Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a	
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period		6,555
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period		8,245
	Age: <1		
	Age: 1-4		
	Age: 5-9		
	Age: 10-14		
	Age: 15-19		
	Age: 20+		
	Sum of Age disaggregates		
Aggregated Age: <15			433

	Aggregated Age: 15+		6,122
	Sum of Aggregated Age disaggregates		6,555
	Male		2,351
	Female		4,204
	Sum of Sex disaggregates		6,555
	Known HIV-positive		2,918
	Newly tested		
	Sum of Test Status disaggregates		2,918
	Timeliness: Art initiation <8 weeks of start of TB treatment		
	Timeliness: Art initiation >8 weeks of start of TB treatment		
TB_SCREEN_DSD	TB_SCREEN_DSD Percentage of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period.	112 %	
	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	927,212	736,489
	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	828,370	737,292
	Age: <1	0	

	Age: 1-4	0	
	Age: 5-9	0	
	Age: 10-14	0	
	Age: 15-19	0	
	Age: 20+		
	Sum of Age disaggregates	0	
	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	124,246	51,554
	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	802,966	684,935
	Sum of Aggregated Age disaggregates	927,212	736,489
	Sex: Male	322,670	255,598
	Sex: Female	604,542	480,891
	Sum of Sex disaggregates	927,212	736,489
TB_SCREEN_TA	TB_SCREEN_TA Percentage of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period.	n/a	
	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period		350,142
	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	201,867	349,339

	Age: <1		
	Age: 1-4		
	Age: 5-9		
	Age: 10-14		
	Age: 15-19		
	Age: 20+		
	Sum of Age disaggregates		
	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15		24,510
	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+		325,632
	Sum of Aggregated Age disaggregates		350,142
	Sex: Female		228,679
	Sex: Male		121,463
	Sum of Sex disaggregates		350,142
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	80 %	
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	94,459	43,964
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	118,074	
	By infants who received a		39,613

	virologic test within 2 months of birth		
	By infants who received their first virologic HIV test between 2 and 12 months of age	94,459	4,352
	Sum of Infant Age disaggregates	94,459	43,965
	By infants with a positive virologic test result within 12 months of birth	5,904	
	Number of infants with a positive virological test result within 2 months of birth		1,982
	Number of infants with a positive virological test result within 12 months of birth		228
PMTCT_EID_TA	PMTCT_EID_TA Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)	n/a	
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period		44,778
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)		
	By infants who received a virologic test within 2 months of birth		40,250
	By infants who received their		4,550

	first virologic HIV test between 2 and 12 months of age		
	Sum of Infant Age disaggregates		44,800
	By infants with a positive virologic test result within 12 months of birth		
	Number of infants with a positive virological test result within 2 months of birth		2,011
	Number of infants with a positive virological test result within 12 months of birth		211
PMTCT_CTX_DSD	PMTCT_CTX_DSD Percentage of infants born to HIV-positive pregnant women who were started on cotrimoxazole (CTX) prophylaxis within two months of birth	n/a	
	Number of infants born to HIV-infected women who were started on cotrimoxazole (CTX) prophylaxis within two months of birth within the reporting period		43,964
	Number of HIV-positive pregnant women identified in the reporting period (include known HIV- positive at entry)		
PMTCT_CTX_TA	PMTCT_CTX_TA Percentage of infants born to HIV-positive pregnant women who were started on	n/a	

	cotrimoxazole (CTX) prophylaxis within two months of birth		
	Number of infants born to HIV-infected women who were started on cotrimoxazole (CTX) prophylaxis within two months of birth within the reporting period		44,778
	Number of HIV-positive pregnant women identified in the reporting period (include known HIV- positive at entry)		
	Number of HIV-infected adults and children receiving care and support services outside of the health facility		325,420
CARE_COMM_DSD	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-9 Male		
	Age/Sex: 10-14 Male		
	Age/Sex: 15-19 Male		
	Age/Sex: 20-24 Male		
	Age/Sex: 25-49 Male		
	Age/Sex: 50+ Male		
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-9 Female		
	Age/Sex: 10-14 Female		
	Age/Sex: 15-19 Female		
	Age/Sex: 20-24 Female		
Age/Sex: 25-49 Female			
Age/Sex: 50+ Female			
CARE_COMM_TA	Number of HIV-infected		207,538

	adults and children receiving care and support services outside of the health facility		
	Age/Sex: <1 Female		
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Female		
	Age/Sex: 1-4 Male		
	Age/Sex: 10-14 Female		
	Age/Sex: 10-14 Male		
	Age/Sex: 15-19 Female		
	Age/Sex: 15-19 Male		
	Age/Sex: 20-24 Female		
	Age/Sex: 20-24 Male		
	Age/Sex: 25-49 Female		
	Age/Sex: 25-49 Male		
	Age/Sex: 5-9 Female		
	Age/Sex: 5-9 Male		
	Age/Sex: 50+ Female		
	Age/Sex: 50+ Male		
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	750,686	690,981
	Age/Sex: <1 Male	0	
	Age/Sex: 1-4 Male	0	
	Age/Sex: 5-14 Male	0	
	Age/Sex: 15-19 Male		
	Age/Sex: 20+ Male		
	Age/Sex: <1 Female	0	
	Age/Sex: 1-4 Female	0	
	Age/Sex: 5-14 Female	0	
	Age/Sex: 15-19 Female		
	Age/Sex: 20+ Female		

	Aggregated Age/Sex: <1 Male	0	
	Aggregated Age/Sex: <1 Female	0	
	Aggregated Age/Sex: 15+ Male	232,713	438,316
	Aggregated Age/Sex: 1-14 Female		24,181
	Aggregated Age/Sex: 15+ Female	460,171	201,797
	Sum of Aggregated Age/Sex <15	57,802	
	Sum of Aggregated Age/Sex 15+	692,884	640,113
	Sum of Aggregated Age/Sex disaggregates	750,686	640,113
	Aggregated Age/Sex: 1-14 Male		26,687
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	0	50,868
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	172,725	320,629
	Age/Sex: <1 Male	0	
	Age/Sex: 1-4 Male	0	
	Age/Sex: 5-14 Male	0	
	Age/Sex: 15-19 Male		
	Age/Sex: 20+ Male		
	Age/Sex: <1 Female	0	
	Age/Sex: 1-4 Female	0	
	Age/Sex: 5-14 Female	0	
	Age/Sex: 15-19 Female		
	Age/Sex: 20+ Female		

	Sum of Age/Sex disaggregations	0	
	Aggregated Age/Sex: <1 Male	0	
	Aggregated Age/Sex: <1 Female	0	
	Aggregated Age/Sex: 1-14 Male		12,364
	Aggregated Age/Sex: 15+ Male	53,545	203,449
	Aggregated Age/Sex: 1-14 Female		11,238
	Aggregated Age/Sex: 15+ Female	105,880	93,578
	Sum of Aggregated Age/Sex <15	13,300	
	Sum of Aggregated Age/Sex 15+	159,425	297,027
	Sum of Aggregated Age/Sex disaggregates	172,725	297,027
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	0	23,602
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	246,452	156,419
	By Age/Sex: <1 Male	0	
	By Age/Sex: 1-4 Male	0	
	By Age/Sex: 5-9 Male	0	
	By Age/Sex: 10-14 Male	0	
	By Age/Sex: 15-19 Male	0	
	By Age/Sex: 20-24 Male	0	
	By Age/Sex: 25-49 Male	0	
	By Age/Sex: 50+ Male	0	
	By Age/Sex: <1 Female	0	

	By Age/Sex: 1-4 Female	0	
	By Age/Sex: 5-9 Female	0	
	By Age/Sex: 10-14 Female	0	
	By Age/Sex: 15-19 Female	0	
	By Age/Sex: 20-24 Female	0	
	By Age/Sex: 25-49 Female	0	
	By Age/Sex: 50+ Female	0	
	Sum of Age/Sex disaggregates	0	
	Aggregated Grouping by Age: <1 Male		
	Aggregated Grouping by Age/Sex: 1-14 Male		3,522
	Aggregated Grouping by Age/Sex: 15+ Male	64,077	101,650
	Aggregated Grouping by Age/Sex: <1 Female		
	Aggregated Grouping by Age/Sex: 15+ Female	164,383	48,259
	Sum of Aggregated Age/Sex disaggregates	246,451	149,909
	Pregnancy status	71,199	9,985
	Breastfeeding status		566
	Aggregated Grouping by Age/Sex: 1-14 Female		2,988
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)		100,296
	By Age/Sex: <1 Male		
	By Age/Sex: 1-4 Male		
	By Age/Sex: 5-9 Male		
	By Age/Sex: 10-14 Male		
	By Age/Sex: 15-19 Male		

	By Age/Sex: 20-24 Male		
	By Age/Sex: 25-49 Male		
	By Age/Sex: 50+ Male		
	By Age/Sex: <1 Female		
	By Age/Sex: 1-4 Female		
	By Age/Sex: 5-9 Female		
	By Age/Sex: 10-14 Female		
	By Age/Sex: 15-19 Female		
	By Age/Sex: 20-24 Female		
	By Age/Sex: 25-49 Female		
	By Age/Sex: 50+ Female		
	Sum of Age/Sex disaggregates		
	Aggregated Grouping by Age: <1 Male		
	Aggregated Grouping by Age/Sex: 1-14 Male		2,245
	Aggregated Grouping by Age/Sex: 15+ Male		65,355
	Aggregated Grouping by Age: <1 Female		
	Aggregated Grouping by Age/Sex: 1-14 Female		1,891
	Aggregated Grouping by Age/Sex: 15+ Female		30,805
	Sum of Aggregated Age/Sex disaggregates		96,160
	Pregnancy status		6,917
	Breastfeeding status		337
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of	91 %	

	antiretroviral therapy		
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	304,966	121,238
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	335,128	142,894
	Age/Sex: <5 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 5-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 20+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		

	ART)		
	Age/Sex: <5 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 5-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 20+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: <5 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 5-14 Male		

	(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 20+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: <5 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have		

	died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 5-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 20+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Numerator by Status: Pregnant		
	Numerator by Status:		

	Breastfeeding		
	Denominator by Status: Pregnant		
	Denominator by Status: Breastfeeding		
TX_RET_TA	TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a	
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART		89,673
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up		105,898
	Age/Sex: <5 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 5-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 15-19 Male		

	(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 20+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: <5 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 5-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 20+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: <5 Male		

	(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 5-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 20+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have		

	died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: <5 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 5-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 20+ Female (Denominator: Total number of adults and children who		

	initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Numerator by Status: Pregnant		
	Numerator by Status: Breastfeeding		
	Denominator by Status: Pregnant		
	Denominator by Status: Breastfeeding		
TX_VIRAL_DSD	TX_VIRAL_DSD Percentage of ART patients with an undetectable viral load at 12 months after initiation of ART	n/a	
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record within the past 12 months		550,228
	Number of adults and children on ART at least 6 months whose medical records were reviewed		688,433
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-14 Male		
	Age/Sex: 15-19 Male		
	Age/Sex: 20+ Male		
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		

	Age/Sex: 5-14 Female		
	Age/Sex: 15-19 Female		
	Age/Sex: 20+ Female		
	Results Category: Undetectable		495,163
	Results Category: Detectable		55,065
TX_VIRAL_TA	TX_VIRAL_TA Percentage of ART patients with an undetectable viral load at 12 months after initiation of ART	n/a	
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record within the past 12 months.		259,060
	Number of adults and children on ART at least 6 months whose medical records were reviewed.		323,729
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-14 Male		
	Age/Sex: 15-19 Male		
	Age/Sex: 20+Male		
	Age/Sex: <1 Female		
	Age/Ses: 1-4 Female		
	Age/Sex: 5-14 Female		
	Age/Sex: 15-19 Female		
	Age/Sex: 20+ Female		
	Result Category: Undetectable		233,195
	Result Category: Detectable		25,865
	LAB_ACC_DSD	Number of PEPFAR-supported testing	100

	facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation		
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	1,455	321
	By clinical laboratories	1,444	321
	By Point-of-care testing sites	0	884
LAB_CAP_TA	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests		1,021
	By clinical laboratories		1,021
	By Point-of-care testing sites		2,322
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	0	
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	0	1,342
	HIV serologic/diagnostic testing: Number of	0	16,000

	laboratories that participate in this PT program		
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0	12,800
	CD4: Number of laboratories that perform this testing	0	201
	CD4: Number of laboratories that participate in this PT program	0	200
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program		160
	Early infant diagnostics: Number of laboratories that perform this testing		1
	Early infant diagnostics: Number of laboratories that participate in this PT program		1
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program		1
	HIV viral load: Number of laboratories that perform this testing		1
	HIV viral load: Number of laboratories that participate in this PT program		1

	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program		1
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing		
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program		1,457
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program		1,166
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing		1
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program		1
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program		1
	TB diagnostics (Culture/DST): Number of laboratories that perform this		

	testing		
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program		
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program		
TX_UNDETECT_DSD	TX_UNDETECT_DSD Proportion of viral load tests with an undetectable viral load (<1000 copies/ml)	n/a	
	Number of viral load tests from adult and pediatric ART patients conducted in the past 12 months with a viral load <1,000 copies/ml		495,633
	Number of viral load tests performed from adults and children on ART within the current reporting period		550,472
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-14 Male		
	Age/Sex: 15-19 Male		
	Age/Sex: 20+ Male		
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-14 Female		
	Age/Sex: 15-19 Female		

	Age/Sex: 20+ Female		
	Pregnant		
	Breastfeeding		
	Test indication: Routine monitoring		495,633
	Test indication: Targeted monitoring		
TX_UNDETECT_TA	TX_UNDETECT_TA Proportion of viral load tests with an undetectable viral load (<1000 copies/ml)	n/a	
	Number of viral load tests from adult and pediatric ART patients conducted in the past 12 months with a viral load <1,000 copies/ml		232,726
	Number of viral load tests performed from adults and children on ART within the current reporting period		259,070
	Age/Sex: <1 Female		
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Female		
	Age/Sex: 1-4 Male		
	Age/Sex: 15-19 Female		
	Age/Sex: 15-19 Male		
	Age/Sex: 20+ Female		
	Age/Sex: 20+ Male		
	Age/Sex: 5-14 Female		
	Age/Sex: 5-14 Male		
	Breastfeeding		
	Pregnant		
	Test indication: Routine		232,726

	monitoring		
	Test indication: Targeted monitoring		
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	1,038	644
	By Graduates: Doctors	0	
	By Graduates: Nurses	0	10
	By Graduates: Midwives	491	477
	By Graduates: Social service workers	0	
	By Graduates: Laboratory professionals	361	
	By Graduates: Other	186	157
	Sum of Graduates disaggreagtes	1,038	644
FPINT_SITE_DSD	FPINT_SITE_DSD Family Planning and HIV Integration: Percentage of HIV service delivery points supported by PEPFAR that are directly providing integrated voluntary family planning services	95 %	
	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	2,310	



	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	2,432	
	Service delivery type: Care and Support		
	Service delivery type: Treatment		
	Service delivery type: PMTCT		
	Sum of Service delivery type (Care, Tx and PMTCT) disaggregates		

Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
7308	Partnership for Supply Chain Management	Private Contractor	U.S. Agency for International Development	GHP-State	41,322,161
9043	Henry Jackson Foundation	Private Contractor	U.S. Department of Defense	GHP-State	8,351,507
9167	Kalangala District Health Office	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,904,053
9183	The AIDS Support Organization	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	6,939,143
9240	Uganda Prisons Services	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	247,386
9301	John Snow, Inc.	Private Contractor	U.S. Agency for International	GHP-State	8,342,746

			Development		
9303	U.S. Department of Defense (Defense)	Other USG Agency	U.S. Department of Defense	GHP-State	683,266
9483	Infectious Disease Institute	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GAP	0
9541	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Agency for International Development	GHP-State	722,394
9879	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-State	0
10281	University of California at San Francisco	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
10326	University Research Corporation, LLC	Private Contractor	U.S. Agency for International Development	GHP-State	8,064,028
11479	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	42,400
11480	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	350,439
12477	Baylor College of Medicine Children's	University	U.S. Department of Health and Human	GHP-State	0

	Foundation		Services/Centers for Disease Control and Prevention		
12486	Associazione Volontari Per Il Servizio Internazionale, Uganda	FBO	U.S. Agency for International Development	GHP-State	4,000,405
12496	Social and Scientific Systems	Private Contractor	U.S. Agency for International Development	GHP-State	1,500,000
12801	Cardno Emerging Markets	Private Contractor	U.S. Agency for International Development	GHP-State	13,871,868
12835	International HIV/AIDS Alliance	NGO	U.S. Agency for International Development	GHP-State	0
12935	Johns Hopkins University Bloomberg School of Public Health	University	U.S. Agency for International Development	GHP-State	0
12981	Uganda Virus Research Institute	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,519,546
13002	United Nations High Commissioner for Refugees	Multi-lateral Agency	U.S. Department of State/Bureau of Population, Refugees, and Migration	GHP-State	324,721
13026	National Medical	Host Country	U.S. Department	GHP-State	0



	Stores	Government Agency	of Health and Human Services/Centers for Disease Control and Prevention		
13029	Regional Procurement Support Office/Frankfurt	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	500,000
13047	Makerere University School of Medicine	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	9,518,235
13093	PACE	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13102	Uganda Blood Transfusion Services	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	927,809
13104	Baylor College of Medicine Children's Foundation	University	U.S. Department of Health and Human Services/Centers for Disease	GHP-State	7,677,793



			Control and Prevention		
13136	Infectious Disease Institute	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,244,252
13138	Public Health Informatics Institute	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13161	Uganda Virus Research Institute	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	581,688
13170	Makerere University School of Public Health	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	393,729
13226	Medical Access Uganda Limited (MAUL)	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	59,464,568

			Prevention		
13317	Joint Clinical Research Center, Uganda	NGO	U.S. Agency for International Development	GHP-State	1,424,623
13325	Reach Out Mbuya	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	965,884
13383	African Medical and Research Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,148,689
13416	Mildmay International	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	9,755,670
13466	Uganda Protestant Medical Board	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,402,688
13486	Protecting Families from AIDS, Uganda	NGO	U.S. Department of Health and Human Services/Centers	GHP-State	2,458,270

			for Disease Control and Prevention		
13717	Registered Trustees for the Uganda Episcopal Conference	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	6,635,263
13833	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-State	1,255,760
13835	Baylor College of Medicine Children's Foundation	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	9,543,755
13837	QED Group, LLC	Private Contractor	U.S. Agency for International Development	GHP-State	1,460,247
13841	World Health Organization	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	280,000
13864	Ministry of Health, Uganda	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	1,780,000

			Prevention		
13874	Program for Appropriate Technology in Health	NGO	U.S. Agency for International Development	GHP-State	253,251
13877	Children's AIDS Fund	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,860,007
13880	Makerere University School of Public Health	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,170,833
13885	John Snow Inc (JSI)	Implementing Agency	U.S. Agency for International Development	GHP-State	0
13892	Research Triangle International	Private Contractor	U.S. Agency for International Development	GHP-State	840,894
13897	African Field Epidemiology Network	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	473,777
13900	PLAN International	NGO	U.S. Agency for International Development	GHP-State	0

13901	FHI 360	NGO	U.S. Agency for International Development	GHP-State	1,468,804
13924	RECO Industries	Implementing Agency	U.S. Agency for International Development	GHP-State	2,046,338
13944	Uganda Health Marketing Group	NGO	U.S. Agency for International Development	GHP-State	0
16594	University of North Carolina at Chapel Hill, Carolina Population Center	University	U.S. Agency for International Development	GHP-State	231,624
16606	TBD	TBD	Redacted	Redacted	Redacted
16626	Cardno Emerging Markets	Private Contractor	U.S. Agency for International Development	GHP-State	6,639,080
17061	TBD	TBD	Redacted	Redacted	Redacted
17062	HOSPICE AFRICA, Uganda	NGO	U.S. Agency for International Development	GHP-State	0
17063	TBD	TBD	Redacted	Redacted	Redacted
17064	TBD	TBD	Redacted	Redacted	Redacted
17065	Catholic Relief Services	FBO	U.S. Agency for International Development	GHP-State	5,468,164
17066	TBD	TBD	Redacted	Redacted	Redacted
17078	University Research Council	NGO	U.S. Agency for International Development	GHP-State	6,696,212
17079	Ministry of Health, Uganda	Host Country Government Agency	U.S. Department of Health and Human Services/Centers	GHP-State	0

			for Disease Control and Prevention		
17089	John Snow Inc (JSI)	Implementing Agency	U.S. Agency for International Development	GHP-State	2,000,000
17090	TBD	TBD	Redacted	Redacted	Redacted
17094	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-State	3,200,000
17649	TBD	TBD	Redacted	Redacted	Redacted
17651	TBD	TBD	Redacted	Redacted	Redacted
17654	TBD	TBD	Redacted	Redacted	Redacted
17682	New Partner	TBD	U.S. Agency for International Development	GHP-State	100,000
17686	New Partner	TBD	U.S. Agency for International Development	GHP-State	100,000
17688	TBD	TBD	Redacted	Redacted	Redacted
17690	IntraHealth International, Inc	NGO	U.S. Agency for International Development	GHP-State	2,648,876
17695	TBD	TBD	Redacted	Redacted	Redacted
17696	TBD	TBD	Redacted	Redacted	Redacted
17698	Uganda Prisons Services	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	247,146
17703	Makerere University School	University	U.S. Department of Health and	GHP-State	5,358,000



	of Public Health		Human Services/Centers for Disease Control and Prevention		
17704	African Society for Laboratory Medicine	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	145,223
17705	Makerere University John Hopkins University Collaboration	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
17706	Infectious Disease Institute	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	9,422,086
17779	International Center for AIDS Care and Treatment Programs, Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
17855	Research Triangle International	Private Contractor	U.S. Department of Defense	GHP-State	1,503,370
17874	National Medical	NGO	U.S. Department	GHP-State	1,303,845

	Research Unit		of Defense		
17976	Association of Public Health Laboratories	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	400,000
17977	American International Health Alliance Twinning Center	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	450,000
17978	TBD	TBD	Redacted	Redacted	Redacted
17979	TBD	TBD	Redacted	Redacted	Redacted
18003	Global Healthcare Public Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,000,000
18017	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	74,998
18029	TBD	TBD	Redacted	Redacted	Redacted
18030	TBD	TBD	Redacted	Redacted	Redacted
18031	TBD	TBD	Redacted	Redacted	Redacted
18032	TBD	TBD	Redacted	Redacted	Redacted



18033	TBD	TBD	Redacted	Redacted	Redacted
18034	TBD	TBD	Redacted	Redacted	Redacted
18041	TBD	TBD	Redacted	Redacted	Redacted
18042	TBD	TBD	Redacted	Redacted	Redacted
18077	World Education	NGO	U.S. Agency for International Development	GHP-State	4,473,953
18085	TBD	TBD	Redacted	Redacted	Redacted



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 7308	Mechanism Name: Partnership for Supply Chain Management Systems (SCMS)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Partnership for Supply Chain Management	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 41,322,161	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	41,322,161

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 7308



Mechanism Name:	Partnership for Supply Chain Management Systems (SCMS)		
Prime Partner Name:	Partnership for Supply Chain Management		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	3,389,432	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	38,250	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	490,499	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	3,548,694	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	977,179	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	1,495,421	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	25,558,372	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	5,664,968	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	PDTX	159,346	0
-----------	------	---------	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 9043	Mechanism Name: Makerere University Walter Reed Project (MUWRP)
Funding Agency: DOD	Procurement Type: Cooperative Agreement
Prime Partner Name: Henry Jackson Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 8,351,507	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	8,351,507

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Key Populations: FSW	400,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs



	and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Key Populations: MSM and TG	300,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Water	10,000
Economic Strengthening	100,000
Food and Nutrition: Commodities	30,000
Food and Nutrition: Policy, Tools, and Service Delivery	50,000
Human Resources for Health	372,115
Construction	2,700,000
Motor Vehicles: Purchased	270,000

Key Issues

(No data provided.)



Budget Code Information

Mechanism ID: 9043			
Mechanism Name: Makerere University Walter Reed Project (MUWRP)			
Prime Partner Name: Henry Jackson Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,393,607	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	542,158	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	838,530	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	459,623	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	1,750,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	649,891	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	55,870	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	291,162	0

Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	476,516	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	328,317	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,303,755	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	162,078	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	2,914	1,324
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	3,238	1,324
PMTCT_ARV_DSD	Life-long ART (including Option B+)	2,914	
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	1,952	221
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	962	1,103
PMTCT_ARV_DSD	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
PMTCT_ARV_DSD	Maternal AZT (prophylaxis component of	0	

	WHO Option A during pregnancy and delivery)		
PMTCT_ARV_DSD	Single-dose nevirapine (with or without tail)	0	
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	2,914	
PMTCT_ARV_DSD	Sum of New and Current disaggregates	2,914	1,324
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	46,253	14,174
PMTCT_STAT_DSD	Number of new ANC and L&D clients	48,688	15,102
PMTCT_STAT_DSD	By: Known positives at entry	1,230	1,134
PMTCT_STAT_DSD	By: Number of new positives identified	2,007	190
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	3,237	1,324
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	54	42
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	2	
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	0	
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	21	
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	47	
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical	43	

	post-operative AE(s)		
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	4	
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	14	
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)	14	
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	22	
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	16,485	12,889
VMMC_CIRC_DSD	By Age: 10-14	2,967	
VMMC_CIRC_DSD	By Age: 15-19	3,257	
VMMC_CIRC_DSD	By Age: 20-24	2,730	
VMMC_CIRC_DSD	By Age: 25-49	7,201	
VMMC_CIRC_DSD	By Age: 50+	330	
VMMC_CIRC_DSD	Sum of age disaggregates	16,485	
VMMC_CIRC_DSD	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	386	233
VMMC_CIRC_DSD	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	12,473	8,918
VMMC_CIRC_DSD	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	3,627	3,738

VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	14,251	12,889
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	2,234	3
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	14,251	12,889
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	3
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	17,347	23,153
PP_PREV_DSD	Age/sex: 10-14 Male	561	239
PP_PREV_DSD	Age/sex: 15-19 Male	1,340	3,598
PP_PREV_DSD	Age/sex: 20-24 Male	1,123	4,802
PP_PREV_DSD	Age/sex: 25-49 Male	2,962	2,998
PP_PREV_DSD	Age/sex: 50+ Male	120	354
PP_PREV_DSD	Age/sex: 10-14 Female	765	221
PP_PREV_DSD	Age/sex: 15-19 Female	2,461	3,347
PP_PREV_DSD	Age/sex: 20-24 Female	2,154	4,469
PP_PREV_DSD	Age/sex: 25-49 Female	5,641	2,792
PP_PREV_DSD	Age/sex: 50+ Female	220	333
PP_PREV_DSD	Sum of Age/Sex disaggregates	17,347	23,153
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	35,328	50,351
PP_PREV_TA	Age/sex: 10-14 Male	1,899	2,155
PP_PREV_TA	Age/sex: 15-19 Male	2,503	4,948
PP_PREV_TA	Age/sex: 20-24 Male	2,097	6,068
PP_PREV_TA	Age/sex: 25-49 Male	5,532	9,359

PP_PREV_TA	Age/sex: 50+ Male	230	700
PP_PREV_TA	Age/sex: 10-14 Female	923	2,825
PP_PREV_TA	Age/sex: 15-19 Female	5,295	5,118
PP_PREV_TA	Age/sex: 20-24 Female	4,633	7,550
PP_PREV_TA	Age/sex: 25-49 Female	12,134	10,899
PP_PREV_TA	Age/sex: 50+ Female	83	729
PP_PREV_TA	Sum of Age/Sex disaggregates	35,329	50,351
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	60,914	96,531
HTC_TST_DSD	By Test Result: Negative	59,087	93,208
HTC_TST_DSD	By Test Result: Positive	1,827	3,323
HTC_TST_DSD	Sum of Test Result disaggregates	60,914	96,531
HTC_TST_DSD	Age/sex: 10-14 Male	2,860	
HTC_TST_DSD	Age/sex: 15-19 Male	3,140	
HTC_TST_DSD	Age/sex: 20-24 Male	2,631	
HTC_TST_DSD	Age/sex: 25-49 Male	6,941	
HTC_TST_DSD	Age/sex: 50+ Male	318	
HTC_TST_DSD	Age/sex: 15-19 Female	10,806	
HTC_TST_DSD	Age/sex: 20-24 Female	9,455	
HTC_TST_DSD	Age/sex: 25-49 Female	24,763	
HTC_TST_DSD	Sum of Age/Sex disaggregates	60,914	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,860	4,895
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	13,031	35,668
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,896	6,488
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	45,023	49,480
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	5,756	11,383
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	58,054	85,148
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	63,810	96,531

HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	32,966	53,299
HTC_TST_TA	By Test Result: Negative	29,220	51,339
HTC_TST_TA	By Test Result: Positive	3,746	1,960
HTC_TST_TA	Sum of Test Result disaggregates	32,966	53,299
HTC_TST_TA	Age/sex: <1 Male	0	
HTC_TST_TA	Age/sex: 1-4 Male	0	
HTC_TST_TA	Age/sex: 5-9 Male	2,501	
HTC_TST_TA	Age/sex: 10-14 Male	1,887	
HTC_TST_TA	Age/sex: 15-19 Male	3,117	
HTC_TST_TA	Age/sex: 20-24 Male	2,612	
HTC_TST_TA	Age/sex: 25-49 Male	6,890	
HTC_TST_TA	Age/sex: 50+ Male	258	
HTC_TST_TA	Age/sex: <1 Female	0	
HTC_TST_TA	Age/sex: 1-4 Female	0	
HTC_TST_TA	Age/sex: 5-9 Female	3,057	
HTC_TST_TA	Age/sex: 10-14 Female	2,306	
HTC_TST_TA	Age/sex: 15-19 Female	2,431	
HTC_TST_TA	Age/sex: 20-24 Female	2,128	
HTC_TST_TA	Age/sex: 25-49 Female	5,572	
HTC_TST_TA	Age/sex: 50+ Female	207	
HTC_TST_TA	Sum of Age/Sex disaggregates	32,966	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	4,388	2,698
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	12,877	19,694
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	5,364	3,577
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	10,337	27,330
HTC_TST_TA	Sum of Aggregated Age/Sex <15	9,752	6,275
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	23,214	47,024

HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	32,966	53,299
GEND_GBV_DSD	Number of people receiving post-GBV care	48,950	2,809
GEND_GBV_DSD	Age: 10-14	1,463	
GEND_GBV_DSD	Age: 15-17	10,200	
GEND_GBV_DSD	Age: 18-24	8,689	
GEND_GBV_DSD	Age: 25+	28,598	
GEND_GBV_DSD	Sum of Age disaggregates	48,950	
GEND_GBV_DSD	Sex: Male	28,115	
GEND_GBV_DSD	Sex: Female	20,835	
GEND_GBV_DSD	Sum of Sex disaggregates	48,950	
GEND_GBV_TA	Sum of Age disaggregates	48,950	
GEND_GBV_TA	Sum of Sex disaggregates	48,950	
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	50,140	2,394
GEND_NORM_DSD	By Age: 10-14	1,963	
GEND_NORM_DSD	By Age: 15-19	10,433	
GEND_NORM_DSD	By Age: 20-24	8,887	
GEND_NORM_DSD	By Age: 25+	28,857	
GEND_NORM_DSD	Sum of Age disaggregates	50,140	
GEND_NORM_DSD	By Sex: Male	27,142	
GEND_NORM_DSD	By Sex: Female	22,998	
GEND_NORM_DSD	Sum of Sex disaggregates	50,140	
GEND_NORM_TA	Sum of Sex disaggregates	50,140	
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	1,256	5,591
OVC_ACC_DSD	Sex: Male	570	
OVC_ACC_DSD	Sex: Female	686	
OVC_ACC_DSD	Sum of Sex disaggregates	1,256	
OVC_ACC_DSD	Age: <1	53	
OVC_ACC_DSD	Age: 1-4	198	

OVC_ACC_DSD	Age: 5-9	352	
OVC_ACC_DSD	Age: 10-14	359	
OVC_ACC_DSD	Age: 15-17	231	
OVC_ACC_DSD	Age: 18+	63	
OVC_ACC_DSD	Sum of Age disaggregates	1,256	
OVC_ACC_TA	Sum of Sex disaggregates	1,256	
OVC_ACC_TA	Sum of Age disaggregates	1,256	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	6,179	10,879
OVC_SERV_DSD	Sex: Male	2,805	
OVC_SERV_DSD	Sex: Female	3,374	
OVC_SERV_DSD	Sum of Sex disaggregates	6,179	
OVC_SERV_DSD	Age: <1	260	
OVC_SERV_DSD	Age: 1-4	976	
OVC_SERV_DSD	Age: 5-9	1,730	
OVC_SERV_DSD	Age: 10-14	1,767	
OVC_SERV_DSD	Age: 15-17	1,137	
OVC_SERV_DSD	Age: 18+	309	
OVC_SERV_DSD	Sum of Age disaggregates	6,179	
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	687	
OVC_SERV_TA	Sex: Male	312	
OVC_SERV_TA	Sex: Female	375	
OVC_SERV_TA	Sum of Sex disaggregates	687	
OVC_SERV_TA	Age: <1	29	
OVC_SERV_TA	Age: 1-4	109	
OVC_SERV_TA	Age: 5-9	193	
OVC_SERV_TA	Age: 10-14	196	
OVC_SERV_TA	Age: 15-17	126	
OVC_SERV_TA	Age: 18+	34	

OVC_SERV_TA	Sum of Age disaggregates	687	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	27,453	21,110
CARE_CURR_DSD	Age/sex: <1 Male	0	
CARE_CURR_DSD	Age/sex: 1-4 Male	0	
CARE_CURR_DSD	Age/sex: 5-9 Male	0	
CARE_CURR_DSD	Age/sex: 10-14 Male	0	
CARE_CURR_DSD	Age/sex: 15-19 Male	0	
CARE_CURR_DSD	Age/sex: 20-24 Male	0	
CARE_CURR_DSD	Age/sex: 25-49 Male	0	
CARE_CURR_DSD	Age/sex: 50+ Male	0	
CARE_CURR_DSD	Age/sex: <1 Female	0	
CARE_CURR_DSD	Age/sex: 1-4 Female	0	
CARE_CURR_DSD	Age/sex: 5-9 Female	0	
CARE_CURR_DSD	Age/sex: 10-14 Female	0	
CARE_CURR_DSD	Age/sex: 15-19 Female	0	
CARE_CURR_DSD	Age/sex: 20-24 Female	0	
CARE_CURR_DSD	Age/sex: 25-49 Female	0	
CARE_CURR_DSD	Age/sex: 50+ Female	0	
CARE_CURR_DSD	Sun of Age/Sex disaggregates	0	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,016	672
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	8,510	801
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,098	6,638
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	16,829	12,999
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	27,453	21,110
CARE_CURR_TA	Number of HIV positive adults and children	9,105	7,669

	who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load		
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	303	249
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,542	292
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	328	2,428
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	5,027	4,700
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	8,200	7,669
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	6,020	4,565
CARE_NEW_DSD	Age/sex: 10-14 Male	0	
CARE_NEW_DSD	Age/sex: 15-19 Male	0	
CARE_NEW_DSD	Age/sex: 20-24 Male	0	
CARE_NEW_DSD	Age/sex: 25-49 Male	0	
CARE_NEW_DSD	Age/sex: 50+ Male	0	
CARE_NEW_DSD	Age/sex: <1 Female	0	
CARE_NEW_DSD	Age/sex: 1-4 Female	0	
CARE_NEW_DSD	Age/sex: 5-9 Female	0	
CARE_NEW_DSD	Age/sex: 10-14 Female	0	
CARE_NEW_DSD	Age/sex: 15-19 Female	0	
CARE_NEW_DSD	Age/sex: 20-24 Female	0	
CARE_NEW_DSD	Age/sex: 25-49 Female	0	
CARE_NEW_DSD	Age/sex: 50+ Female	0	
CARE_NEW_DSD	Sum of Age/sex disaggregates	0	

CARE_NEW_DSD	Aggregated Age/sex: <15 Male	265	141
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	1,848	1,502
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	247	157
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	3,660	2,765
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	6,020	4,565
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	6,020	4,565
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	1,021	533
FN_THER_DSD	Aggregated Age: <18	628	207
FN_THER_DSD	Aggregated Age: 18+	393	326
FN_THER_DSD	Sum of Aggregated Age disaggregates	1,021	533
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,176	177
TB_ART_DSD	Age: 0-4	2	
TB_ART_DSD	Age: 5-14	27	
TB_ART_DSD	Age: 15+	1,147	
TB_ART_DSD	Male	764	62
TB_ART_DSD	Female	412	115
TB_ART_DSD	Sum of Sex disaggregates	1,176	177
TB_ART_DSD	Newly tested	29	
TB_ART_DSD	Known HIV-positive	1,147	80
TB_ART_DSD	Sum of Test Status disaggregates	1,176	80
TB_ART_DSD	Aggregated Age: <15	29	11
TB_ART_DSD	Aggregated Age: 15+	1,147	166
TB_ART_DSD	Sum of Aggregated Age disaggregates	1,176	177
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,590	1,316
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include	3,238	

	known HIV-positive women at entry into PMTCT)		
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	2,590	131
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,590	1,316
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	162	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	27,453	19,844
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,016	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	8,510	12,572
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,098	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	16,829	5,796
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,114	
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	25,339	18,368
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	27,453	18,368
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	8,200	6,405
TX_CURR_TA	Aggregated Age/Sex: <15 Male	303	
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	2,542	4,079
TX_CURR_TA	Aggregated Age/Sex: <15 Female	328	
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	5,027	1,869
TX_CURR_TA	Sum of Aggregated Age/Sex <15	631	
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	7,569	5,948
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	8,200	5,948
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	8,126	6,856
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	276	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	2,113	4,461
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	317	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	5,420	2,112



TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	8,126	6,573
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	6	1
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	3	
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	3	
LAB_ACC_DSD	Sum of Support Type disaggregates	6	
LAB_ACC_TA	Sum of Support Type disaggregates	6	
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	33	3
LAB_CAP_DSD	By clinical laboratories	33	3
LAB_CAP_DSD	By Point-of-care testing sites	8	11
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	33	
LAB_CAP_DSD	Sum of Site Support Type disaggregates	33	
LAB_CAP_TA	Sum of Site Support Type disaggregates	33	
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	42	
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	42	
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	42	
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	42	
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	42	
LAB_PT_DSD	CD4: Number of laboratories that achieve	42	

	acceptable successful passing criteria in this PT program		
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	40	
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	40	
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	40	
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	42	
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	42	
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	42	
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that perform this testing	42	
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that participate in this PT program	42	
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	42	
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	42	
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	42	
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points	42	

	supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services		
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	42	
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	42	
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	42	
FPINT_SITE_TA	Sum of Denominator Site Support Type disaggregates	42	
FPINT_SITE_TA	Sum of Numerator Site Support Type disaggregates	42	
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	35,629	21,110
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	27,453	21,110
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	4,774	1,478
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	30,855	19,632
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	35,629	21,110
TB_SCREEN_DSD	Sex: Male	12,399	7,338
TB_SCREEN_DSD	Sex: Female	23,230	13,772
TB_SCREEN_DSD	Sum of Sex disaggregates	35,629	21,110
TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count	9,105	7,669



	OR viral load		
--	---------------	--	--

Implementing Mechanism Details

Mechanism ID: 9167	Mechanism Name: Provision of Comprehensive Public Health services for the fishing communities in Kalangala District in the Republic of Uganda under the President's Emergency Plan for AIDS Relief		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: Kalangala District Health Office			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: N/A			
G2G: Yes	Managing Agency: HHS/CDC		

Total All Funding Sources: 1,904,053	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	1,904,053

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Gender: GBV	100,000
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	50,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms



Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Key Populations: FSW	80,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	9167		
Mechanism Name:	Provision of Comprehensive Public Health services for the fishing communities in Kalangala District in the Republic of Uganda under the		
Prime Partner Name:	President's Emergency Plan for AIDS Relief Kalangala District Health Office		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	493,712	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HKID	1,706	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	83,489	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	105,536	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	32,388	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	63,513	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	231,105	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	42,724	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	702,952	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	46,928	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	62	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	62	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	0		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	0	6	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	0	56	Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	0		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	0	62	Redacted
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	219	710	Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	244	710	Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	219		Redacted

PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	147	71	Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	72	639	Redacted
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0		Redacted
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	219		Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	219	710	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	214	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	0	230	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	0	56	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	0	6	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	0	62	Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	3,479	2,171	Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	3,662	2,280	Redacted
PMTCT_STAT_TA	By: Known positives at entry	93	639	Redacted

PMTCT_STAT_TA	By: Number of new positives identified	151	71	Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	244	710	Redacted
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	0		Redacted
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	0		Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	0		Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	0		Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	0		Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	0		Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0		Redacted
VMMC_CIRC_DS D	By Age: <1	0		Redacted

VMMC_CIRC_DS D	By Age: 1-9	0		Redacted
VMMC_CIRC_DS D	By Age: 10-14	0		Redacted
VMMC_CIRC_DS D	By Age: 15-19	0		Redacted
VMMC_CIRC_DS D	By Age: 20-24	0		Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	0		Redacted
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0		Redacted
VMMC_CIRC_TA	By Age: <1	0		Redacted
VMMC_CIRC_TA	By Age: 1-9	0		Redacted
VMMC_CIRC_TA	By Age: 10-14	0		Redacted
VMMC_CIRC_TA	By Age: 15-19	0		Redacted
VMMC_CIRC_TA	By Age: 20-24	0		Redacted
VMMC_CIRC_TA	Sum of Age disaggregations	0		Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	9,418	12,226	Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	297	170	Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	554	1,821	Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	463	2,180	Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	2,845	4,043	Redacted
PP_PREV_DSD	Age/sex: 50+ Male	20	339	Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	331	182	Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	740	731	Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	645	1,096	Redacted

PP_PREV_DSD	Age/sex: 25-49 Female	3,486	1,561	Redacted
PP_PREV_DSD	Age/sex: 50+ Female	37	103	Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	9,418	12,226	Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	4,750	14,771	Redacted
PP_PREV_TA	Age/sex: 10-14 Male	58	617	Redacted
PP_PREV_TA	Age/sex: 15-19 Male	517	1,214	Redacted
PP_PREV_TA	Age/sex: 20-24 Male	433	1,319	Redacted
PP_PREV_TA	Age/sex: 25-49 Male	1,143	2,377	Redacted
PP_PREV_TA	Age/sex: 50+ Male	43	200	Redacted
PP_PREV_TA	Age/sex: 10-14 Female	71	788	Redacted
PP_PREV_TA	Age/sex: 15-19 Female	591	1,741	Redacted
PP_PREV_TA	Age/sex: 20-24 Female	517	2,574	Redacted
PP_PREV_TA	Age/sex: 25-49 Female	1,354	3,693	Redacted
PP_PREV_TA	Age/sex: 50+ Female	23	248	Redacted
PP_PREV_TA	Sum of Age/Sex disaggregates	4,750	14,771	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	3,386	1,615	Redacted
HTC_TST_DSD	By Test Result: Negative	3,285	1,551	Redacted
HTC_TST_DSD	By Test Result: Positive	101	64	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	3,386	1,615	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	0		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	0		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	0		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	0		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	0		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	813		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	711		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	1,862		Redacted

HTC_TST_DSD	Sum of Age/Sex disaggregates	3,386		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	82	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0	596	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,386	829	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	0	190	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	3,386	1,425	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	3,386	1,615	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	9,024	20,086	Redacted
HTC_TST_TA	By Test Result: Negative	7,173	19,267	Redacted
HTC_TST_TA	By Test Result: Positive	1,851	819	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	9,024	20,086	Redacted
HTC_TST_TA	Age/sex: <1 Male	0		Redacted
HTC_TST_TA	Age/sex: 1-4 Male	0		Redacted
HTC_TST_TA	Age/sex: 5-9 Male	193		Redacted
HTC_TST_TA	Age/sex: 10-14 Male	146		Redacted
HTC_TST_TA	Age/sex: 15-19 Male	1,293		Redacted
HTC_TST_TA	Age/sex: 20-24 Male	1,083		Redacted
HTC_TST_TA	Age/sex: 25-49 Male	2,858		Redacted
HTC_TST_TA	Age/sex: 50+ Male	107		Redacted
HTC_TST_TA	Age/sex: <1 Female	0		Redacted
HTC_TST_TA	Age/sex: 1-4 Female	0		Redacted
HTC_TST_TA	Age/sex: 5-9 Female	236		Redacted
HTC_TST_TA	Age/sex: 10-14 Female	178		Redacted
HTC_TST_TA	Age/sex: 15-19 Female	689		Redacted
HTC_TST_TA	Age/sex: 20-24 Female	603		Redacted
HTC_TST_TA	Age/sex: 25-49 Female	1,579		Redacted
HTC_TST_TA	Age/sex: 50+ Female	59		Redacted

HTC_TST_TA	Sum of Age/Sex disaggregates	9,024		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	339	1,015	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	5,340	7,421	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	415	1,344	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,930	10,306	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	754	2,359	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	8,270	17,727	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	9,024	20,086	Redacted
GEND_GBV_DSD	Number of people receiving post-GBV care	9,681	348	Redacted
GEND_GBV_DSD	Age: 0-9	0		Redacted
GEND_GBV_DSD	Age: 10-14	0		Redacted
GEND_GBV_DSD	Age: 15-17	1,630		Redacted
GEND_GBV_DSD	Age: 18-24	1,389		Redacted
GEND_GBV_DSD	Age: 25+	6,662		Redacted
GEND_GBV_DSD	Sum of Age disaggregates	9,681		Redacted
GEND_GBV_DSD	Sex: Male	5,763		Redacted
GEND_GBV_DSD	Sex: Female	3,918		Redacted
GEND_GBV_DSD	Sum of Sex disaggregates	9,681		Redacted
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	0	259	Redacted
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	0	89	Redacted
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	0		Redacted
GEND_GBV_TA	Sum of Age disaggregates	9,681		Redacted
GEND_GBV_TA	Sum of Sex disaggregates	9,681		Redacted

GEND_NORM_DS D	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	8,094		Redacted
GEND_NORM_DS D	By Age: 0-9	0		Redacted
GEND_NORM_DS D	By Age: 10-14	443		Redacted
GEND_NORM_DS D	By Age: 15-19	1,227		Redacted
GEND_NORM_DS D	By Age: 20-24	1,045		Redacted
GEND_NORM_DS D	By Age: 25+	5,379		Redacted
GEND_NORM_DS D	Sum of Age disaggregates	8,094		Redacted
GEND_NORM_DS D	By Sex: Male	4,802		Redacted
GEND_NORM_DS D	By Sex: Female	3,292		Redacted
GEND_NORM_DS D	Sum of Sex disaggregates	8,094		Redacted
GEND_NORM_DS D	By type of activity: Individual	0		Redacted
GEND_NORM_DS D	By type of activity: Small Group	0		Redacted
GEND_NORM_DS D	By type of activity: Community-level	0		Redacted
GEND_NORM_TA	Sum of Sex disaggregates	8,094		Redacted
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	242	24	Redacted
OVC_ACC_DSD	Sex: Male	110		Redacted
OVC_ACC_DSD	Sex: Female	132		Redacted
OVC_ACC_DSD	Sum of Sex disaggregates	242		Redacted



OVC_ACC_DSD	Age: <1	10		Redacted
OVC_ACC_DSD	Age: 1-4	38		Redacted
OVC_ACC_DSD	Age: 5-9	68		Redacted
OVC_ACC_DSD	Age: 10-14	69		Redacted
OVC_ACC_DSD	Age: 15-17	45		Redacted
OVC_ACC_DSD	Age: 18+	12		Redacted
OVC_ACC_DSD	Sum of Age disaggregates	242		Redacted
OVC_ACC_TA	Sum of Sex disaggregates	242		Redacted
OVC_ACC_TA	Sum of Age disaggregates	242		Redacted
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	1,258	47	Redacted
OVC_SERV_DSD	Sex: Male	571		Redacted
OVC_SERV_DSD	Sex: Female	687		Redacted
OVC_SERV_DSD	Sum of Sex disaggregates	1,258		Redacted
OVC_SERV_DSD	Age: <1	53		Redacted
OVC_SERV_DSD	Age: 1-4	199		Redacted
OVC_SERV_DSD	Age: 5-9	352		Redacted
OVC_SERV_DSD	Age: 10-14	360		Redacted
OVC_SERV_DSD	Age: 15-17	231		Redacted
OVC_SERV_DSD	Age: 18+	63		Redacted
OVC_SERV_DSD	Sum of Age disaggregates	1,258		Redacted
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	66		Redacted
OVC_SERV_TA	Sex: Male	30		Redacted
OVC_SERV_TA	Sex: Female	36		Redacted
OVC_SERV_TA	Sum of Sex disaggregates	66		Redacted
OVC_SERV_TA	Age: <1	3		Redacted
OVC_SERV_TA	Age: 1-4	10		Redacted
OVC_SERV_TA	Age: 5-9	19		Redacted
OVC_SERV_TA	Age: 10-14	19		Redacted

OVC_SERV_TA	Age: 15-17	12		Redacted
OVC_SERV_TA	Age: 18+	3		Redacted
OVC_SERV_TA	Sum of Age disaggregates	66		Redacted
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	6,558	19,392	Redacted
CARE_CURR_TA	Age/sex: <1 Male	0		Redacted
CARE_CURR_TA	Age/sex: 1-4 Male	0		Redacted
CARE_CURR_TA	Age/sex: 5-9 Male	0		Redacted
CARE_CURR_TA	Age/sex: 10-14 Male	0		Redacted
CARE_CURR_TA	Age/sex: 15-19 Male	0		Redacted
CARE_CURR_TA	Sum of Age/Sex disaggregates	0		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	216	620	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,092	737	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	295	6,109	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,955	11,926	Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	6,558	19,392	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	2,112	22	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	93		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	648	8	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	87		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	1,284	14	Redacted

CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	2,112	22	Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	2,112	22	Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	169	6	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	2,118	64	Redacted
FN_THER_DSD	Aggregated Age: <18	97	2	Redacted
FN_THER_DSD	Aggregated Age: 18+	61	4	Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	158	6	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	156	6	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	195	8	Redacted
TB_ART_DSD	Age: 0-4	0		Redacted
TB_ART_DSD	Age: 5-14	4		Redacted
TB_ART_DSD	Age: 15+	190		Redacted
TB_ART_DSD	Male	127	2	Redacted
TB_ART_DSD	Female	68	4	Redacted
TB_ART_DSD	Sum of Sex disaggregates	195	6	Redacted
TB_ART_DSD	Aggregated Age: <15	5		Redacted
TB_ART_DSD	Aggregated Age: 15+	190	6	Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	195	6	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth	2,102	49	Redacted

	during the reporting period			
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	2,627		Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	2,102	5	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,102	49	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	12		Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	5,162	17,738	Redacted
TX_CURR_TA	Age/Sex: <1 Male	0		Redacted
TX_CURR_TA	Age/Sex: 1-4 Male	0		Redacted
TX_CURR_TA	Age/Sex: 5-14 Male	0		Redacted
TX_CURR_TA	Age/Sex: 15+ Male	0		Redacted
TX_CURR_TA	Age/Sex: <1 Female	0		Redacted
TX_CURR_TA	Sum of Age/Sex disaggregations	0		Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	191		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	1,600	11,253	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	206		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	3,165	5,179	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	397		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	4,765	16,432	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	5,162	16,432	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,395	82	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	81		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	623	52	Redacted

TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	93		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,598	26	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	2,395	78	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,122	114	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	3,430	134	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	228		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,894		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	250		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	3,180		Redacted

	those who have stopped ART, and those lost to follow-up)			
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	1		Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	1		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	1		Redacted
LAB_ACC_TA	Sum of Support Type disaggregates	1		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	1		Redacted
LAB_CAP_DSD	By clinical laboratories	1		Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	1		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	1		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	1		Redacted
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	0		Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	0		Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	0		Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing:	0		Redacted

	Number of laboratories that achieve acceptable successful passing criteria in this PT program			
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	0		Redacted
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	0		Redacted
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	0		Redacted
HRH_PRE	By Graduates: Doctors	0		Redacted
HRH_PRE	By Graduates: Nurses	0		Redacted
HRH_PRE	By Graduates: Midwives	0		Redacted
HRH_PRE	By Graduates: Social service workers	0		Redacted
HRH_PRE	By Graduates: Laboratory professionals	0		Redacted
HRH_PRE	Sum of Graduates disaggregated	0		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0		Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	0		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by	0		Redacted

	PEPFAR for HIV services that are directly providing integrated voluntary family planning services			
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	0		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	0		Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	0		Redacted
FPINT_SITE_TA	Sum of Denominator Site Support Type disaggregates	0		Redacted
FPINT_SITE_TA	Sum of Numerator Site Support Type disaggregates	0		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	5,903	214	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	791	16	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	5,112	198	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	5,903	214	Redacted
TB_SCREEN_DSD	Sex: Male	2,054	74	Redacted
TB_SCREEN_DSD	Sex: Female	3,849	140	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	5,903	214	Redacted
TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	6,558	19,392	Redacted

Implementing Mechanism Details

Mechanism ID: 9183	Mechanism Name: Accelerating Delivery of
---------------------------	---



Comprehensive HIV/AIDS/TB services including Prevention, Care, Support and Treatment of people living with HIV/AIDS in the Republic of Uganda under the President's Emergency Plan for AIDS Relief	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: The AIDS Support Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 6,939,143	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	6,939,143

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	425,000
Gender: GBV	800,000
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	400,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information



Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Key Populations: FSW	800,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: Mechanism Name: Prime Partner Name:	9183 Accelerating Delivery of Comprehensive HIV/AIDS/TB services including Prevention, Care, Support and Treatment of people living with HIV/AIDS in the Republic of Uganda under the President's Emergency Plan for AIDS Relief The AIDS Support Organization		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	2,272,754	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HVTB	335,419	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	402,731	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	249,466	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	413,877	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	29,113	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	255,793	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,807,031	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	172,959	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	4,041	1,190	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	4,490	1,190	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	4,041		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	2,708	135	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,333	1,055	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	4,041		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	4,041	1,190	Redacted
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	125	2,245	Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	139	2,245	Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	125		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	84	230	Redacted

PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	41	2,015	Redacted
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0		Redacted
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	125		Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	125	2,245	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	64,140	20,842	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	67,516	23,058	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	1,706	1,051	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	2,784	139	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	4,490	1,190	Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,984	35,894	Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	2,088	41,060	Redacted
PMTCT_STAT_TA	By: Known positives at entry	53	2,022	Redacted
PMTCT_STAT_TA	By: Number of new positives identified	86	223	Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	139	2,245	Redacted
VMMC_AE_DSD	Number of males circumcised surgically	25	23	Redacted

	or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)			
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	1		Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	1		Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	17		Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	25		Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	22		Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	2		Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	0		Redacted
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more	0		Redacted

	moderate medical device-related AE(s), but no severe medical device-related AE(s)			
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	17		Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	7,436	7,147	Redacted
VMMC_CIRC_DS D	By Age: 10-14	1,338		Redacted
VMMC_CIRC_DS D	By Age: 15-19	1,469		Redacted
VMMC_CIRC_DS D	By Age: 20-24	1,231		Redacted
VMMC_CIRC_DS D	By Age: 25-49	3,248		Redacted
VMMC_CIRC_DS D	By Age: 50+	149		Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	7,435		Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	174	129	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	5,626	7,018	Redacted
VMMC_CIRC_DS D	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	1,636	1,572	Redacted
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	7,436	7,147	Redacted

VMMC_CIRC_DS D	By circumcision technique: Device-based VMMC	0		Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	7,436	7,147	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0		Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	7,542	7,008	Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	350	94	Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	752	483	Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	639	662	Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	1,678	1,291	Redacted
PP_PREV_DSD	Age/sex: 50+ Male	26	157	Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	394	786	Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	1,051	874	Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	903	884	Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	1,701	1,613	Redacted
PP_PREV_DSD	Age/sex: 50+ Female	48	164	Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	7,542	7,008	Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0	121,558	Redacted
PP_PREV_TA	Age/sex: 10-14 Male	0	3,347	Redacted
PP_PREV_TA	Age/sex: 15-19 Male	0	10,433	Redacted
PP_PREV_TA	Age/sex: 20-24 Male	0	12,010	Redacted

PP_PREV_TA	Age/sex: 25-49 Male	0	20,585	Redacted
PP_PREV_TA	Age/sex: 10-14 Female	0	4,276	Redacted
PP_PREV_TA	Age/sex: 15-19 Female	0	14,422	Redacted
PP_PREV_TA	Age/sex: 20-24 Female	0	21,614	Redacted
PP_PREV_TA	Age/sex: 25-49 Female	0	31,153	Redacted
PP_PREV_TA	Age/sex: 50+ Female	0	2,053	Redacted
PP_PREV_TA	Sum of Age/Sex disaggregates	0	121,558	Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	920	6,644	Redacted
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	920	6,644	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	123,632	163,619	Redacted
HTC_TST_DSD	By Test Result: Negative	118,176	32,316	Redacted
HTC_TST_DSD	By Test Result: Positive	5,456	131,303	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	123,632	163,619	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	0		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	5,357		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	5,085		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	5,001		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	4,191		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	11,056		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	435		Redacted

HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	0		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	6,547		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	4,939		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	19,365		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	16,944		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	44,378		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	333		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	123,631		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	10,442	5,057	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	20,683	60,081	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	11,486	6,703	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	81,021	91,778	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	21,928	11,760	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	101,704	151,859	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	123,632	163,619	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	3,535	100,447	Redacted
HTC_TST_TA	By Test Result: Negative	3,377	37,944	Redacted
HTC_TST_TA	By Test Result: Positive	158	62,503	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	3,535	100,447	Redacted
HTC_TST_TA	Age/sex: 5-9 Male	161		Redacted
HTC_TST_TA	Age/sex: 10-14 Male	121		Redacted
HTC_TST_TA	Age/sex: 15-19 Male	116		Redacted
HTC_TST_TA	Age/sex: 20-24 Male	97		Redacted
HTC_TST_TA	Age/sex: 25-49 Male	256		Redacted
HTC_TST_TA	Age/sex: 50+ Male	10		Redacted

HTC_TST_TA	Age/sex: 5-9 Female	196		Redacted
HTC_TST_TA	Age/sex: 10-14 Female	148		Redacted
HTC_TST_TA	Age/sex: 15-19 Female	581		Redacted
HTC_TST_TA	Age/sex: 20-24 Female	508		Redacted
HTC_TST_TA	Age/sex: 25-49 Female	1,331		Redacted
HTC_TST_TA	Age/sex: 50+ Female	10		Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	3,535		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	282	3,573	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	478	36,940	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	345	4,731	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,430	55,203	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	627	8,304	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	2,908	92,143	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	3,535	100,447	Redacted
GEND_GBV_DSD	Number of people receiving post-GBV care	211,959	4,261	Redacted
GEND_GBV_DSD	Age: 0-9	0		Redacted
GEND_GBV_DSD	Age: 10-14	4,711		Redacted
GEND_GBV_DSD	Age: 15-17	40,395		Redacted
GEND_GBV_DSD	Age: 18-24	34,410		Redacted
GEND_GBV_DSD	Age: 25+	132,443		Redacted
GEND_GBV_DSD	Sum of Age disaggregates	211,959		Redacted
GEND_GBV_DSD	Sex: Male	115,806		Redacted
GEND_GBV_DSD	Sex: Female	96,153		Redacted
GEND_GBV_DSD	Sum of Sex disaggregates	211,959		Redacted
GEND_GBV_TA	Sum of Age disaggregates	211,959		Redacted
GEND_GBV_TA	Sum of Sex disaggregates	211,959		Redacted
GEND_NORM_DS	Number of people completing an	472,336		Redacted

D	intervention pertaining to gender norms, that meets minimum criteria			
GEND_NORM_DS D	By Age: 10-14	11,475		Redacted
GEND_NORM_DS D	By Age: 15-19	99,640		Redacted
GEND_NORM_DS D	By Age: 20-24	84,878		Redacted
GEND_NORM_DS D	By Age: 25+	276,343		Redacted
GEND_NORM_DS D	Sum of Age disaggregates	472,336		Redacted
GEND_NORM_DS D	By Sex: Male	268,831		Redacted
GEND_NORM_DS D	By Sex: Female	203,505		Redacted
GEND_NORM_DS D	Sum of Sex disaggregates	472,336		Redacted
GEND_NORM_TA	Sum of Sex disaggregates	472,336		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	92,429	82,744	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,666	2,644	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	25,776	3,149	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,636	26,064	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	48,723	50,887	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	80,801	82,744	Redacted

CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	7,325	6,710	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	322	209	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	2,249	2,205	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	300	233	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	4,454	4,063	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	7,325	6,710	Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	7,325	6,710	Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	2,063	1,963	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	27,729	24,727	Redacted
FN_THER_DSD	Aggregated Age: <18	1,269	751	Redacted
FN_THER_DSD	Aggregated Age: 18+	794	1,212	Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	2,063	1,963	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2,196	1,173	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	27,452	1,462	Redacted
TB_ART_DSD	Age: 0-4	4		Redacted

TB_ART_DSD	Age: 5-14	51		Redacted
TB_ART_DSD	Age: 15+	2,141		Redacted
TB_ART_DSD	Male	1,427	419	Redacted
TB_ART_DSD	Female	769	754	Redacted
TB_ART_DSD	Sum of Sex disaggregates	2,196	1,173	Redacted
TB_ART_DSD	Aggregated Age: <15	64	78	Redacted
TB_ART_DSD	Aggregated Age: 15+	2,489	1,095	Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	2,553	1,173	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	3,703	952	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	4,629		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	0	859	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	94,459	93	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	94,459	952	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	5,904		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	81,671	78,312	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2,877		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	24,109	49,680	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	3,111		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	47,673	22,867	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	5,988		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	71,782	72,547	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	77,770	72,547	Redacted

TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	2,526	16,907	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	89		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	746	10,727	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	96		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	1,474	4,936	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	185		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	2,220	15,663	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	2,405	15,663	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	11,508	12,359	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	391		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	2,992	8,040	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	449		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	7,676	3,813	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	11,508	11,853	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	17,259	8,627	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	18,966	10,163	Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating	163		Redacted

	ART)			
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0		Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0		Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0		Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0		Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0		Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are	0		Redacted

	still alive and on treatment at 12 months after initiating ART)			
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0		Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	1		Redacted
LAB_ACC_DSD	By site support type: Direct Service	1		Redacted

	Delivery (DSD)			
LAB_ACC_DSD	Sum of Support Type disaggregates	1		Redacted
LAB_ACC_TA	Sum of Support Type disaggregates	1		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	58	11	Redacted
LAB_CAP_DSD	By clinical laboratories	58	11	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	58		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	58		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	58		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	83,187	82,859	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	92,429	82,744	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	10,367	5,804	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	66,996	77,055	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	77,363	82,859	Redacted
TB_SCREEN_DSD	Sex: Male	26,922	28,751	Redacted
TB_SCREEN_DSD	Sex: Female	50,441	54,108	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	77,363	82,859	Redacted

Implementing Mechanism Details

Mechanism ID: 9240	Mechanism Name: Strengthening HIV Prevention, Care and Treatment among Prisoner
---------------------------	--



	and Staff of the Prisons Service
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Uganda Prisons Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 247,386	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	247,386

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	9240		
Mechanism Name:	Strengthening HIV Prevention, Care and Treatment among Prisoner and Staff of the Prisons Service		
Prime Partner Name:	Uganda Prisons Services		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	79,254	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	14,251	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	21,462	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	14,214	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	110,671	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	7,534	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget
Custom				

				Targets
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	124		Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	137		Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	124		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	83		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	41		Redacted
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0		Redacted
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	124		Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	124		Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,962		Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	2,065		Redacted
PMTCT_STAT_TA	By: Known positives at entry	52		Redacted
PMTCT_STAT_TA	By: Number of new positives identified	85		Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	137		Redacted

PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	1,070		Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	35		Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	83		Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	69		Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	183		Redacted
PP_PREV_DSD	Age/sex: 50+ Male	7		Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	47		Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	152		Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	133		Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	348		Redacted
PP_PREV_DSD	Age/sex: 50+ Female	14		Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	1,071		Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	1,841		Redacted
PP_PREV_TA	Age/sex: 10-14 Male	98		Redacted
PP_PREV_TA	Age/sex: 15-19 Male	104		Redacted
PP_PREV_TA	Age/sex: 20-24 Male	87		Redacted
PP_PREV_TA	Age/sex: 25-49 Male	230		Redacted
PP_PREV_TA	Age/sex: 50+ Male	9		Redacted
PP_PREV_TA	Age/sex: 10-14 Female	120		Redacted
PP_PREV_TA	Age/sex: 15-19 Female	284		Redacted
PP_PREV_TA	Age/sex: 20-24 Female	249		Redacted
PP_PREV_TA	Age/sex: 25-49 Female	651		Redacted
PP_PREV_TA	Age/sex: 50+ Female	9		Redacted
PP_PREV_TA	Sum of Age/Sex disaggregates	1,841		Redacted
HTC_TST_DSD	Number of individuals who received	1,910		Redacted

	T&C services for HIV and received their test results during the past 12 months			
HTC_TST_DSD	By Test Result: Negative	1,852		Redacted
HTC_TST_DSD	By Test Result: Positive	57		Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	1,909		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	0		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	0		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	0		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	0		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	0		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	444		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	389		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	1,018		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	1,851		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,910		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	0		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	1,910		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	1,910		Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	3,413		Redacted
HTC_TST_TA	By Test Result: Negative	3,142		Redacted
HTC_TST_TA	By Test Result: Positive	271		Redacted
HTC_TST_TA	Sum of Test Result disaggregates	3,413		Redacted
HTC_TST_TA	Age/sex: <1 Male	0		Redacted
HTC_TST_TA	Age/sex: 1-4 Male	0		Redacted
HTC_TST_TA	Age/sex: 5-9 Male	325		Redacted

HTC_TST_TA	Age/sex: 10-14 Male	245		Redacted
HTC_TST_TA	Age/sex: 15-19 Male	260		Redacted
HTC_TST_TA	Age/sex: 20-24 Male	218		Redacted
HTC_TST_TA	Age/sex: 25-49 Male	574		Redacted
HTC_TST_TA	Age/sex: 50+ Male	21		Redacted
HTC_TST_TA	Age/sex: 5-9 Female	397		Redacted
HTC_TST_TA	Age/sex: 10-14 Female	300		Redacted
HTC_TST_TA	Age/sex: 15-19 Female	252		Redacted
HTC_TST_TA	Age/sex: 20-24 Female	221		Redacted
HTC_TST_TA	Age/sex: 25-49 Female	578		Redacted
HTC_TST_TA	Age/sex: 50+ Female	21		Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	3,412		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	571		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,073		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	697		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,072		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	1,268		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	2,145		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	3,413		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	2,625		Redacted
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	2,446		Redacted

CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	81		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	780		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	110		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,475		Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	2,446		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	394		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	17		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	121		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	16		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	240		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	394		Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	394		Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	9		Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	10		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART	59		Redacted

	during TB treatment during the reporting period			
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	73		Redacted
TB_ART_DSD	Age: 0-4	0		Redacted
TB_ART_DSD	Age: 5-14	2		Redacted
TB_ART_DSD	Age: 15+	71		Redacted
TB_ART_DSD	Male	47		Redacted
TB_ART_DSD	Female	26		Redacted
TB_ART_DSD	Sum of Sex disaggregates	73		Redacted
TB_ART_DSD	Aggregated Age: <15	2		Redacted
TB_ART_DSD	Aggregated Age: 15+	71		Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	73		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	110		Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	137		Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	110		Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	110		Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	7		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	0		Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	2,170		Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	80		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	673		Redacted

TX_CURR_TA	Aggregated Age/Sex: <15 Female	87		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	1,330		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	167		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	2,003		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	2,170		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	532		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	18		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	138		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	21		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	355		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	532		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	668		Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	734		Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	49		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12	619		Redacted

	months after initiating ART)			
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	54		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	680		Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	2		Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	1		Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	1		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	2		Redacted
LAB_ACC_TA	Sum of Support Type disaggregates	2		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	13		Redacted
LAB_CAP_DSD	By clinical laboratories	13		Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	13		Redacted
LAB_CAP_DSD	Sum of Site Support Type	13		Redacted

	disaggregates			
LAB_CAP_TA	Sum of Site Support Type disaggregates	13		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	2,201		Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	2,625		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	295		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	1,906		Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	2,201		Redacted
TB_SCREEN_DSD	Sex: Male	766		Redacted
TB_SCREEN_DSD	Sex: Female	1,435		Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	2,201		Redacted
TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	2,446		Redacted

Implementing Mechanism Details

Mechanism ID: 9301	Mechanism Name: Strengthening TB and HIV & AIDS Responses in East Central Uganda (STAR-EC)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: John Snow, Inc.	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 8,342,746	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	8,342,746

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	25,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	25,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Gender: GBV	30,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic



	Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	20,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Key Issues

(No data provided.)

Budget Code Information



Mechanism ID:	9301		
Mechanism Name:	Strengthening TB and HIV & AIDS Responses in East Central Uganda		
Prime Partner Name:	(STAR-EC) John Snow, Inc.		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,763,006	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	308,703	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	504,595	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	104,715	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,860,678	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	353,375	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	614,636	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	HTXS	2,604,455	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	178,583	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	11,320
PMTCT_STAT_DSD	Number of new ANC and L&D clients	0	11,914
PMTCT_STAT_DSD	By: Known positives at entry	0	482
PMTCT_STAT_DSD	By: Number of new positives identified	0	51
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	0	533
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	127,076
PMTCT_STAT_TA	Number of new ANC and L&D clients	0	133,766
PMTCT_STAT_TA	By: Known positives at entry	0	3,810
PMTCT_STAT_TA	By: Number of new positives identified	0	425
PMTCT_STAT_TA	Sum of Positives Status disaggregates	0	4,235
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0	
PP_PREV_DSD	Age/sex: 10-14 Male	0	
PP_PREV_DSD	Age/sex: 15-19 Male	0	
PP_PREV_DSD	Age/sex: 20-24 Male	0	
PP_PREV_DSD	Age/sex: 25-49 Male	0	
PP_PREV_DSD	Age/sex: 50+ Male	0	
PP_PREV_DSD	Age/sex: 10-14 Female	0	

PP_PREV_DSD	Age/sex: 15-19 Female	0	
PP_PREV_DSD	Age/sex: 20-24 Female	0	
PP_PREV_DSD	Age/sex: 25-49 Female	0	
PP_PREV_DSD	Age/sex: 50+ Female	0	
PP_PREV_DSD	Sum of Age/Sex disaggregates	0	
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0	302,011
PP_PREV_TA	Age/sex: 10-14 Male	0	14,836
PP_PREV_TA	Age/sex: 15-19 Male	0	26,636
PP_PREV_TA	Age/sex: 20-24 Male	0	29,012
PP_PREV_TA	Age/sex: 25-49 Male	0	51,147
PP_PREV_TA	Age/sex: 50+ Male	0	4,399
PP_PREV_TA	Age/sex: 10-14 Female	0	19,588
PP_PREV_TA	Age/sex: 15-19 Female	0	32,870
PP_PREV_TA	Age/sex: 20-24 Female	0	48,523
PP_PREV_TA	Age/sex: 25-49 Female	0	70,308
PP_PREV_TA	Age/sex: 50+ Female	0	4,692
PP_PREV_TA	Sum of Age/Sex disaggregates	0	302,011
HTC_TST_DSD	By Test Result: Negative	0	165,712
HTC_TST_DSD	Sum of Test Result disaggregates	0	171,826
HTC_TST_DSD	Age/sex: 10-14 Male	0	
HTC_TST_DSD	Age/sex: 15-19 Male	0	
HTC_TST_DSD	Age/sex: 20-24 Male	0	
HTC_TST_DSD	Age/sex: 25-49 Male	0	
HTC_TST_DSD	Age/sex: 50+ Male	0	
HTC_TST_DSD	Sum of Age/Sex disaggregates	0	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	8,708
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0	63,488



HTC_TST_DSD	Sum of Aggregated Age/Sex <15	0	20,253
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	0	151,573
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	0	171,826
HTC_TST_TA	Age/sex: 5-9 Male	0	
HTC_TST_TA	Age/sex: 10-14 Male	0	
HTC_TST_TA	Age/sex: 15-19 Male	0	
HTC_TST_TA	Age/sex: 20-24 Male	0	
HTC_TST_TA	Age/sex: 25-49 Male	0	
HTC_TST_TA	Age/sex: 50+ Male	0	
HTC_TST_TA	Age/sex: 5-9 Female	0	
HTC_TST_TA	Age/sex: 10-14 Female	0	
HTC_TST_TA	Age/sex: 15-19 Female	0	
HTC_TST_TA	Age/sex: 20-24 Female	0	
HTC_TST_TA	Age/sex: 25-49 Female	0	
HTC_TST_TA	Age/sex: 50+ Female	0	
HTC_TST_TA	Sum of Age/Sex disaggregates	0	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	33,950
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0	247,270
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	44,999
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0	342,981
HTC_TST_TA	Sum of Aggregated Age/Sex <15	0	78,949
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	0	590,251
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	0	669,200
GEND_NORM_DSD	By Age: 0-9	0	
GEND_NORM_DSD	By Age: 10-14	0	
GEND_NORM_DSD	By Age: 15-19	0	
GEND_NORM_DSD	By Age: 20-24	0	
GEND_NORM_DSD	By Age: 25+	0	

GEND_NORM_DSD	Sum of Age disaggregates	0	
GEND_NORM_DSD	By Sex: Male	0	
GEND_NORM_DSD	By Sex: Female	0	
GEND_NORM_DSD	Sum of Sex disaggregates	0	
GEND_NORM_TA	Sum of Sex disaggregates	0	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	48,278	10,764
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,593	344
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	15,401	407
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,173	3,391
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	29,112	6,622
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	48,279	10,764
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	11,352	2,475
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	500	76
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	3,485	815
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	465	86
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	6,902	1,498
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	11,352	2,475
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	11,352	2,475
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	1,158	259

FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	12,776	3,259
FN_THER_DSD	Aggregated Age: <18	712	102
FN_THER_DSD	Aggregated Age: 18+	446	157
FN_THER_DSD	Sum of Aggregated Age disaggregates	1,158	259
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,147	92
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,434	115
TB_ART_DSD	Age: 0-4	3	
TB_ART_DSD	Age: 5-14	33	
TB_ART_DSD	Age: 15+	1,398	
TB_ART_DSD	Male	932	32
TB_ART_DSD	Female	502	60
TB_ART_DSD	Sum of Sex disaggregates	1,434	92
TB_ART_DSD	Aggregated Age: <15	36	7
TB_ART_DSD	Aggregated Age: 15+	1,398	85
TB_ART_DSD	Sum of Aggregated Age disaggregates	1,434	92
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	0	423
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	0	
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	0	384
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	0	43

PMTCT_EID_DSD	Sum of Infant Age disaggregates	0	427
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	0	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	43,183	9,426
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,598	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	13,387	5,977
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,727	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	26,471	2,754
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	3,325	
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	39,858	8,731
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	43,183	8,731
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	13,399	3,566
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	456	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	3,484	2,318
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	522	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	8,937	1,098
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	13,399	3,416
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	14,629	3,047
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	17,211	3,586
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	267	
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at	1,599	

	12 months after initiating ART)		
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	13,796	
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,143	
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	14,519	
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,256	
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	15,954	
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	43,450	10,762
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	48,278	10,764
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	5,822	753
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	37,628	10,009
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	43,450	10,762



TB_SCREEN_DSD	Sex: Male	15,120	3,734
TB_SCREEN_DSD	Sex: Female	28,330	7,028
TB_SCREEN_DSD	Sum of Sex disaggregates	43,450	10,762

Implementing Mechanism Details

Mechanism ID: 9303	Mechanism Name: DOD Mechanism
Funding Agency: DOD	Procurement Type: Cooperative Agreement
Prime Partner Name: U.S. Department of Defense (Defense)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 683,266	
Applied Pipeline Amount: 900,000	
Funding Source	Funding Amount
GHP-State	683,266

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Condom programming	5,000
Gender: Gender Equality	5,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Condom procurement	10,000
Gender: GBV	10,000
Focus Area:	GBV Prevention



Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 9303			
Mechanism Name: DOD Mechanism			
Prime Partner Name: U.S. Department of Defense (Defense)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	199,420	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	94,985	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	54,753	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	37,077	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	6,073	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	43,828	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	96,122	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	13,517	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	113,761	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	23,730	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	

PMTCT_ARV_DSD	Life-long ART (including Option B+)	0	
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	0	
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	0	
PMTCT_ARV_DSD	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
PMTCT_ARV_DSD	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	
PMTCT_ARV_DSD	Single-dose nevirapine (with or without tail)	0	
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	0	
PMTCT_ARV_DSD	Sum of New and Current disaggregates	0	
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	266	201
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	296	201
PMTCT_ARV_TA	Life-long ART (including Option B+)	266	
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	178	35
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	88	166
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	

PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0	
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	266	
PMTCT_ARV_TA	Sum of New and Current disaggregates	266	201
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	
PMTCT_STAT_DSD	Number of new ANC and L&D clients	0	
PMTCT_STAT_DSD	By: Known positives at entry	0	
PMTCT_STAT_DSD	By: Number of new positives identified	0	
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	0	
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	4,223	2,045
PMTCT_STAT_TA	Number of new ANC and L&D clients	4,446	2,153
PMTCT_STAT_TA	By: Known positives at entry	112	166
PMTCT_STAT_TA	By: Number of new positives identified	183	35
PMTCT_STAT_TA	Sum of Positives Status disaggregates	295	201
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	17	
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	0	
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	0	
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	17	
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical	10	

	post-operative AE(s)		
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	9	
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	1	
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	16	
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)	16	
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	17	
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	5,167	
VMMC_CIRC_DSD	By Age: <1	0	
VMMC_CIRC_DSD	By Age: 1-9	0	
VMMC_CIRC_DSD	By Age: 10-14	930	
VMMC_CIRC_DSD	By Age: 15-19	1,021	
VMMC_CIRC_DSD	By Age: 20-24	856	
VMMC_CIRC_DSD	By Age: 25-49	2,257	
VMMC_CIRC_DSD	By Age: 50+	103	
VMMC_CIRC_DSD	Sum of age disaggregates	5,167	

VMMC_CIRC_DSD	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	121	
VMMC_CIRC_DSD	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	3,909	
VMMC_CIRC_DSD	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	1,137	
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	2,933	
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	2,234	
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	2,933	
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	
VMMC_CIRC_TA	By Age: <1	0	
VMMC_CIRC_TA	By Age: 1-9	0	
VMMC_CIRC_TA	By Age: 10-14	0	
VMMC_CIRC_TA	By Age: 15-19	0	
VMMC_CIRC_TA	By Age: 20-24	0	
VMMC_CIRC_TA	By Age: 25-49	0	
VMMC_CIRC_TA	By Age: 50+	0	
VMMC_CIRC_TA	Sum of Age disaggregations	0	
VMMC_CIRC_TA	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	0	
VMMC_CIRC_TA	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	0	

VMMC_CIRC_TA	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	
VMMC_CIRC_TA	By circumcision technique: Surgical VMMC	0	
VMMC_CIRC_TA	By circumcision technique: Device-based VMMC	0	
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	0	
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	11,525	
PP_PREV_DSD	Age/sex: 10-14 Male	373	
PP_PREV_DSD	Age/sex: 15-19 Male	890	
PP_PREV_DSD	Age/sex: 20-24 Male	746	
PP_PREV_DSD	Age/sex: 25-49 Male	1,968	
PP_PREV_DSD	Age/sex: 50+ Male	80	
PP_PREV_DSD	Age/sex: 10-14 Female	508	
PP_PREV_DSD	Age/sex: 15-19 Female	1,635	
PP_PREV_DSD	Age/sex: 20-24 Female	1,431	
PP_PREV_DSD	Age/sex: 25-49 Female	3,747	
PP_PREV_DSD	Age/sex: 50+ Female	146	
PP_PREV_DSD	Sum of Age/Sex disaggregates	11,524	
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	9,653	3,516
PP_PREV_TA	Age/sex: 10-14 Male	901	55

PP_PREV_TA	Age/sex: 15-19 Male	982	525
PP_PREV_TA	Age/sex: 20-24 Male	823	842
PP_PREV_TA	Age/sex: 25-49 Male	2,170	940
PP_PREV_TA	Age/sex: 50+ Male	88	40
PP_PREV_TA	Age/sex: 10-14 Female	663	66
PP_PREV_TA	Age/sex: 15-19 Female	955	222
PP_PREV_TA	Age/sex: 20-24 Female	836	328
PP_PREV_TA	Age/sex: 25-49 Female	2,189	466
PP_PREV_TA	Age/sex: 50+ Female	48	32
PP_PREV_TA	Sum of Age/Sex disaggregates	9,655	3,516
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	

KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	9,092	
HTC_TST_DSD	By Test Result: Negative	8,819	
HTC_TST_DSD	By Test Result: Positive	273	
HTC_TST_DSD	Sum of Test Result disaggregates	9,092	
HTC_TST_DSD	Age/sex: <1 Male	0	
HTC_TST_DSD	Age/sex: 1-4 Male	0	
HTC_TST_DSD	Age/sex: 5-9 Male	0	
HTC_TST_DSD	Age/sex: 10-14 Male	897	
HTC_TST_DSD	Age/sex: 15-19 Male	984	
HTC_TST_DSD	Age/sex: 20-24 Male	825	
HTC_TST_DSD	Age/sex: 25-49 Male	2,176	
HTC_TST_DSD	Age/sex: 50+ Male	100	
HTC_TST_DSD	Age/sex: <1 Female	0	
HTC_TST_DSD	Age/sex: 1-4 Female	0	
HTC_TST_DSD	Age/sex: 5-9 Female	0	
HTC_TST_DSD	Age/sex: 10-14 Female	0	
HTC_TST_DSD	Age/sex: 15-19 Female	987	
HTC_TST_DSD	Age/sex: 20-24 Female	862	
HTC_TST_DSD	Age/sex: 25-49 Female	2,261	
HTC_TST_DSD	Age/sex: 50+ Female	0	
HTC_TST_DSD	Sum of Age/Sex disaggregates	9,092	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	897	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ	4,084	

	PERMISSION ONLY: 15+ Male		
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	4,111	
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	897	
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	8,195	
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	9,092	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	19,034	51,348
HTC_TST_TA	By Test Result: Negative	17,625	49,423
HTC_TST_TA	By Test Result: Positive	1,409	1,925
HTC_TST_TA	Sum of Test Result disaggregates	19,034	51,348
HTC_TST_TA	Age/sex: <1 Male	0	
HTC_TST_TA	Age/sex: 1-4 Male	0	
HTC_TST_TA	Age/sex: 5-9 Male	1,797	
HTC_TST_TA	Age/sex: 10-14 Male	1,356	
HTC_TST_TA	Age/sex: 15-19 Male	1,470	
HTC_TST_TA	Age/sex: 20-24 Male	1,232	
HTC_TST_TA	Age/sex: 25-49 Male	3,249	
HTC_TST_TA	Age/sex: 50+ Male	121	
HTC_TST_TA	Age/sex: <1 Female	0	
HTC_TST_TA	Age/sex: 1-4 Female	0	
HTC_TST_TA	Age/sex: 5-9 Female	2,196	
HTC_TST_TA	Age/sex: 10-14 Female	1,657	
HTC_TST_TA	Age/sex: 15-19 Female	1,401	
HTC_TST_TA	Age/sex: 20-24 Female	1,226	
HTC_TST_TA	Age/sex: 25-49 Female	3,210	
HTC_TST_TA	Age/sex: 50+ Female	119	
HTC_TST_TA	Sum of Age/Sex disaggregates	19,034	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ	3,153	2,600

	PERMISSION ONLY: <15 Male		
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	6,072	18,972
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,853	3,446
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	5,956	26,330
HTC_TST_TA	Sum of Aggregated Age/Sex <15	7,006	6,046
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	12,028	45,302
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	19,034	51,348
GEND_GBV_DSD	Number of people receiving post-GBV care	406	
GEND_GBV_DSD	Age: 0-9	0	
GEND_GBV_DSD	Age: 10-14	0	
GEND_GBV_DSD	Age: 15-17	66	
GEND_GBV_DSD	Age: 18-24	57	
GEND_GBV_DSD	Age: 25+	283	
GEND_GBV_DSD	Sum of Age disaggregates	406	
GEND_GBV_DSD	Sex: Male	175	
GEND_GBV_DSD	Sex: Female	231	
GEND_GBV_DSD	Sum of Sex disaggregates	406	
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	0	
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	0	
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	0	
GEND_GBV_TA	Sum of Age disaggregates	406	
GEND_GBV_TA	Sum of Sex disaggregates	406	
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	428	
GEND_NORM_DSD	By Age: 0-9	0	
GEND_NORM_DSD	By Age: 10-14	0	



GEND_NORM_DSD	By Age: 15-19	76	
GEND_NORM_DSD	By Age: 20-24	65	
GEND_NORM_DSD	By Age: 25+	287	
GEND_NORM_DSD	Sum of Age disaggregates	428	
GEND_NORM_DSD	By Sex: Male	240	
GEND_NORM_DSD	By Sex: Female	188	
GEND_NORM_DSD	Sum of Sex disaggregates	428	
GEND_NORM_DSD	By type of activity: Individual	0	
GEND_NORM_DSD	By type of activity: Small Group	0	
GEND_NORM_DSD	By type of activity: Community-level	0	
GEND_NORM_TA	Sum of Sex disaggregates	428	
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	1,158	916
OVC_ACC_DSD	Sex: Male	526	
OVC_ACC_DSD	Sex: Female	632	
OVC_ACC_DSD	Sum of Sex disaggregates	1,158	
OVC_ACC_DSD	Age: <1	49	
OVC_ACC_DSD	Age: 1-4	183	
OVC_ACC_DSD	Age: 5-9	324	
OVC_ACC_DSD	Age: 10-14	331	
OVC_ACC_DSD	Age: 15-17	213	
OVC_ACC_DSD	Age: 18+	58	
OVC_ACC_DSD	Sum of Age disaggregates	1,158	
OVC_ACC_TA	Sum of Sex disaggregates	1,158	
OVC_ACC_TA	Sum of Age disaggregates	1,158	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	6,328	1,782
OVC_SERV_DSD	Sex: Male	2,873	
OVC_SERV_DSD	Sex: Female	3,455	
OVC_SERV_DSD	Sum of Sex disaggregates	6,328	

OVC_SERV_DSD	Age: <1	266	
OVC_SERV_DSD	Age: 1-4	1,000	
OVC_SERV_DSD	Age: 5-9	1,772	
OVC_SERV_DSD	Age: 10-14	1,810	
OVC_SERV_DSD	Age: 15-17	1,164	
OVC_SERV_DSD	Age: 18+	316	
OVC_SERV_DSD	Sum of Age disaggregates	6,328	
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	0	
OVC_SERV_TA	Sex: Male	0	
OVC_SERV_TA	Sex: Female	0	
OVC_SERV_TA	Sum of Sex disaggregates	0	
OVC_SERV_TA	Age: <1	0	
OVC_SERV_TA	Age: 1-4	0	
OVC_SERV_TA	Age: 5-9	0	
OVC_SERV_TA	Age: 10-14	0	
OVC_SERV_TA	Age: 15-17	0	
OVC_SERV_TA	Age: 18+	0	
OVC_SERV_TA	Sum of Age disaggregates	0	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	
CARE_CURR_DSD	Age/sex: <1 Male	0	
CARE_CURR_DSD	Age/sex: 1-4 Male	0	
CARE_CURR_DSD	Age/sex: 5-9 Male	0	
CARE_CURR_DSD	Age/sex: 10-14 Male	0	
CARE_CURR_DSD	Age/sex: 15-19 Male	0	
CARE_CURR_DSD	Age/sex: 20-24 Male	0	
CARE_CURR_DSD	Age/sex: 25-49 Male	0	
CARE_CURR_DSD	Age/sex: 50+ Male	0	

CARE_CURR_DSD	Age/sex: <1 Female	0	
CARE_CURR_DSD	Age/sex: 1-4 Female	0	
CARE_CURR_DSD	Age/sex: 5-9 Female	0	
CARE_CURR_DSD	Age/sex: 10-14 Female	0	
CARE_CURR_DSD	Age/sex: 15-19 Female	0	
CARE_CURR_DSD	Age/sex: 20-24 Female	0	
CARE_CURR_DSD	Age/sex: 25-49 Female	0	
CARE_CURR_DSD	Age/sex: 50+ Female	0	
CARE_CURR_DSD	Sun of Age/Sex disaggregates	0	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0	
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	0	
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	26,334	5,071
CARE_CURR_TA	Age/sex: <1 Male	0	
CARE_CURR_TA	Age/sex: 1-4 Male	0	
CARE_CURR_TA	Age/sex: 5-9 Male	0	
CARE_CURR_TA	Age/sex: 10-14 Male	0	
CARE_CURR_TA	Age/sex: 15-19 Male	0	
CARE_CURR_TA	Age/sex: 20-24 Male	0	
CARE_CURR_TA	Age/sex: 25-49 Male	0	
CARE_CURR_TA	Age/sex: 50+ Male	0	
CARE_CURR_TA	Age/sex: <1 Female	0	
CARE_CURR_TA	Age/sex: 1-4 Female	0	

CARE_CURR_TA	Age/sex: 5-9 Female	0	
CARE_CURR_TA	Age/sex: 10-14 Female	0	
CARE_CURR_TA	Age/sex: 15-19 Female	0	
CARE_CURR_TA	Age/sex: 20-24 Female	0	
CARE_CURR_TA	Age/sex: 25-49 Female	0	
CARE_CURR_TA	Age/sex: 50+ Female	0	
CARE_CURR_TA	Sum of Age/Sex disaggregates	0	
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	869	163
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	8,401	192
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,185	1,596
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	15,879	3,120
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	26,334	5,071
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	2,025	
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	89	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	622	
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	83	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	1,231	
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	2,025	
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	2,025	
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	0	
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	0	

FN_THER_DSD	Age: <1	0	
FN_THER_DSD	Age: 1-4	0	
FN_THER_DSD	Age: 5-14	0	
FN_THER_DSD	Age: 15-17	0	
FN_THER_DSD	Age: 18+	0	
FN_THER_DSD	Sum of Age disaggregates	0	
FN_THER_DSD	Aggregated Age: <18	0	
FN_THER_DSD	Aggregated Age: 18+	0	
FN_THER_DSD	Sum of Aggregated Age disaggregates	0	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	626	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	782	
TB_ART_DSD	Age: 0-4	2	
TB_ART_DSD	Age: 5-14	18	
TB_ART_DSD	Age: 15+	762	
TB_ART_DSD	Male	508	
TB_ART_DSD	Female	274	
TB_ART_DSD	Sum of Sex disaggregates	782	
TB_ART_DSD	Newly tested	3	
TB_ART_DSD	Known HIV-positive	96	
TB_ART_DSD	Sum of Test Status disaggregates	99	
TB_ART_DSD	Aggregated Age: <15	20	
TB_ART_DSD	Aggregated Age: 15+	762	
TB_ART_DSD	Sum of Aggregated Age disaggregates	782	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	237	
PMTCT_EID_DSD	Number of HIV- positive pregnant women	296	

	identified during the reporting period (include known HIV-positive women at entry into PMTCT)		
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	0	
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	237	
PMTCT_EID_DSD	Sum of Infant Age disaggregates	237	
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	15	
TX_CURR_DSD	Age/Sex: <1 Male	0	
TX_CURR_DSD	Age/Sex: 1-4 Male	0	
TX_CURR_DSD	Age/Sex: 5-14 Male	0	
TX_CURR_DSD	Age/Sex: 15+ Male	0	
TX_CURR_DSD	Age/Sex: <1 Female	0	
TX_CURR_DSD	Age/Sex: 1-4 Female	0	
TX_CURR_DSD	Age/Sex: 5-14 Female	0	
TX_CURR_DSD	Age/Sex: 15+ Female	0	
TX_CURR_DSD	Sum of age/sex disaggregates	0	
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	0	
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	0	
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	0	
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	0	
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	0	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	23,678	4,710
TX_CURR_TA	Age/Sex: <1 Male	0	
TX_CURR_TA	Age/Sex: 1-4 Male	0	

TX_CURR_TA	Age/Sex: 5-14 Male	0	
TX_CURR_TA	Age/Sex: 15+ Male	0	
TX_CURR_TA	Age/Sex: <1 Female	0	
TX_CURR_TA	Sum of Age/Sex disaggregations	0	
TX_CURR_TA	Aggregated Age/Sex: <15 Male	876	
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	7,340	2,986
TX_CURR_TA	Aggregated Age/Sex: <15 Female	947	
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	14,515	1,376
TX_CURR_TA	Sum of Aggregated Age/Sex <15	1,823	
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	21,855	4,362
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	23,678	4,362
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4,294	
TX_NEW_DSD	By Age/Sex: <1 Male	0	
TX_NEW_DSD	By Age/Sex: 1-4 Male	0	
TX_NEW_DSD	By Age/Sex: 5-9 Male	0	
TX_NEW_DSD	By Age/Sex: 10-14 Male	0	
TX_NEW_DSD	By Age/Sex: 15-19 Male	0	
TX_NEW_DSD	By Age/Sex: 20-24 Male	0	
TX_NEW_DSD	By Age/Sex: 25-49 Male	0	
TX_NEW_DSD	By Age/Sex: 50+ Male	0	
TX_NEW_DSD	By Age/Sex: <1 Female	0	
TX_NEW_DSD	By Age/Sex: 1-4 Female	0	
TX_NEW_DSD	By Age/Sex: 5-9 Female	0	
TX_NEW_DSD	By Age/Sex: 10-14 Female	0	
TX_NEW_DSD	By Age/Sex: 15-19 Female	0	
TX_NEW_DSD	By Age/Sex: 20-24 Female	0	
TX_NEW_DSD	By Age/Sex: 25-49 Female	0	
TX_NEW_DSD	By Age/Sex: 50+ Female	0	
TX_NEW_DSD	Sum of Age/Sex disaggregates	0	
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	0	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	146	

TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,116	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	0	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	167	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,865	
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	4,294	
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	7,279	
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	7,998	
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those	0	

	lost to follow-up)		
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	531	
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,747	
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	584	
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,415	
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	

LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	0	
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	0	
LAB_ACC_DSD	Sum of Support Type disaggregates	0	
LAB_ACC_TA	Sum of Support Type disaggregates	0	
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	0	
LAB_CAP_DSD	By clinical laboratories	0	
LAB_CAP_DSD	By Point-of-care testing sites	0	
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	0	
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	0	
LAB_CAP_DSD	Sum of Site Support Type disaggregates	0	
LAB_CAP_TA	Sum of Site Support Type disaggregates	0	
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	0	
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	0	
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0	
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	0	
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	0	
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0	
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	0	
LAB_PT_DSD	Early infant diagnostics: Number of	0	

	laboratories that participate in this PT program		
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0	
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	0	
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	0	
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0	
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that perform this testing	0	
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that participate in this PT program	0	
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0	
HRH_PRE	By Graduates: Doctors	0	
HRH_PRE	By Graduates: Nurses	0	
HRH_PRE	By Graduates: Midwives	0	
HRH_PRE	By Graduates: Social service workers	0	
HRH_PRE	By Graduates: Laboratory professionals	0	
HRH_PRE	By Graduates: Other	0	
HRH_PRE	Sum of Graduates disaggreagtes	0	
HRH_PRE	By new graduates who are licensed and registered: Doctors	0	
HRH_PRE	By new graduates who are licensed and registered: Nurses	0	
HRH_PRE	By new graduates who are licensed and registered: Midwives	0	

HRH_PRE	By new graduates who are licensed and registered: Social service workers	0	
HRH_PRE	By new graduates who are licensed and registered: Laboratorians	0	
HRH_PRE	By new graduates who are licensed and registered: Other (where applicable)	0	
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	0	
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	0	
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	0	
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0	
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	0	
FPINT_SITE_DSD	Service delivery type: Community	0	

FPINT_SITE_DSD	Service delivery type: Clinical	0	
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	0	
FPINT_SITE_TA	Sum of Denominator Site Support Type disaggregates	0	
FPINT_SITE_TA	Sum of Numerator Site Support Type disaggregates	0	
FPINT_SITE_TA	Sum of Service Delivery Type disaggregates	0	
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	23,701	
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	
TB_SCREEN_DSD	Age: <1	0	
TB_SCREEN_DSD	Age: 1-4	0	
TB_SCREEN_DSD	Age: 5-9	0	
TB_SCREEN_DSD	Age: 10-14	0	
TB_SCREEN_DSD	Age: 15-19	0	
TB_SCREEN_DSD	Age: 20-24	0	
TB_SCREEN_DSD	Age: 25-49	0	
TB_SCREEN_DSD	Age: 50+	0	
TB_SCREEN_DSD	Sum of Age disaggregates	0	
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	3,176	
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	20,525	
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	23,701	
TB_SCREEN_DSD	Sex: Male	8,249	
TB_SCREEN_DSD	Sex: Female	15,452	
TB_SCREEN_DSD	Sum of Sex disaggregates	23,701	
TB_SCREEN_TA	Number of HIV positive adults and children	26,334	5,071



	<p>who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load</p>		
--	---	--	--

Implementing Mechanism Details

Mechanism ID: 9483	Mechanism Name: Expansion of Routine Confidential HCT and provision of basic Care in Clinics, Hospitals and HC lvs
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Infectious Disease Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GAP	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)



Budget Code Information

Mechanism ID:	9483		
Mechanism Name:	Expansion of Routine Confidential HCT and provision of basic Care in Clinics, Hospitals and HC Ivs		
Prime Partner Name:	Infectious Disease Institute		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	2,792		Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	3,102		Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	2,792		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	1,871		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	921		Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	2,792		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	2,792		Redacted
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of	4,017		Redacted

	mother-to-child-transmission (MTCT) during pregnancy and delivery			
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	4,464		Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	4,017		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	2,692		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,325		Redacted
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0		Redacted
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	4,017		Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	4,017		Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	44,312		Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	46,645		Redacted
PMTCT_STAT_DS D	By: Known positives at entry	1,179		Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	1,923		Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	3,102		Redacted

PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	63,767		Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	67,123		Redacted
PMTCT_STAT_TA	By: Known positives at entry	1,696		Redacted
PMTCT_STAT_TA	By: Number of new positives identified	2,767		Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	4,463		Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	15,159		Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	490		Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	1,171		Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	981		Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	2,588		Redacted
PP_PREV_DSD	Age/sex: 50+ Male	105		Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	669		Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	2,151		Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	1,882		Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	4,929		Redacted
PP_PREV_DSD	Age/sex: 50+ Female	193		Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	15,159		Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	60,104		Redacted
PP_PREV_TA	Total number of people in the target population	0		Redacted
PP_PREV_TA	Age/sex: 10-14 Male	1,922		Redacted
PP_PREV_TA	Age/sex: 15-19 Male	1,581		Redacted

PP_PREV_TA	Age/sex: 20-24 Male	1,325		Redacted
PP_PREV_TA	Age/sex: 25-49 Male	3,496		Redacted
PP_PREV_TA	Age/sex: 50+ Male	131		Redacted
PP_PREV_TA	Age/sex: 10-14 Female	2,349		Redacted
PP_PREV_TA	Age/sex: 15-19 Female	11,797		Redacted
PP_PREV_TA	Age/sex: 20-24 Female	10,323		Redacted
PP_PREV_TA	Age/sex: 25-49 Female	27,036		Redacted
PP_PREV_TA	Age/sex: 50+ Female	144		Redacted
PP_PREV_TA	Sum of Age/Sex disaggregates	60,104		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	105,204	220,744	Redacted
HTC_TST_DSD	By Test Result: Negative	102,048	213,945	Redacted
HTC_TST_DSD	By Test Result: Positive	3,156	6,799	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	105,204	220,744	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	25,249		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	22,093		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	57,862		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	105,204		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	11,217	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0	81,568	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	105,204	113,094	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	0	26,082	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	105,204	194,662	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	105,204	220,744	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	59,215	141,308	Redacted
HTC_TST_TA	By Test Result: Negative	55,811	136,942	Redacted

HTC_TST_TA	By Test Result: Positive	3,404	4,366	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	59,215	141,308	Redacted
HTC_TST_TA	Age/sex: <1 Male	0		Redacted
HTC_TST_TA	Age/sex: 1-4 Male	0		Redacted
HTC_TST_TA	Age/sex: 5-9 Male	6,370		Redacted
HTC_TST_TA	Age/sex: 10-14 Male	4,806		Redacted
HTC_TST_TA	Age/sex: 15-19 Male	3,954		Redacted
HTC_TST_TA	Age/sex: 20-24 Male	3,313		Redacted
HTC_TST_TA	Age/sex: 25-49 Male	8,740		Redacted
HTC_TST_TA	Age/sex: 50+ Male	327		Redacted
HTC_TST_TA	Age/sex: <1 Female	0		Redacted
HTC_TST_TA	Age/sex: 1-4 Female	0		Redacted
HTC_TST_TA	Age/sex: 5-9 Female	7,786		Redacted
HTC_TST_TA	Age/sex: 10-14 Female	5,874		Redacted
HTC_TST_TA	Age/sex: 15-19 Female	4,244		Redacted
HTC_TST_TA	Age/sex: 20-24 Female	3,714		Redacted
HTC_TST_TA	Age/sex: 25-49 Female	9,726		Redacted
HTC_TST_TA	Age/sex: 50+ Female	361		Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	59,215		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	11,176	7,179	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	16,334	52,215	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	13,660	9,517	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	18,045	72,397	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	24,836	16,696	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	34,379	124,612	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	59,215	141,308	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of	12,424		Redacted

	the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load			
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	410		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,963		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	559		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	7,492		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	12,424		Redacted
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	22,087		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	729		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	7,046		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	994		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	13,318		Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	22,087		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	9,115		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	406		Redacted

CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	2,834		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	378		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	5,612		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	9,230		Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	9,230		Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	828		Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	11,146		Redacted
FN_THER_DSD	Aggregated Age: <18	509		Redacted
FN_THER_DSD	Aggregated Age: 18+	319		Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	828		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	883		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,103		Redacted
TB_ART_DSD	Age: 0-4	2		Redacted
TB_ART_DSD	Age: 5-14	24		Redacted
TB_ART_DSD	Age: 15+	999		Redacted
TB_ART_DSD	Male	666		Redacted
TB_ART_DSD	Female	359		Redacted
TB_ART_DSD	Sum of Sex disaggregates	1,025		Redacted
TB_ART_DSD	Aggregated Age: <15	26		Redacted
TB_ART_DSD	Aggregated Age: 15+	999		Redacted

TB_ART_DSD	Sum of Aggregated Age disaggregates	1,025		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	6,052		Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	7,566		Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	6,052		Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	6,052		Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	378		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	32,545		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	423		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	3,547		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	458		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	7,015		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	881		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	10,562		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	11,443		Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	19,484		Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	721		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	6,040		Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	779		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	11,944		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	1,500		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	17,984		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex	19,484		Redacted

	disaggregates			
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	10,761		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	366		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	2,798		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	420		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	7,177		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	10,761		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	12,364		Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	13,587		Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	903		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11,461		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	992		Redacted

	those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12,595		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	94		Redacted
LAB_CAP_DSD	By clinical laboratories	94		Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	94		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	94		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	94		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	31,060		Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	12,424		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	4,162		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	26,898		Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	31,060		Redacted
TB_SCREEN_DSD	Sex: Male	10,809		Redacted
TB_SCREEN_DSD	Sex: Female	20,251		Redacted

TB_SCREEN_DSD	Sum of Sex disaggregates	31,060		Redacted
TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	22,087		Redacted

Implementing Mechanism Details

Mechanism ID: 9541	Mechanism Name: Strengthening the Tuberculosis and HIV/AIDS Response in the South Western Region of Uganda (STAR-SW)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 722,394	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	722,394

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	10,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information



Sub Area:	Implementation
Key Populations: FSW	10,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Condom programming	20,000

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	9541		
Mechanism Name:	Strengthening the Tuberculosis and HIV/AIDS Response in the South		
Prime Partner Name:	Western Region of Uganda (STAR-SW)		
	Elizabeth Glaser Pediatric AIDS Foundation		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	722,394	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	

PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0	
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	0	
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	98	72
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	3	
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	3	
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	33	
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	91	
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	83	
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	8	
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	16	
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical	16	

	device-related AE(s), but no severe medical device-related AE(s)		
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	33	
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	29,821	21,296
VMMC_CIRC_DSD	By Age: 10-14	5,367	
VMMC_CIRC_DSD	By Age: 15-19	5,892	
VMMC_CIRC_DSD	By Age: 20-24	4,938	
VMMC_CIRC_DSD	By Age: 25-49	13,028	
VMMC_CIRC_DSD	By Age: 50+	596	
VMMC_CIRC_DSD	Sum of age disaggregates	29,821	
VMMC_CIRC_DSD	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	697	384
VMMC_CIRC_DSD	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	22,562	16,228
VMMC_CIRC_DSD	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	6,560	4,687
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	27,590	19,168
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	2,231	2,133
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	27,586	21,296
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	

PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0	
PP_PREV_DSD	Age/sex: 10-14 Male	0	
PP_PREV_DSD	Age/sex: 15-19 Male	0	
PP_PREV_DSD	Age/sex: 20-24 Male	0	
PP_PREV_DSD	Age/sex: 25-49 Male	0	
PP_PREV_DSD	Age/sex: 50+ Male	0	
PP_PREV_DSD	Age/sex: 10-14 Female	0	
PP_PREV_DSD	Age/sex: 15-19 Female	0	
PP_PREV_DSD	Age/sex: 20-24 Female	0	
PP_PREV_DSD	Age/sex: 25-49 Female	0	
PP_PREV_DSD	Age/sex: 50+ Female	0	
PP_PREV_DSD	Sum of Age/Sex disaggregates	0	
HTC_TST_DSD	Age/sex: <1 Male	0	
HTC_TST_DSD	Age/sex: 1-4 Male	0	
HTC_TST_DSD	Sum of Age/Sex disaggregates	0	
HTC_TST_TA	Age/sex: <1 Male	0	
HTC_TST_TA	Age/sex: 1-4 Male	0	
HTC_TST_TA	Sum of Age/Sex disaggregates	0	
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	0	
GEND_NORM_DSD	By Age: 0-9	0	
GEND_NORM_DSD	By Age: 10-14	0	
GEND_NORM_DSD	By Age: 15-19	0	
GEND_NORM_DSD	By Age: 20-24	0	
GEND_NORM_DSD	By Age: 25+	0	
GEND_NORM_DSD	Sum of Age disaggregates	0	
GEND_NORM_DSD	By Sex: Male	0	
GEND_NORM_DSD	By Sex: Female	0	

GEND_NORM_DSD	Sum of Sex disaggregates	0	
GEND_NORM_TA	Sum of Sex disaggregates	0	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	67,114	51,158
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,215	1,633
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	21,410	1,942
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,020	16,120
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	40,469	31,463
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	67,114	51,158
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	15,743	16,440
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	519	528
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	5,021	626
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	708	5,169
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	9,495	10,117
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	15,743	16,440
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical	19,086	3,275

	assessment (WHO staging) OR CD4 count OR viral load		
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	839	104
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	5,859	1,063
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	782	118
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	11,602	1,990
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	19,082	3,275
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	19,082	3,275
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2,969	817
TB_ART_DSD	Age: 0-4	6	
TB_ART_DSD	Age: 5-14	68	
TB_ART_DSD	Age: 15+	2,895	
TB_ART_DSD	Male	1,930	292
TB_ART_DSD	Female	1,039	525
TB_ART_DSD	Sum of Sex disaggregates	2,969	817
TB_ART_DSD	Aggregated Age: <15	74	62
TB_ART_DSD	Aggregated Age: 15+	2,895	755
TB_ART_DSD	Sum of Aggregated Age disaggregates	2,969	817
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	0	4,257
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	0	
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	0	3,835
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	0	420
PMTCT_EID_DSD	Sum of Infant Age disaggregates	0	4,255

PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	0	
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2,611	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	21,874	30,259
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	2,822	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	43,255	13,983
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	5,433	
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	65,129	44,242
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	70,562	44,242
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	16,552	15,515
TX_CURR_TA	Aggregated Age/Sex: <15 Male	612	
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	5,132	9,884
TX_CURR_TA	Aggregated Age/Sex: <15 Female	662	
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	10,146	4,487
TX_CURR_TA	Sum of Aggregated Age/Sex <15	1,274	
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	15,278	14,371
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	16,552	14,371
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	22,968	8,374
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	940	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	7,195	5,450
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1,078	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	18,450	2,576
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	27,663	8,026
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	37,974	11,929
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including	44,676	14,022

	those who have died, those who have stopped ART, and those lost to follow-up		
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	390	
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,770	
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	25,741	
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	428	
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,945	
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	28,287	
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,160	
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	25,741	

TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,374	
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	28,287	
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8,767	
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9,634	
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	8	
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	8	
LAB_ACC_DSD	Sum of Support Type disaggregates	8	
LAB_ACC_TA	Sum of Support Type disaggregates	8	
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical	156	31



	laboratory tests		
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	156	
LAB_CAP_DSD	Sum of Site Support Type disaggregates	156	
LAB_CAP_TA	Sum of Site Support Type disaggregates	156	
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	221	
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	233	
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	221	
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	221	
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	221	
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0	
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	221	
FPINT_SITE_DSD	Service delivery type: Community	0	
FPINT_SITE_DSD	Service delivery type: Clinical	221	



FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	221	
FPINT_SITE_TA	Sum of Denominator Site Support Type disaggregates	221	
FPINT_SITE_TA	Sum of Numerator Site Support Type disaggregates	221	
FPINT_SITE_TA	Sum of Service Delivery Type disaggregates	221	
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	74,571	51,247
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	67,114	51,158
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	9,993	3,586
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	64,578	47,661
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	74,571	51,247
TB_SCREEN_DSD	Sex: Male	25,951	17,776
TB_SCREEN_DSD	Sex: Female	48,620	33,471
TB_SCREEN_DSD	Sum of Sex disaggregates	74,571	51,247
TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	15,743	16,440

Implementing Mechanism Details

Mechanism ID: 9879	Mechanism Name: STRENGTHENING TUBERCULOSIS AND HIV/AIDS RESPONSES IN THE EASTERN REGION OF UGANDA (STAR-E)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Management Sciences for Health	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	9879		
Mechanism Name:	STRENGTHENING TUBERCULOSIS AND HIV/AIDS RESPONSES IN THE		
Prime Partner Name:	EASTERN REGION OF UGANDA (STAR-E)		
	Management Sciences for Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
------------------	-------	------	------

PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0	
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	0	
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	3,636	5,578
VMMC_CIRC_DSD	By Age: 10-14	654	
VMMC_CIRC_DSD	By Age: 15-19	718	
VMMC_CIRC_DSD	By Age: 20-24	603	
VMMC_CIRC_DSD	By Age: 25-49	1,588	
VMMC_CIRC_DSD	By Age: 50+	73	
VMMC_CIRC_DSD	Sum of age disaggregates	3,636	
VMMC_CIRC_DSD	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	85	100
VMMC_CIRC_DSD	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	2,751	4,251
VMMC_CIRC_DSD	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	800	1,227
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	1,402	5,020
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	2,234	558
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	1,402	5,020
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who did NOT return for	0	

	follow-up care within 14 days of circumcision surgery		
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0	4,460
PP_PREV_DSD	Total number of people in the target population	0	12,880
PP_PREV_DSD	Age/sex: 10-14 Male	0	
PP_PREV_DSD	Age/sex: 15-19 Male	0	538
PP_PREV_DSD	Age/sex: 20-24 Male	0	558
PP_PREV_DSD	Age/sex: 25-49 Male	0	1,028
PP_PREV_DSD	Age/sex: 50+ Male	0	89
PP_PREV_DSD	Age/sex: 10-14 Female	0	
PP_PREV_DSD	Age/sex: 15-19 Female	0	480
PP_PREV_DSD	Age/sex: 20-24 Female	0	699
PP_PREV_DSD	Age/sex: 25-49 Female	0	1,000
PP_PREV_DSD	Age/sex: 50+ Female	0	68
PP_PREV_DSD	Sum of Age/Sex disaggregates	0	4,460
HTC_TST_DSD	Age/sex: 50+ Male	0	
HTC_TST_DSD	Sum of Age/Sex disaggregates	0	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	38,796	11,322
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,280	361
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	12,376	432
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,746	3,567
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	23,394	6,962

CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	38,796	11,322
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	8,456	2,284
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	372	56
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	2,596	809
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	347	79
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	5,141	1,340
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	8,456	2,284
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	8,456	2,284
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	0	270
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	0	3,394
FN_THER_DSD	Aggregated Age: <18	573	111
FN_THER_DSD	Aggregated Age: 18+	358	159
FN_THER_DSD	Sum of Aggregated Age disaggregates	931	270
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	0	247
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	0	314
TB_ART_DSD	Age: 0-4	2	
TB_ART_DSD	Age: 5-14	27	
TB_ART_DSD	Age: 15+	1,123	
TB_ART_DSD	Male	749	84

TB_ART_DSD	Female	403	163
TB_ART_DSD	Sum of Sex disaggregates	1,152	247
TB_ART_DSD	Aggregated Age: <15	29	21
TB_ART_DSD	Aggregated Age: 15+	1,123	226
TB_ART_DSD	Sum of Aggregated Age disaggregates	1,152	247
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	35,322	10,659
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,307	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	10,950	6,762
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,413	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	21,652	3,113
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,720	
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	32,602	9,875
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	35,322	9,875
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	11,134	3,082
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	379	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	2,895	2,004
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	434	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	7,426	946
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	11,134	2,950
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	14,200	3,666
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	16,707	4,318
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at	0	

	12 months after initiating ART)		
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have	0	

	died, those who have stopped ART, and those lost to follow-up)		
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	150	
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	158	
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	150	
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	

FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	150	
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	150	
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0	
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	150	
FPINT_SITE_DSD	Service delivery type: Community	0	
FPINT_SITE_DSD	Service delivery type: Clinical	150	
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	150	
FPINT_SITE_TA	Sum of Denominator Site Support Type disaggregates	150	
FPINT_SITE_TA	Sum of Numerator Site Support Type disaggregates	150	
FPINT_SITE_TA	Sum of Service Delivery Type disaggregates	150	
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	37,680	11,322
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	38,796	11,322
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	4,679	794
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	30,238	10,528
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	34,917	11,322
TB_SCREEN_DSD	Sex: Male	12,151	3,931
TB_SCREEN_DSD	Sex: Female	22,765	7,391



TB_SCREEN_DSD	Sum of Sex disaggregates	34,916	11,322
---------------	--------------------------	--------	--------

Implementing Mechanism Details

Mechanism ID: 10281	Mechanism Name: Technical Assistance for Data Use/M&E Systems Strengthening for Implementing Partners
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of California at San Francisco	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 10281



Mechanism Name: Technical Assistance for Data Use/M&E Systems Strengthening for			
Prime Partner Name: Implementing Partners			
University of California at San Francisco			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10326	Mechanism Name: Strengthening Uganda's Systems for Treating AIDS Nationally (SUSTAIN)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 8,064,028	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	8,064,028



Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	335,000
Key Populations: MSM and TG	100,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Key Populations: FSW	200,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs

Key Issues

(No data provided.)



Budget Code Information

Mechanism ID:	10326		
Mechanism Name:	Strengthening Uganda's Systems for Treating AIDS Nationally		
Prime Partner Name:	(SUSTAIN) University Research Corporation, LLC		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	2,671,466	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	290,933	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	545,498	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	449,611	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	387,757	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	375,135	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,937,644	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	205,984	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	4,288	4,068
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	4,765	4,068
PMTCT_ARV_DSD	Life-long ART (including Option B+)	4,288	
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	2,873	618
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,415	3,450
PMTCT_ARV_DSD	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
PMTCT_ARV_DSD	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	
PMTCT_ARV_DSD	Single-dose nevirapine (with or without tail)	0	
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	4,288	
PMTCT_ARV_DSD	Sum of New and Current disaggregates	4,288	4,068
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	68,068	54,643
PMTCT_STAT_DSD	Number of new ANC and L&D clients	71,650	57,520
PMTCT_STAT_DSD	By: Known positives at entry	1,811	3,450
PMTCT_STAT_DSD	By: Number of new positives identified	2,954	618
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	4,765	4,068
VMMC_AE_DSD	Number of males circumcised surgically or by	37	43

	medical device that experienced at least one moderate or severe adverse event(s) (AEs)		
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	1	
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	1	
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	43	
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	37	
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	33	
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	3	
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	0	
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)	0	
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by	43	

	maximum severity category: Number of clients with one or more severe medical device-related AE(s)		
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	11,110	12,881
VMMC_CIRC_DSD	By Age: 10-14	2,000	
VMMC_CIRC_DSD	By Age: 15-19	2,195	
VMMC_CIRC_DSD	By Age: 20-24	1,840	
VMMC_CIRC_DSD	By Age: 25-49	4,853	
VMMC_CIRC_DSD	By Age: 50+	222	
VMMC_CIRC_DSD	Sum of age disaggregates	11,110	
VMMC_CIRC_DSD	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	260	232
VMMC_CIRC_DSD	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	8,406	9,815
VMMC_CIRC_DSD	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	2,444	2,834
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	11,110	11,593
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	0	1,288
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	11,110	11,593
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum	25,610	

	components during the reporting period.		
PP_PREV_DSD	Age/sex: 10-14 Male	829	
PP_PREV_DSD	Age/sex: 15-19 Male	1,978	
PP_PREV_DSD	Age/sex: 20-24 Male	1,658	
PP_PREV_DSD	Age/sex: 25-49 Male	4,373	
PP_PREV_DSD	Age/sex: 50+ Male	177	
PP_PREV_DSD	Age/sex: 10-14 Female	1,130	
PP_PREV_DSD	Age/sex: 15-19 Female	3,634	
PP_PREV_DSD	Age/sex: 20-24 Female	3,179	
PP_PREV_DSD	Age/sex: 25-49 Female	8,327	
PP_PREV_DSD	Age/sex: 50+ Female	325	
PP_PREV_DSD	Sum of Age/Sex disaggregates	25,610	
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	44,827	140,277
PP_PREV_TA	Age/sex: 10-14 Male	2,030	5,343
PP_PREV_TA	Age/sex: 15-19 Male	2,246	10,879
PP_PREV_TA	Age/sex: 20-24 Male	1,882	12,488
PP_PREV_TA	Age/sex: 25-49 Male	4,965	20,824
PP_PREV_TA	Age/sex: 50+ Male	201	1,689
PP_PREV_TA	Age/sex: 10-14 Female	1,539	6,974
PP_PREV_TA	Age/sex: 15-19 Female	7,645	17,271
PP_PREV_TA	Age/sex: 20-24 Female	6,689	26,110
PP_PREV_TA	Age/sex: 25-49 Female	17,521	36,847
PP_PREV_TA	Age/sex: 50+ Female	109	1,852
PP_PREV_TA	Sum of Age/Sex disaggregates	44,827	140,277
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,314	

HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	121,340	259,919
HTC_TST_DSD	By Test Result: Negative	115,098	250,851
HTC_TST_DSD	By Test Result: Positive	6,242	9,068
HTC_TST_DSD	Sum of Test Result disaggregates	121,340	259,919
HTC_TST_DSD	Age/sex: 5-9 Male	4,172	
HTC_TST_DSD	Age/sex: 10-14 Male	5,075	
HTC_TST_DSD	Age/sex: 15-19 Male	5,615	
HTC_TST_DSD	Age/sex: 20-24 Male	4,706	
HTC_TST_DSD	Age/sex: 25-49 Male	12,413	
HTC_TST_DSD	Age/sex: 50+ Male	503	
HTC_TST_DSD	Age/sex: 5-9 Female	5,100	
HTC_TST_DSD	Age/sex: 10-14 Female	3,847	
HTC_TST_DSD	Age/sex: 15-19 Female	19,113	
HTC_TST_DSD	Age/sex: 20-24 Female	16,724	
HTC_TST_DSD	Age/sex: 25-49 Female	43,800	
HTC_TST_DSD	Age/sex: 50+ Female	272	
HTC_TST_DSD	Sum of Age/Sex disaggregates	121,340	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	9,248	13,178
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	23,237	96,041
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	8,947	17,469
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	79,908	133,231
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	18,195	30,647
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	103,145	229,272
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	121,340	259,919
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical	58,311	74,606

	assessment (WHO staging) OR CD4 count OR viral load		
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,924	2,387
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	18,601	2,835
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,624	23,501
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	35,162	45,883
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	58,311	74,606
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	8,233	9,558
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	362	296
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	2,527	3,145
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	339	335
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	5,005	5,782
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	8,233	9,558
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	8,233	9,558
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	1,399	1,791
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	18,831	22,382
FN_THER_DSD	Age: <1	0	
FN_THER_DSD	Age: 1-4	0	
FN_THER_DSD	Age: 5-14	0	
FN_THER_DSD	Age: 15-17	0	
FN_THER_DSD	Age: 18+	0	

FN_THER_DSD	Sum of Age disaggregates	0	
FN_THER_DSD	Aggregated Age: <18	861	689
FN_THER_DSD	Aggregated Age: 18+	538	1,102
FN_THER_DSD	Sum of Aggregated Age disaggregates	1,399	1,791
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	0	1,070
TB_ART_DSD	Age: 0-4	0	
TB_ART_DSD	Age: 5-14	0	
TB_ART_DSD	Age: 15+	0	
TB_ART_DSD	Male	0	380
TB_ART_DSD	Female	0	690
TB_ART_DSD	Sum of Sex disaggregates	0	1,070
TB_ART_DSD	Aggregated Age: <15	0	75
TB_ART_DSD	Aggregated Age: 15+	0	995
TB_ART_DSD	Sum of Aggregated Age disaggregates	0	1,070
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	3,812	3,256
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	4,765	
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	3,182	325
PMTCT_EID_DSD	Sum of Infant Age disaggregates	3,182	3,253
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	238	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	53,760	69,639
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,989	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	16,666	44,179

TX_CURR_DSD	Aggregated Age/Sex: <15 Female	2,150	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	32,955	20,334
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	4,139	
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	49,621	64,513
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	53,760	64,513
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	9,946	15,476
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	338	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	2,586	10,068
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	388	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	6,634	4,766
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	9,946	14,834
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	10,959	11,028
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	12,893	12,974
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the	0	

	reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12	0	

	months after initiating ART)		
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	18	
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	18	
LAB_ACC_DSD	Sum of Support Type disaggregates	18	
LAB_ACC_TA	Sum of Support Type disaggregates	18	
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	19	18
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	19	
LAB_CAP_DSD	Sum of Site Support Type disaggregates	19	
LAB_CAP_TA	Sum of Site Support Type disaggregates	19	
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	17	
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	17	
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that	17	

	are directly providing integrated voluntary family planning services		
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	17	
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	17	
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0	
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	17	
FPINT_SITE_DSD	Service delivery type: Community	0	
FPINT_SITE_DSD	Service delivery type: Clinical	17	
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	17	
FPINT_SITE_TA	Sum of Denominator Site Support Type disaggregates	17	
FPINT_SITE_TA	Sum of Numerator Site Support Type disaggregates	17	
FPINT_SITE_TA	Sum of Service Delivery Type disaggregates	17	
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	58,311	74,606
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	58,311	74,606



TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	7,032	5,222
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	45,448	69,384
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	52,480	74,606
TB_SCREEN_DSD	Sex: Male	18,263	25,888
TB_SCREEN_DSD	Sex: Female	34,217	48,718
TB_SCREEN_DSD	Sum of Sex disaggregates	52,480	74,606

Implementing Mechanism Details

Mechanism ID: 11479	Mechanism Name: State Department
Funding Agency: State/AF	Procurement Type: USG Core
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 42,400	
Applied Pipeline Amount: 157,600	
Funding Source	Funding Amount
GHP-State	42,400

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues



(No data provided.)

Budget Code Information

Mechanism ID: 11479			
Mechanism Name: State Department			
Prime Partner Name: U.S. Department of State			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	8,614	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	25,173	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	8,613	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 11480	Mechanism Name: US Peace Corps
Funding Agency: PC	Procurement Type: USG Core
Prime Partner Name: U.S. Peace Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 350,439	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount



GHP-State	350,439
-----------	---------

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 11480			
Mechanism Name: US Peace Corps			
Prime Partner Name: U.S. Peace Corps			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	90,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	260,439	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12477	Mechanism Name: Strengthening And Improving
----------------------------	--



		National Training Systems in the Republic of Uganda under PEPFAR	
Funding Agency: HHS/CDC		Procurement Type: Cooperative Agreement	
Prime Partner Name: Baylor College of Medicine Children's Foundation			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: No	
Global Fund / Multilateral Engagement: N/A			
G2G: No		Managing Agency:	

Total All Funding Sources: 0			
Applied Pipeline Amount: 0			
Funding Source		Funding Amount	
GHP-State		0	

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	12477		
Mechanism Name:	Strengthening And Improving National Training Systems in the Republic of Uganda under PEPFAR		
Prime Partner Name:	Baylor College of Medicine Children's Foundation		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	OHSS	0	0
------------------------	------	---	---

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	695		Redacted
HRH_PRE	By Graduates: Midwives	291		Redacted
HRH_PRE	By Graduates: Laboratory professionals	361		Redacted
HRH_PRE	By Graduates: Other	43		Redacted
HRH_PRE	Sum of Graduates disaggregated	695		Redacted
HRH_PRE	By new graduates who are licensed and registered: Midwives	291		Redacted
HRH_PRE	By new graduates who are licensed and registered: Laboratorians	361		Redacted
HRH_PRE	By new graduates who are licensed and registered: Other (where applicable)	43		Redacted

Implementing Mechanism Details

Mechanism ID: 12486	Mechanism Name: Scaling Up Community Based OVC Response (SCORE)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Associazione Volontari Per Il Servizio Internazionale, Uganda	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 4,000,405	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	4,000,405

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Food and Nutrition: Policy, Tools, and Service Delivery	120,000
Economic Strengthening	168,000
Education	20,000
Water	15,000
Gender: GBV	20,000
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Gender: Gender Equality	20,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Focus Area:	Increase gender-equitable access to income and productive resources, including education

Key Issues



(No data provided.)

Budget Code Information

Mechanism ID: 12486			
Mechanism Name: Scaling Up Community Based OVC Response (SCORE)			
Prime Partner Name: Associazione Volontari Per Il Servizio Internazionale, Uganda			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	4,000,405	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	15,436	57,361
OVC_ACC_DSD	Sex: Male	7,008	
OVC_ACC_DSD	Sex: Female	8,428	
OVC_ACC_DSD	Sum of Sex disaggregates	15,436	
OVC_ACC_DSD	Age: <1	648	
OVC_ACC_DSD	Age: 1-4	2,439	
OVC_ACC_DSD	Age: 5-9	4,322	
OVC_ACC_DSD	Age: 10-14	4,415	
OVC_ACC_DSD	Age: 15-17	2,840	
OVC_ACC_DSD	Age: 18+	772	
OVC_ACC_DSD	Sum of Age disaggregates	15,436	
OVC_ACC_TA	Sum of Sex disaggregates	15,436	
OVC_ACC_TA	Sum of Age disaggregates	15,436	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	80,156	110,937
OVC_SERV_DSD	Sex: Male	36,391	

OVC_SERV_DSD	Sex: Female	43,765	
OVC_SERV_DSD	Sum of Sex disaggregates	80,156	
OVC_SERV_DSD	Age: <1	3,367	
OVC_SERV_DSD	Age: 1-4	12,664	
OVC_SERV_DSD	Age: 5-9	22,443	
OVC_SERV_DSD	Age: 10-14	22,925	
OVC_SERV_DSD	Age: 15-17	14,749	
OVC_SERV_DSD	Age: 18+	4,008	
OVC_SERV_DSD	Sum of Age disaggregates	80,156	
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	4,219	45,306
OVC_SERV_TA	Sex: Male	1,915	
OVC_SERV_TA	Sex: Female	2,304	
OVC_SERV_TA	Sum of Sex disaggregates	4,219	
OVC_SERV_TA	Age: <1	177	
OVC_SERV_TA	Age: 1-4	667	
OVC_SERV_TA	Age: 5-9	1,181	
OVC_SERV_TA	Age: 10-14	1,207	
OVC_SERV_TA	Age: 15-17	776	
OVC_SERV_TA	Age: 18+	211	
OVC_SERV_TA	Sum of Age disaggregates	4,219	

Implementing Mechanism Details

Mechanism ID: 12496	Mechanism Name: Monitoring and Evaluation of Emergency Plan Progress– Phase Two (MEEPP II)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Social and Scientific Systems	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 1,500,000	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	1,500,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	12496		
Mechanism Name:	Monitoring and Evaluation of Emergency Plan Progress– Phase Two		
Prime Partner Name:	(MEEPP II) Social and Scientific Systems		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	1,500,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details



Mechanism ID: 12801	Mechanism Name: Strengthening Decentralization for Sustainability (SDS)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Cardno Emerging Markets	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 13,871,868	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	13,871,868

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	5,535,416
Renovation	270,000
Condom programming	100,000
Key Populations: FSW	200,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Collection and use of strategic information on SWs and clients

Key Issues

(No data provided.)



Budget Code Information

Mechanism ID: 12801			
Mechanism Name: Strengthening Decentralization for Sustainability (SDS)			
Prime Partner Name: Cardno Emerging Markets			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	2,191,834	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,050,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	235,847	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	1,111,692	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	270,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	350,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	1,242,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	1,142,441	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HMIN	1,003,275	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	306,060	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	267,649	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	722,214	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	3,399,744	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	579,112	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12835	Mechanism Name: Strengthening the Uganda National Response for Implementation for Services for Orphans and Other Vulnerable Children (SUNRISE)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: International HIV/AIDS Alliance	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	



Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	12835		
Mechanism Name:	Strengthening the Uganda National Response for Implementation for Services for Orphans and Other Vulnerable Children (SUNRISE)		
Prime Partner Name:	International HIV/AIDS Alliance		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	6,172	
OVC_ACC_DSD	Sex: Male	2,802	



OVC_ACC_DSD	Sex: Female	3,370	
OVC_ACC_DSD	Sum of Sex disaggregates	6,172	
OVC_ACC_DSD	Age: <1	259	
OVC_ACC_DSD	Age: 1-4	975	
OVC_ACC_DSD	Age: 5-9	1,728	
OVC_ACC_DSD	Age: 10-14	1,765	
OVC_ACC_DSD	Age: 15-17	1,136	
OVC_ACC_DSD	Age: 18+	309	
OVC_ACC_DSD	Sum of Age disaggregates	6,172	
OVC_ACC_TA	Sum of Sex disaggregates	6,172	
OVC_ACC_TA	Sum of Age disaggregates	6,172	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	3,374	
OVC_SERV_DSD	Sex: Male	1,532	
OVC_SERV_DSD	Sex: Female	1,842	
OVC_SERV_DSD	Sum of Sex disaggregates	3,374	
OVC_SERV_DSD	Age: <1	142	
OVC_SERV_DSD	Age: 1-4	532	
OVC_SERV_DSD	Age: 5-9	945	
OVC_SERV_DSD	Age: 10-14	965	
OVC_SERV_DSD	Age: 15-17	621	
OVC_SERV_DSD	Age: 18+	169	
OVC_SERV_DSD	Sum of Age disaggregates	3,374	
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	30,361	
OVC_SERV_TA	Sex: Male	13,784	
OVC_SERV_TA	Sex: Female	16,577	
OVC_SERV_TA	Sum of Sex disaggregates	30,361	
OVC_SERV_TA	Age: <1	1,275	
OVC_SERV_TA	Age: 1-4	4,797	



OVC_SERV_TA	Age: 5-9	8,501	
OVC_SERV_TA	Age: 10-14	8,683	
OVC_SERV_TA	Age: 15-17	5,586	
OVC_SERV_TA	Age: 18+	1,519	
OVC_SERV_TA	Sum of Age disaggregates	30,361	

Implementing Mechanism Details

Mechanism ID: 12935	Mechanism Name: AFFORD Health Marketing Initiative
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Johns Hopkins University Bloomberg School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)



Budget Code Information

Mechanism ID: 12935			
Mechanism Name: AFFORD Health Marketing Initiative			
Prime Partner Name: Johns Hopkins University Bloomberg School of Public Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12981	Mechanism Name: Strengthening capacity through improved management and coordination of laboratory, surveillance, and epidemiology activities, public health evaluations and training in Uganda – Lab Quality Assurance
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Uganda Virus Research Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC
Total All Funding Sources: 2,519,546	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	2,519,546

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	12981		
Mechanism Name:	Strengthening capacity through improved management and coordination of laboratory, surveillance, and epidemiology activities, public health evaluations and training in Uganda – Lab Quality Assurance		
Prime Partner Name:	Uganda Virus Research Institute		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	1,000,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Governance and Systems	HVSI	980,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	539,546	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	1	1	Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	1		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	1		Redacted
LAB_ACC_TA	Sum of Support Type disaggregates	1		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	1,501	1	Redacted
LAB_CAP_DSD	By clinical laboratories	1,501	1	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	1		Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	1,500		Redacted



LAB_CAP_DSD	Sum of Site Support Type disaggregates	1,501		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	1,501		Redacted

Implementing Mechanism Details

Mechanism ID: 13002	Mechanism Name: Supporting the Continuity of HIV/AIDS prevention and care programs for refugees in Uganda
Funding Agency: State/PRM	Procurement Type: Cooperative Agreement
Prime Partner Name: United Nations High Commissioner for Refugees	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 324,721	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	324,721

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)



Budget Code Information

Mechanism ID:	13002		
Mechanism Name:	Supporting the Continuity of HIV/AIDS prevention and care programs for refugees in Uganda		
Prime Partner Name:	United Nations High Commissioner for Refugees		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	75,025	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	46,972	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	14,615	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	26,361	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	18,782	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	33,332	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	102,799	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	6,835	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	406	366
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	451	366
PMTCT_ARV_DSD	Life-long ART (including Option B+)	406	
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	272	104
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	134	262
PMTCT_ARV_DSD	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
PMTCT_ARV_DSD	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	
PMTCT_ARV_DSD	Single-dose nevirapine (with or without tail)	0	
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	406	
PMTCT_ARV_DSD	Sum of New and Current disaggregates	406	366
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	6,445	6,273
PMTCT_STAT_DSD	Number of new ANC and L&D clients	6,784	6,603
PMTCT_STAT_DSD	By: Known positives at entry	171	262
PMTCT_STAT_DSD	By: Number of new positives identified	280	104
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	451	366

VMMC_CIRC_TA	By Age: <1	0	
VMMC_CIRC_TA	By Age: 1-9	0	
VMMC_CIRC_TA	By Age: 10-14	0	
VMMC_CIRC_TA	By Age: 15-19	0	
VMMC_CIRC_TA	By Age: 20-24	0	
VMMC_CIRC_TA	By Age: 25-49	0	
VMMC_CIRC_TA	By Age: 50+	0	
VMMC_CIRC_TA	Sum of Age disaggregations	0	
VMMC_CIRC_TA	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	0	
VMMC_CIRC_TA	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	0	
VMMC_CIRC_TA	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	
VMMC_CIRC_TA	By circumcision technique: Surgical VMMC	0	
VMMC_CIRC_TA	By circumcision technique: Device-based VMMC	0	
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	0	
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	4,952	
PP_PREV_DSD	Age/sex: 10-14 Male	547	
PP_PREV_DSD	Age/sex: 15-19 Male	787	
PP_PREV_DSD	Age/sex: 20-24 Male	658	
PP_PREV_DSD	Age/sex: 25-49 Male	248	

PP_PREV_DSD	Age/sex: 50+ Male	10	
PP_PREV_DSD	Age/sex: 10-14 Female	564	
PP_PREV_DSD	Age/sex: 15-19 Female	881	
PP_PREV_DSD	Age/sex: 20-24 Female	767	
PP_PREV_DSD	Age/sex: 25-49 Female	472	
PP_PREV_DSD	Age/sex: 50+ Female	18	
PP_PREV_DSD	Sum of Age/Sex disaggregates	4,952	
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	3,597	3,931
PP_PREV_TA	Age/sex: 10-14 Male	117	180
PP_PREV_TA	Age/sex: 15-19 Male	95	333
PP_PREV_TA	Age/sex: 20-24 Male	80	363
PP_PREV_TA	Age/sex: 25-49 Male	212	651
PP_PREV_TA	Age/sex: 50+ Male	8	57
PP_PREV_TA	Age/sex: 10-14 Female	143	233
PP_PREV_TA	Age/sex: 15-19 Female	704	445
PP_PREV_TA	Age/sex: 20-24 Female	616	659
PP_PREV_TA	Age/sex: 25-49 Female	1,613	947
PP_PREV_TA	Age/sex: 50+ Female	9	63
PP_PREV_TA	Sum of Age/Sex disaggregates	3,597	3,931
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	

KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	10	
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	6,274	13,435
HTC_TST_DSD	By Test Result: Negative	6,085	13,031
HTC_TST_DSD	By Test Result: Positive	189	404
HTC_TST_DSD	Sum of Test Result disaggregates	6,274	13,435
HTC_TST_DSD	Age/sex: <1 Male	0	
HTC_TST_DSD	Age/sex: 1-4 Male	0	
HTC_TST_DSD	Age/sex: 5-9 Male	0	
HTC_TST_DSD	Age/sex: 10-14 Male	0	
HTC_TST_DSD	Age/sex: 15-19 Male	0	
HTC_TST_DSD	Age/sex: 20-24 Male	0	
HTC_TST_DSD	Age/sex: 25-49 Male	0	
HTC_TST_DSD	Age/sex: 50+ Male	0	

HTC_TST_DSD	Age/sex: <1 Female	0	
HTC_TST_DSD	Age/sex: 1-4 Female	0	
HTC_TST_DSD	Age/sex: 5-9 Female	0	
HTC_TST_DSD	Age/sex: 10-14 Female	0	
HTC_TST_DSD	Age/sex: 15-19 Female	1,506	
HTC_TST_DSD	Age/sex: 20-24 Female	1,317	
HTC_TST_DSD	Age/sex: 25-49 Female	3,451	
HTC_TST_DSD	Age/sex: 50+ Female	0	
HTC_TST_DSD	Sum of Age/Sex disaggregates	6,274	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	683
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0	4,964
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	906
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	6,274	6,882
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	0	1,589
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	6,274	11,846
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	6,274	13,435
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	3,579	503
HTC_TST_TA	By Test Result: Negative	3,371	488
HTC_TST_TA	By Test Result: Positive	208	15
HTC_TST_TA	Sum of Test Result disaggregates	3,579	503
HTC_TST_TA	Age/sex: <1 Male	0	
HTC_TST_TA	Age/sex: 1-4 Male	0	
HTC_TST_TA	Age/sex: 5-9 Male	387	
HTC_TST_TA	Age/sex: 10-14 Male	292	
HTC_TST_TA	Age/sex: 15-19 Male	240	
HTC_TST_TA	Age/sex: 20-24 Male	201	
HTC_TST_TA	Age/sex: 25-49 Male	530	

HTC_TST_TA	Age/sex: 50+ Male	20	
HTC_TST_TA	Age/sex: <1 Female	0	
HTC_TST_TA	Age/sex: 1-4 Female	0	
HTC_TST_TA	Age/sex: 5-9 Female	473	
HTC_TST_TA	Age/sex: 10-14 Female	356	
HTC_TST_TA	Age/sex: 15-19 Female	254	
HTC_TST_TA	Age/sex: 20-24 Female	222	
HTC_TST_TA	Age/sex: 25-49 Female	583	
HTC_TST_TA	Age/sex: 50+ Female	21	
HTC_TST_TA	Sum of Age/Sex disaggregates	3,579	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	678	26
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	991	186
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	829	34
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,081	257
HTC_TST_TA	Sum of Aggregated Age/Sex <15	1,507	60
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	2,072	443
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	3,579	503
GEND_GBV_DSD	Number of people receiving post-GBV care	1,944	
GEND_GBV_DSD	Age: 0-9	0	
GEND_GBV_DSD	Age: 10-14	409	
GEND_GBV_DSD	Age: 15-17	384	
GEND_GBV_DSD	Age: 18-24	328	
GEND_GBV_DSD	Age: 25+	823	
GEND_GBV_DSD	Sum of Age disaggregates	1,944	
GEND_GBV_DSD	Sex: Male	893	
GEND_GBV_DSD	Sex: Female	1,051	
GEND_GBV_DSD	Sum of Sex disaggregates	1,944	
GEND_GBV_DSD	By type of service: Physical and/or Emotional	0	

	Violence (Other Post-GBV Care)		
GEND_GBVDSD	By type of service: Sexual Violence (Post-Rape Care)	0	
GEND_GBVDSD	By PEP service provision (related to sexual violence services provided)	0	
GEND_GBVT A	Sum of Age disaggregates	1,944	
GEND_GBVT A	Sum of Sex disaggregates	1,944	
GEND_NORMDSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	4,304	
GEND_NORMDSD	By Age: 0-9	0	
GEND_NORMDSD	By Age: 10-14	1,140	
GEND_NORMDSD	By Age: 15-19	964	
GEND_NORMDSD	By Age: 20-24	822	
GEND_NORMDSD	By Age: 25+	1,378	
GEND_NORMDSD	Sum of Age disaggregates	4,304	
GEND_NORMDSD	By Sex: Male	2,367	
GEND_NORMDSD	By Sex: Female	1,937	
GEND_NORMDSD	Sum of Sex disaggregates	4,304	
GEND_NORMDSD	By type of activity: Individual	0	
GEND_NORMDSD	By type of activity: Small Group	0	
GEND_NORMDSD	By type of activity: Community-level	0	
GEND_NORMT A	Sum of Sex disaggregates	4,304	
OVC_ACCDSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	134	526
OVC_ACCDSD	Sex: Male	61	
OVC_ACCDSD	Sex: Female	73	
OVC_ACCDSD	Sum of Sex disaggregates	134	
OVC_ACCDSD	Age: <1	6	
OVC_ACCDSD	Age: 1-4	21	
OVC_ACCDSD	Age: 5-9	38	
OVC_ACCDSD	Age: 10-14	38	



OVC_ACC_DSD	Age: 15-17	25	
OVC_ACC_DSD	Age: 18+	6	
OVC_ACC_DSD	Sum of Age disaggregates	134	
OVC_ACC_TA	Sum of Sex disaggregates	134	
OVC_ACC_TA	Sum of Age disaggregates	134	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	734	1,023
OVC_SERV_DSD	Sex: Male	333	
OVC_SERV_DSD	Sex: Female	401	
OVC_SERV_DSD	Sum of Sex disaggregates	734	
OVC_SERV_DSD	Age: <1	31	
OVC_SERV_DSD	Age: 1-4	116	
OVC_SERV_DSD	Age: 5-9	206	
OVC_SERV_DSD	Age: 10-14	210	
OVC_SERV_DSD	Age: 15-17	135	
OVC_SERV_DSD	Age: 18+	37	
OVC_SERV_DSD	Sum of Age disaggregates	735	
OVC_SERV_TA	Sex: Male	0	
OVC_SERV_TA	Sex: Female	0	
OVC_SERV_TA	Sum of Sex disaggregates	0	
OVC_SERV_TA	Age: <1	0	
OVC_SERV_TA	Age: 1-4	0	
OVC_SERV_TA	Age: 5-9	0	
OVC_SERV_TA	Age: 10-14	0	
OVC_SERV_TA	Age: 15-17	0	
OVC_SERV_TA	Age: 18+	0	
OVC_SERV_TA	Sum of Age disaggregates	0	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	3,313	2,797

CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	109	89
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,057	106
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	149	881
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,998	1,721
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	3,313	2,797
CARE_CURR_TA	Age/sex: <1 Male	0	
CARE_CURR_TA	Age/sex: 1-4 Male	0	
CARE_CURR_TA	Age/sex: 5-9 Male	0	
CARE_CURR_TA	Age/sex: 10-14 Male	0	
CARE_CURR_TA	Age/sex: 15-19 Male	0	
CARE_CURR_TA	Age/sex: 20-24 Male	0	
CARE_CURR_TA	Age/sex: 25-49 Male	0	
CARE_CURR_TA	Age/sex: 50+ Male	0	
CARE_CURR_TA	Age/sex: <1 Female	0	
CARE_CURR_TA	Age/sex: 1-4 Female	0	
CARE_CURR_TA	Age/sex: 5-9 Female	0	
CARE_CURR_TA	Age/sex: 10-14 Female	0	
CARE_CURR_TA	Age/sex: 15-19 Female	0	
CARE_CURR_TA	Age/sex: 20-24 Female	0	
CARE_CURR_TA	Age/sex: 25-49 Female	0	
CARE_CURR_TA	Age/sex: 50+ Female	0	
CARE_CURR_TA	Sum of Age/Sex disaggregates	0	
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	5
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0	6
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	49
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0	95

	PERMISSION ONLY: 15+ Female		
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	0	155
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	580	339
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	203	111
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	377	205
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	580	339
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	580	339
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	79	38
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	98	46
TB_ART_DSD	Age: 0-4	0	
TB_ART_DSD	Age: 5-14	2	
TB_ART_DSD	Age: 15+	96	
TB_ART_DSD	Male	64	13
TB_ART_DSD	Female	34	25
TB_ART_DSD	Sum of Sex disaggregates	98	38
TB_ART_DSD	Newly tested	0	
TB_ART_DSD	Known HIV-positive	0	17
TB_ART_DSD	Sum of Test Status disaggregates	0	17
TB_ART_DSD	Aggregated Age: <15	2	3
TB_ART_DSD	Aggregated Age: 15+	96	35
TB_ART_DSD	Sum of Aggregated Age disaggregates	98	38
PMTCT_EID_DSD	Number of infants who had a virologic HIV test	361	293

	within 12 months of birth during the reporting period		
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	451	
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	361	29
PMTCT_EID_DSD	Sum of Infant Age disaggregates	361	293
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	23	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	2,907	2,558
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	108	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	901	1,623
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	116	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	1,782	747
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	224	
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	2,683	2,370
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	2,907	2,370
TX_CURR_TA	Age/Sex: <1 Male	0	
TX_CURR_TA	Age/Sex: 1-4 Male	0	
TX_CURR_TA	Age/Sex: 5-14 Male	0	
TX_CURR_TA	Age/Sex: 15+ Male	0	
TX_CURR_TA	Age/Sex: <1 Female	0	
TX_CURR_TA	Age/Sex: 1-4 Female	0	
TX_CURR_TA	Age/Sex: 5-14 Female	0	
TX_CURR_TA	Age/Sex: 15+ Female	0	
TX_CURR_TA	Sum of Age/Sex disaggregations	0	
TX_CURR_TA	Aggregated Age/Sex: <1 Male	0	
TX_CURR_TA	Aggregated Age/Sex: <1 Female	0	
TX_CURR_TA	Aggregated Age/Sex: <15 Male	0	
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	0	89

TX_CURR_TA	Aggregated Age/Sex: <15 Female	0	
TX_CURR_TA	Sum of Aggregated Age/Sex <15	0	
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	0	129
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	0	129
TX_CURR_TA	Sum of Aggregated Age/Sex (<1 and 1-14) <15	0	10
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	940	566
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	32	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	244	369
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	37	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	627	174
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	940	543
TX_NEW_DSD	Pregnancy status	233	104
TX_NEW_DSD	Breastfeeding status	233	2
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,420	491
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,560	578
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	104	
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,316	
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of	114	

	the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,446	
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	0	
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	0	
LAB_ACC_DSD	Sum of Support Type disaggregates	0	
LAB_ACC_TA	Sum of Support Type disaggregates	0	
LAB_CAP_DSD	By clinical laboratories	0	
LAB_CAP_DSD	By Point-of-care testing sites	0	
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	0	
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	0	
LAB_CAP_DSD	Sum of Site Support Type disaggregates	0	
LAB_CAP_TA	Sum of Site Support Type disaggregates	0	
HRH_PRE	By Graduates: Doctors	0	
HRH_PRE	By Graduates: Nurses	0	
HRH_PRE	By Graduates: Midwives	0	
HRH_PRE	By Graduates: Social service workers	0	
HRH_PRE	By Graduates: Laboratory professionals	0	
HRH_PRE	By Graduates: Other	0	
HRH_PRE	Sum of Graduates disaggreagtes	0	
HRH_PRE	By new graduates who are licensed and registered: Doctors	0	
HRH_PRE	By new graduates who are licensed and registered: Nurses	0	

HRH_PRE	By new graduates who are licensed and registered: Midwives	0	
HRH_PRE	By new graduates who are licensed and registered: Social service workers	0	
HRH_PRE	By new graduates who are licensed and registered: Laboratorians	0	
HRH_PRE	By new graduates who are licensed and registered: Other (where applicable)	0	
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	2,982	2,797
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	3,313	2,797
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	400	196
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	2,582	2,601
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	2,982	2,797
TB_SCREEN_DSD	Sex: Male	1,038	970
TB_SCREEN_DSD	Sex: Female	1,944	1,827
TB_SCREEN_DSD	Sum of Sex disaggregates	2,982	2,797

Implementing Mechanism Details

Mechanism ID: 13026	Mechanism Name: Purchase, Distribution and Tracking of Cotrimoxazole, HIV/AIDS Related Laboratory Commodities and Supplies in the Republic of Uganda under the Presidents' Emergency Plan for AIDS Relief
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National Medical Stores	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC
Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13026		
Mechanism Name:	Purchase, Distribution and Tracking of Cotrimoxazole, HIV/AIDS Related Laboratory Commodities and Supplies in the Republic of Uganda under		
Prime Partner Name:	the Presidents" Emergency Plan for AIDS Relief		
	National Medical Stores		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and	HLAB	0	0



Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13029	Mechanism Name: National Lab Infrastructure Initiative
Funding Agency: State/AF	Procurement Type: Cooperative Agreement
Prime Partner Name: Regional Procurement Support Office/Frankfurt	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 500,000	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	500,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 13029			
Mechanism Name: National Lab Infrastructure Initiative			
Prime Partner Name: Regional Procurement Support Office/Frankfurt			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	500,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13047	Mechanism Name: Scaling up comprehensive HIV/AIDS Services at Mulago and Mbarara
----------------------------	---



	University Teaching Hospitals
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Makerere University School of Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 9,518,235	
Applied Pipeline Amount: 3,079,946	
Funding Source	Funding Amount
GHP-State	9,518,235

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	100,000
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Key Populations: FSW	500,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Gender: GBV	500,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic



	Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	250,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13047		
Mechanism Name:	Scaling up comprehensive HIV/AIDS Services at Mulago and Mbarara		
Prime Partner Name:	University Teaching Hospitals		
	Makerere University School of Medicine		
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Care	HBHC	781,109	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	431,845	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	455,048	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	1,204,811	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	75,053	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	160,640	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,090,346	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	713,491	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	134,945	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	4,400,435	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	PDTX	70,512	0
-----------	------	--------	---

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	2,560	2,974	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	2,844	2,974	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	2,560		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	1,715	508	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	845	2,466	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	2,560		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	2,560	2,974	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	40,635	24,738	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	42,773	26,423	Redacted

PMTCT_STAT_DS D	By: Known positives at entry	1,081	2,466	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	1,764	508	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	2,845	2,974	Redacted
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	26	2,756	Redacted
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	1		Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	1		Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	9		Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	18		Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	17		Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more	2		Redacted

	severe surgical intra-operative AE(s)			
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	16		Redacted
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)	16		Redacted
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	9		Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	7,768	8,351	Redacted
VMMC_CIRC_DS D	By Age: 10-14	1,398		Redacted
VMMC_CIRC_DS D	By Age: 15-19	1,535		Redacted
VMMC_CIRC_DS D	By Age: 20-24	1,287		Redacted
VMMC_CIRC_DS D	By Age: 25-49	3,393		Redacted
VMMC_CIRC_DS D	By Age: 50+	155		Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	7,768		Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	182	150	Redacted
VMMC_CIRC_DS	By HIV status: Number of HIV-negative	5,878	6,364	Redacted

D	clients (tested HIV negative at VMMC program)			
VMMC_CIRC_DS D	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	1,709	1,837	Redacted
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	5,535	8,351	Redacted
VMMC_CIRC_DS D	By circumcision technique: Device-based VMMC	2,234		Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	5,535	8,351	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0		Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	40,572	2,415	Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	993		Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	3,461	290	Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	2,895	314	Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	9,133	555	Redacted
PP_PREV_DSD	Age/sex: 50+ Male	159	48	Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	1,263		Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	4,945	254	Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	4,317	374	Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	13,114	544	Redacted
PP_PREV_DSD	Age/sex: 50+ Female	292	36	Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	40,572	2,415	Redacted
PP_PREV_TA	Number of the target population who	26,802	64,692	Redacted

	completed a standardized HIV prevention intervention including the minimum components during the reporting period.			
PP_PREV_TA	Age/sex: 10-14 Male	1,008	2,802	Redacted
PP_PREV_TA	Age/sex: 15-19 Male	1,557	5,898	Redacted
PP_PREV_TA	Age/sex: 20-24 Male	1,305	6,839	Redacted
PP_PREV_TA	Age/sex: 25-49 Male	3,441	11,281	Redacted
PP_PREV_TA	Age/sex: 50+ Male	140	903	Redacted
PP_PREV_TA	Age/sex: 10-14 Female	572	3,636	Redacted
PP_PREV_TA	Age/sex: 15-19 Female	4,493	7,022	Redacted
PP_PREV_TA	Age/sex: 20-24 Female	3,931	10,366	Redacted
PP_PREV_TA	Age/sex: 25-49 Female	10,296	14,940	Redacted
PP_PREV_TA	Age/sex: 50+ Female	59	1,005	Redacted
PP_PREV_TA	Sum of Age/Sex disaggregates	26,802	64,692	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	23,408	74,048	Redacted
HTC_TST_DSD	By Test Result: Negative	19,815	71,593	Redacted
HTC_TST_DSD	By Test Result: Positive	3,593	2,455	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	23,408	74,048	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	0		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	1,552		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	1,171		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	2,412		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	2,021		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	5,332		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	199		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	0		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	1,897		Redacted

HTC_TST_DSD	Age/sex: 10-14 Female	1,431		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	1,739		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	1,521		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	3,984		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	148		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	23,407		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,723	3,755	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	9,965	27,362	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,328	4,983	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	7,392	37,948	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	6,051	8,738	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	17,357	65,310	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	23,408	74,048	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	23,408	78,454	Redacted
HTC_TST_TA	By Test Result: Negative	19,815	75,564	Redacted
HTC_TST_TA	By Test Result: Positive	3,593	2,890	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	23,408	78,454	Redacted
HTC_TST_TA	Age/sex: <1 Male	0		Redacted
HTC_TST_TA	Age/sex: 1-4 Male	0		Redacted
HTC_TST_TA	Age/sex: 5-9 Male	1,552		Redacted
HTC_TST_TA	Age/sex: 10-14 Male	1,171		Redacted
HTC_TST_TA	Age/sex: 15-19 Male	2,412		Redacted
HTC_TST_TA	Age/sex: 20-24 Male	2,021		Redacted
HTC_TST_TA	Age/sex: 25-49 Male	5,332		Redacted
HTC_TST_TA	Age/sex: 50+ Male	199		Redacted
HTC_TST_TA	Age/sex: <1 Female	0		Redacted

HTC_TST_TA	Age/sex: 1-4 Female	0		Redacted
HTC_TST_TA	Age/sex: 5-9 Female	1,897		Redacted
HTC_TST_TA	Age/sex: 10-14 Female	1,431		Redacted
HTC_TST_TA	Age/sex: 15-19 Female	1,739		Redacted
HTC_TST_TA	Age/sex: 20-24 Female	1,521		Redacted
HTC_TST_TA	Age/sex: 25-49 Female	3,984		Redacted
HTC_TST_TA	Age/sex: 50+ Female	148		Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	23,407		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,723	3,975	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	9,965	28,987	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,328	5,265	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	7,392	40,227	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	6,051	9,240	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	17,357	69,214	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	23,408	78,454	Redacted
GEND_GBV_DSD	Number of people receiving post-GBV care	895		Redacted
GEND_GBV_DSD	Age: 10-14	120		Redacted
GEND_GBV_DSD	Age: 15-17	85		Redacted
GEND_GBV_DSD	Age: 18-24	72		Redacted
GEND_GBV_DSD	Age: 25+	618		Redacted
GEND_GBV_DSD	Sum of Age disaggregates	895		Redacted
GEND_GBV_DSD	Sex: Male	193		Redacted
GEND_GBV_DSD	Sex: Female	702		Redacted
GEND_GBV_DSD	Sum of Sex disaggregates	895		Redacted
GEND_GBV_TA	Sum of Age disaggregates	895		Redacted
GEND_GBV_TA	Sum of Sex disaggregates	895		Redacted
GEND_NORM_DS	Number of people completing an	176		Redacted

D	intervention pertaining to gender norms, that meets minimum criteria			
GEND_NORM_DS D	By Age: 10-14	56		Redacted
GEND_NORM_DS D	By Age: 15-19	35		Redacted
GEND_NORM_DS D	By Age: 20-24	29		Redacted
GEND_NORM_DS D	By Age: 25+	56		Redacted
GEND_NORM_DS D	Sum of Age disaggregates	176		Redacted
GEND_NORM_DS D	By Sex: Male	89		Redacted
GEND_NORM_DS D	By Sex: Female	87		Redacted
GEND_NORM_DS D	Sum of Sex disaggregates	176		Redacted
GEND_NORM_TA	Sum of Sex disaggregates	176		Redacted
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	530	8,530	Redacted
OVC_ACC_DSD	Sex: Male	341		Redacted
OVC_ACC_DSD	Sex: Female	93		Redacted
OVC_ACC_DSD	Sum of Sex disaggregates	434		Redacted
OVC_ACC_DSD	Age: <1	22		Redacted
OVC_ACC_DSD	Age: 1-4	81		Redacted
OVC_ACC_DSD	Age: 5-9	144		Redacted
OVC_ACC_DSD	Age: 10-14	147		Redacted
OVC_ACC_DSD	Age: 15-17	95		Redacted
OVC_ACC_DSD	Age: 18+	26		Redacted
OVC_ACC_DSD	Sum of Age disaggregates	515		Redacted
OVC_ACC_TA	Sum of Sex disaggregates	434		Redacted

OVC_ACC_TA	Sum of Age disaggregates	515		Redacted
OVC_SERV_DSD	Sex: Male	122,414		Redacted
OVC_SERV_DSD	Sex: Female	147,221		Redacted
OVC_SERV_DSD	Sum of Sex disaggregates	269,635		Redacted
OVC_SERV_DSD	Age: <1	11,325		Redacted
OVC_SERV_DSD	Age: 1-4	42,602		Redacted
OVC_SERV_DSD	Age: 5-9	75,498		Redacted
OVC_SERV_DSD	Age: 10-14	77,116		Redacted
OVC_SERV_DSD	Age: 15-17	49,613		Redacted
OVC_SERV_DSD	Age: 18+	13,482		Redacted
OVC_SERV_DSD	Sum of Age disaggregates	269,636		Redacted
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	140		Redacted
OVC_SERV_TA	Sex: Male	64		Redacted
OVC_SERV_TA	Sex: Female	76		Redacted
OVC_SERV_TA	Sum of Sex disaggregates	140		Redacted
OVC_SERV_TA	Age: <1	6		Redacted
OVC_SERV_TA	Age: 1-4	22		Redacted
OVC_SERV_TA	Age: 5-9	39		Redacted
OVC_SERV_TA	Age: 10-14	40		Redacted
OVC_SERV_TA	Age: 15-17	26		Redacted
OVC_SERV_TA	Age: 18+	7		Redacted
OVC_SERV_TA	Sum of Age disaggregates	140		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	50,889	40,503	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,679	1,297	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	16,234	1,540	Redacted

CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,290	12,758	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	30,686	24,908	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	50,889	40,503	Redacted
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	1,574	10,438	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	52	333	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	502	396	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	71	3,289	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	949	6,420	Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	1,574	10,438	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	6,235	6,001	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	274	184	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	1,914	1,974	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	256	210	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	3,791	3,633	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	6,235	6,001	Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex	6,235	6,001	Redacted

	disaggregates			
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	1,259	971	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	16,889	12,147	Redacted
FN_THER_DSD	Aggregated Age: <18	774	376	Redacted
FN_THER_DSD	Aggregated Age: 18+	485	595	Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	1,259	971	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,247	252	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,558	318	Redacted
TB_ART_DSD	Age: 0-4	3		Redacted
TB_ART_DSD	Age: 5-14	36		Redacted
TB_ART_DSD	Age: 15+	1,519		Redacted
TB_ART_DSD	Male	1,013	89	Redacted
TB_ART_DSD	Female	545	163	Redacted
TB_ART_DSD	Sum of Sex disaggregates	1,558	252	Redacted
TB_ART_DSD	Aggregated Age: <15	39	20	Redacted
TB_ART_DSD	Aggregated Age: 15+	1,519	232	Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	1,558	252	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,276	2,381	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting	2,844		Redacted

	period (include known HIV-positive women at entry into PMTCT)			
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	2,276	236	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,276	2,381	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	142		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	47,550	38,086	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,759		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	14,740	24,164	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,902		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	29,149	11,119	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	3,661		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	43,889	35,283	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	47,550	35,283	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	9,530	9,545	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	324		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	2,478	6,208	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	372		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	6,356	2,943	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	9,530	9,151	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	12,889	4,886	Redacted
TX_RET_DSD	Total number of adults and children	14,164	5,748	Redacted

	who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up			
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	941		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11,948		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,034		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	13,130		Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	1	1	Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	1		Redacted

LAB_ACC_DSD	Sum of Support Type disaggregates	1		Redacted
LAB_ACC_TA	Sum of Support Type disaggregates	1		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	20	3	Redacted
LAB_CAP_DSD	By clinical laboratories	20	3	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	20		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	20		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	20		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	47,217	40,503	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	50,889	40,503	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	6,327	2,834	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	40,890	37,669	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	47,217	40,503	Redacted
TB_SCREEN_DSD	Sex: Male	16,431	14,053	Redacted
TB_SCREEN_DSD	Sex: Female	30,786	26,450	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	47,217	40,503	Redacted
TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	1,574	10,438	Redacted



Implementing Mechanism Details

Mechanism ID: 13093	Mechanism Name: Provision of the Basic Care Package in the Republic of Uganda under the President's Emmergency Plan for AIDS Relief
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: PACE	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13093
Mechanism Name:	Provision of the Basic Care Package in the Republic of Uganda under the President's Emmergency Plan for AIDS Relief
Prime Partner Name:	PACE



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13102	Mechanism Name: Supporting the National Blood Transfusion Service (NBTS) in the Implementation and Strengthening of Blood Safety Activities in the Republic of Uganda under the President's Emergency Plan for AIDS Relief (PEPFAR)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Uganda Blood Transfusion Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 927,809	
Applied Pipeline Amount: 72,191	
Funding Source	Funding Amount
GHP-State	927,809

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13102		
Mechanism Name:	Supporting the National Blood Transfusion Service (NBTS) in the Implementation and Strengthening of Blood Safety Activities in the Republic of Uganda under the President's Emergency Plan for AIDS Relief (PEPFAR)		
Prime Partner Name:	Uganda Blood Transfusion Services		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	927,809	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	6,919		Redacted
PP_PREV_TA	Age/sex: 10-14 Male	631		Redacted
PP_PREV_TA	Age/sex: 15-19 Male	678		Redacted
PP_PREV_TA	Age/sex: 20-24 Male	569		Redacted
PP_PREV_TA	Age/sex: 25-49 Male	1,500		Redacted

PP_PREV_TA	Age/sex: 50+ Male	56		Redacted
PP_PREV_TA	Age/sex: 10-14 Female	771		Redacted
PP_PREV_TA	Age/sex: 15-19 Female	638		Redacted
PP_PREV_TA	Age/sex: 20-24 Female	559		Redacted
PP_PREV_TA	Age/sex: 25-49 Female	1,463		Redacted
PP_PREV_TA	Age/sex: 50+ Female	54		Redacted
PP_PREV_TA	Sum of Age/Sex disaggregates	6,919		Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	21,941		Redacted
HTC_TST_TA	By Test Result: Negative	20,123		Redacted
HTC_TST_TA	By Test Result: Positive	1,818		Redacted
HTC_TST_TA	Sum of Test Result disaggregates	21,941		Redacted
HTC_TST_TA	Age/sex: <1 Male	0		Redacted
HTC_TST_TA	Age/sex: 1-4 Male	0		Redacted
HTC_TST_TA	Age/sex: 5-9 Male	2,090		Redacted
HTC_TST_TA	Age/sex: 10-14 Male	1,576		Redacted
HTC_TST_TA	Age/sex: 15-19 Male	1,696		Redacted
HTC_TST_TA	Age/sex: 20-24 Male	1,422		Redacted
HTC_TST_TA	Age/sex: 25-49 Male	3,750		Redacted
HTC_TST_TA	Age/sex: 50+ Male	140		Redacted
HTC_TST_TA	Age/sex: 5-9 Female	2,554		Redacted
HTC_TST_TA	Age/sex: 10-14 Female	1,927		Redacted
HTC_TST_TA	Age/sex: 15-19 Female	1,596		Redacted
HTC_TST_TA	Age/sex: 20-24 Female	1,397		Redacted
HTC_TST_TA	Age/sex: 25-49 Female	3,658		Redacted
HTC_TST_TA	Age/sex: 50+ Female	135		Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	21,941		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,666		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	7,007		Redacted



HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,481		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	6,787		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	8,147		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	13,794		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	21,941		Redacted

Implementing Mechanism Details

Mechanism ID: 13104	Mechanism Name: Scaling up Comprehensive HIV/AIDS Services including provider initiated Testing and Counseling, TB/HIV, OVC, Care and ART for Adults and children in Eastern and West Nile regions in Uganda under the PEPFAR
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Baylor College of Medicine Children's Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 7,677,793	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	7,677,793

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)



Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13104		
Mechanism Name:	Scaling up Comprehensive HIV/AIDS Services including provider initiated Testing and Counseling, TB/HIV, OVC, Care and ART for Adults and children in Eastern and West Nile regions in Uganda under the		
Prime Partner Name:	PEPFAR		
	Baylor College of Medicine Children's Foundation		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,472,995	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	751,955	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	142,811	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	281,417	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Prevention	CIRC	996,922	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,717,153	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	496,948	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	353,253	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,409,014	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	55,325	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	9,834	2,751	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	10,927	2,751	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	9,834		Redacted
PMTCT_ARV_DS	Sub-Disag of Life-long ART: Newly	6,589	351	Redacted

D	initiated on treatment during the current pregnancy			
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	3,245	2,400	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	9,834		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	9,834	2,751	Redacted
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	5,532	2,106	Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	6,146	2,106	Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	5,532		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	3,706	232	Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,826	1,874	Redacted
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0		Redacted
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	5,532		Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	5,532	2,106	Redacted

PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	156,093	107,553	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	164,309	133,752	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	4,152	2,407	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	6,774	344	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	10,926	2,751	Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	87,803	80,990	Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	92,424	95,491	Redacted
PMTCT_STAT_TA	By: Known positives at entry	2,336	1,839	Redacted
PMTCT_STAT_TA	By: Number of new positives identified	3,811	267	Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	6,147	2,106	Redacted
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	71	42	Redacted
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	2		Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	2		Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category:	5		Redacted

	Number of clients with one or more severe surgical intra-operative AE(s)			
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	50		Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	45		Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	6		Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	16		Redacted
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)	16		Redacted
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	5		Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	17,458	13,000	Redacted
VMMC_CIRC_DS D	By Age: 10-14	3,142		Redacted

VMMC_CIRC_DS D	By Age: 15-19	3,450		Redacted
VMMC_CIRC_DS D	By Age: 20-24	2,891		Redacted
VMMC_CIRC_DS D	By Age: 25-49	7,626		Redacted
VMMC_CIRC_DS D	By Age: 50+	349		Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	17,458		Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	409	234	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	13,209	12,766	Redacted
VMMC_CIRC_DS D	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	3,841		Redacted
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	15,224	13,000	Redacted
VMMC_CIRC_DS D	By circumcision technique: Device-based VMMC	2,234		Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	15,224	13,000	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0		Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	874		Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	2,088		Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	1,750		Redacted

PP_PREV_DSD	Age/sex: 25-49 Male	4,615		Redacted
PP_PREV_DSD	Age/sex: 50+ Male	187		Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	1,192		Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	3,834		Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	3,355		Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	8,787		Redacted
PP_PREV_DSD	Age/sex: 50+ Female	343		Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	27,025		Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	183,097	384,165	Redacted
PP_PREV_TA	Age/sex: 10-14 Male	12,572	13,133	Redacted
PP_PREV_TA	Age/sex: 15-19 Male	12,315	38,255	Redacted
PP_PREV_TA	Age/sex: 20-24 Male	10,321	41,880	Redacted
PP_PREV_TA	Age/sex: 25-49 Male	27,222	72,765	Redacted
PP_PREV_TA	Age/sex: 50+ Male	1,171	6,173	Redacted
PP_PREV_TA	Age/sex: 10-14 Female	6,144	17,324	Redacted
PP_PREV_TA	Age/sex: 15-19 Female	27,116	40,952	Redacted
PP_PREV_TA	Age/sex: 20-24 Female	23,727	60,775	Redacted
PP_PREV_TA	Age/sex: 25-49 Female	62,141	87,079	Redacted
PP_PREV_TA	Age/sex: 50+ Female	368	5,829	Redacted
PP_PREV_TA	Sum of Age/Sex disaggregates	183,097	384,165	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	342,201	494,944	Redacted
HTC_TST_DSD	By Test Result: Negative	331,935	479,216	Redacted
HTC_TST_DSD	By Test Result: Positive	10,266	15,728	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	342,201	494,944	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	18,863		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	20,707		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	17,354		Redacted

HTC_TST_DSD	Age/sex: 25-49 Male	45,773		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	2,096		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	56,978		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	49,856		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	130,575		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	342,202		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	18,863	25,132	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	85,930	182,883	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	237,408	253,608	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	18,863	58,453	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	323,338	436,491	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	342,201	494,944	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	152,559	326,177	Redacted
HTC_TST_TA	By Test Result: Negative	144,986	316,015	Redacted
HTC_TST_TA	By Test Result: Positive	7,573	10,162	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	152,559	326,177	Redacted
HTC_TST_TA	Age/sex: 5-9 Male	16,658		Redacted
HTC_TST_TA	Age/sex: 10-14 Male	12,567		Redacted
HTC_TST_TA	Age/sex: 15-19 Male	10,080		Redacted
HTC_TST_TA	Age/sex: 20-24 Male	8,448		Redacted
HTC_TST_TA	Age/sex: 25-49 Male	22,283		Redacted
HTC_TST_TA	Age/sex: 50+ Male	833		Redacted
HTC_TST_TA	Age/sex: 5-9 Female	20,360		Redacted
HTC_TST_TA	Age/sex: 10-14 Female	15,359		Redacted
HTC_TST_TA	Age/sex: 15-19 Female	10,812		Redacted
HTC_TST_TA	Age/sex: 20-24 Female	9,462		Redacted
HTC_TST_TA	Age/sex: 25-49 Female	24,778		Redacted



HTC_TST_TA	Age/sex: 50+ Female	919		Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	152,559		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	29,225	16,572	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	41,643	120,524	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	35,720	21,969	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	45,971	167,112	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	64,945	38,541	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	87,614	287,636	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	152,559	326,177	Redacted
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	1,544	10,646	Redacted
OVC_ACC_DSD	Sex: Male	701		Redacted
OVC_ACC_DSD	Sex: Female	843		Redacted
OVC_ACC_DSD	Sum of Sex disaggregates	1,544		Redacted
OVC_ACC_DSD	Age: <1	65		Redacted
OVC_ACC_DSD	Age: 1-4	244		Redacted
OVC_ACC_DSD	Age: 5-9	432		Redacted
OVC_ACC_DSD	Age: 10-14	441		Redacted
OVC_ACC_DSD	Age: 15-17	284		Redacted
OVC_ACC_DSD	Age: 18+	77		Redacted
OVC_ACC_DSD	Sum of Age disaggregates	1,543		Redacted
OVC_ACC_TA	Sum of Sex disaggregates	1,544		Redacted
OVC_ACC_TA	Sum of Age disaggregates	1,543		Redacted
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	8,438	20,715	Redacted
OVC_SERV_DSD	Sex: Male	3,831		Redacted

OVC_SERV_DSD	Sex: Female	4,607		Redacted
OVC_SERV_DSD	Sum of Sex disaggregates	8,438		Redacted
OVC_SERV_DSD	Age: <1	337		Redacted
OVC_SERV_DSD	Age: 1-4	1,267		Redacted
OVC_SERV_DSD	Age: 5-9	2,245		Redacted
OVC_SERV_DSD	Age: 10-14	2,293		Redacted
OVC_SERV_DSD	Age: 15-17	1,475		Redacted
OVC_SERV_DSD	Age: 18+	401		Redacted
OVC_SERV_DSD	Sum of Age disaggregates	8,018		Redacted
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	423		Redacted
OVC_SERV_TA	Sex: Male	193		Redacted
OVC_SERV_TA	Sex: Female	230		Redacted
OVC_SERV_TA	Sum of Sex disaggregates	423		Redacted
OVC_SERV_TA	Age: <1	18		Redacted
OVC_SERV_TA	Age: 1-4	67		Redacted
OVC_SERV_TA	Age: 5-9	118		Redacted
OVC_SERV_TA	Age: 10-14	121		Redacted
OVC_SERV_TA	Age: 15-17	78		Redacted
OVC_SERV_TA	Age: 18+	21		Redacted
OVC_SERV_TA	Sum of Age disaggregates	423		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	32,150	43,112	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,061	1,378	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	10,256	1,638	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,447	13,585	Redacted

CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	19,386	26,511	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	32,150	43,112	Redacted
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	30,890	11,566	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,020	371	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	9,854	439	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,390	3,639	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	18,626	7,117	Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	30,890	11,566	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	18,553	8,347	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	816	256	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	5,696	2,746	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	761	299	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	11,280	5,046	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	18,553	8,347	Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	18,553	8,347	Redacted
FN_THER_DSD	Number of clinically malnourished	1,512	1,027	Redacted

	PLHIV who received therapeutic and/or supplementary food during the reporting period.			
FN_THER_DSD	Aggregated Age: <18	930	403	Redacted
FN_THER_DSD	Aggregated Age: 18+	582	624	Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	1,512	1,027	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,574	773	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,967	969	Redacted
TB_ART_DSD	Age: 0-4	4		Redacted
TB_ART_DSD	Age: 5-14	43		Redacted
TB_ART_DSD	Age: 15+	1,825		Redacted
TB_ART_DSD	Male	1,217	275	Redacted
TB_ART_DSD	Female	655	498	Redacted
TB_ART_DSD	Sum of Sex disaggregates	1,872	773	Redacted
TB_ART_DSD	Aggregated Age: <15	47	59	Redacted
TB_ART_DSD	Aggregated Age: 15+	1,825	714	Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	1,872	773	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	13,658	2,367	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	17,073		Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	13,658	233	Redacted

PMTCT_EID_DSD	Sum of Infant Age disaggregates	13,658	2,366	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	854		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	28,246	40,949	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,045		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	8,756	25,976	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,130		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	17,315	11,958	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,175		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	26,071	37,934	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	28,246	37,934	Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	28,246	10,765	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	1,045		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	8,756	6,829	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	1,130		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	17,315	3,143	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	2,175		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	26,071	9,972	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	28,246	9,972	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	21,164	10,432	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	720		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	5,503	6,779	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	825		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	14,116	3,211	Redacted

TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	21,164	9,990	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	22,598	11,280	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	24,833	13,269	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,650		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	20,948		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,813		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	23,020		Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or	9		Redacted

	international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation			
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	9		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	9		Redacted
LAB_ACC_TA	Sum of Support Type disaggregates	9		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	231	44	Redacted
LAB_CAP_DSD	By clinical laboratories	231	44	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	231		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	231		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	231		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	56,736	43,112	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	32,150	43,112	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	7,603	3,023	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	49,133	40,089	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	56,736	43,112	Redacted
TB_SCREEN_DSD	Sex: Male	19,744	14,963	Redacted
TB_SCREEN_DSD	Sex: Female	36,992	28,149	Redacted



TB_SCREEN_DSD	Sum of Sex disaggregates	56,736	43,112	Redacted
TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	30,890	11,566	Redacted

Implementing Mechanism Details

Mechanism ID: 13136	Mechanism Name: Scaling up comprehensive HIV/ Aids Services Including Provider Initiated Testing and Counseling (PITC), MARPI, SGBV at KCC Clinics
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Infectious Disease Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 3,244,252	
Applied Pipeline Amount: 1,025,247	
Funding Source	Funding Amount
GHP-State	3,244,252

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Gender: GBV	400,000
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information



Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	200,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Key Populations: FSW	400,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Key Populations: MSM and TG	400,000
Focus Area:	Training of health workers and community outreach workers

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13136
----------------------	--------------



Mechanism Name:		Scaling up comprehensive HIV/ Aids Services Including Provider	
Prime Partner Name:		Initiated Testing and Counseling (PITC), MARPI, SGBV at KCC Clinics Infectious Disease Institute	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	929,475	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	148,826	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	282,298	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	65,307	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	113,614	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	596,655	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	96,302	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	154,727	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	829,268	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	PDTX	27,780	0
-----------	------	--------	---

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,939	3,297	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	2,154	3,297	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	1,939		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	1,299	821	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	640	2,476	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	1,939		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	1,939	3,297	Redacted
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	426		Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant	473		Redacted

	women identified in the reporting period (including known HIV-positive at entry)			
PMTCT_ARV_TA	Life-long ART (including Option B+)	426		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	286		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	140		Redacted
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0		Redacted
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	426		Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	426		Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	30,778	29,300	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	32,398	30,842	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	819	2,476	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	1,336	821	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	2,155	3,297	Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their	6,756		Redacted

	results)			
PMTCT_STAT_TA	Number of new ANC and L&D clients	7,112		Redacted
PMTCT_STAT_TA	By: Known positives at entry	180		Redacted
PMTCT_STAT_TA	By: Number of new positives identified	293		Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	473		Redacted
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	51	11	Redacted
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	1		Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	1		Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	7		Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	43		Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	39		Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	4		Redacted

VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	16		Redacted
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)	16		Redacted
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	7		Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	15,380	3,309	Redacted
VMMC_CIRC_DS D	By Age: 10-14	2,768		Redacted
VMMC_CIRC_DS D	By Age: 15-19	3,039		Redacted
VMMC_CIRC_DS D	By Age: 20-24	2,547		Redacted
VMMC_CIRC_DS D	By Age: 25-49	6,718		Redacted
VMMC_CIRC_DS D	By Age: 50+	308		Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	15,380		Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	360	60	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC	11,637	3,249	Redacted

	program)			
VMMC_CIRC_DS D	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	3,384		Redacted
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	13,146	3,159	Redacted
VMMC_CIRC_DS D	By circumcision technique: Device-based VMMC	2,234	150	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	13,146	3,159	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0		Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	34,184	3,232	Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	1,106		Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	2,641	268	Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	2,213	345	Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	5,837	851	Redacted
PP_PREV_DSD	Age/sex: 50+ Male	236	202	Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	1,508		Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	4,850	236	Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	4,244	407	Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	11,115	804	Redacted
PP_PREV_DSD	Age/sex: 50+ Female	434	119	Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	34,184	3,232	Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV	21,965	83,755	Redacted

	prevention intervention including the minimum components during the reporting period.			
PP_PREV_TA	Total number of people in the target population	0	209,389	Redacted
PP_PREV_TA	Age/sex: 10-14 Male	1,224	3,988	Redacted
PP_PREV_TA	Age/sex: 15-19 Male	1,289	7,434	Redacted
PP_PREV_TA	Age/sex: 20-24 Male	1,080	8,232	Redacted
PP_PREV_TA	Age/sex: 25-49 Male	2,849	14,258	Redacted
PP_PREV_TA	Age/sex: 50+ Male	128	1,205	Redacted
PP_PREV_TA	Age/sex: 10-14 Female	192	5,246	Redacted
PP_PREV_TA	Age/sex: 15-19 Female	3,646	9,125	Redacted
PP_PREV_TA	Age/sex: 20-24 Female	3,190	13,469	Redacted
PP_PREV_TA	Age/sex: 25-49 Female	8,356	19,494	Redacted
PP_PREV_TA	Age/sex: 50+ Female	12	1,304	Redacted
PP_PREV_TA	Sum of Age/Sex disaggregates	21,966	83,755	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	56,067	212,915	Redacted
HTC_TST_DSD	By Test Result: Negative	53,068	204,682	Redacted
HTC_TST_DSD	By Test Result: Positive	3,000	8,233	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	56,068	212,915	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	0		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	519		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	3,060		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	3,222		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	2,700		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	7,122		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	321		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	0		Redacted

HTC_TST_DSD	Age/sex: 5-9 Female	635		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	479		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	9,115		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	7,976		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	20,889		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	29		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	56,067		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,580	10,774	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	13,364	78,668	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,113	14,281	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	38,010	109,192	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	4,693	25,055	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	51,374	187,860	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	56,067	212,915	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	7,423		Redacted
HTC_TST_TA	By Test Result: Negative	6,963		Redacted
HTC_TST_TA	By Test Result: Positive	460		Redacted
HTC_TST_TA	Sum of Test Result disaggregates	7,423		Redacted
HTC_TST_TA	Age/sex: 5-9 Male	93		Redacted
HTC_TST_TA	Age/sex: 10-14 Male	71		Redacted
HTC_TST_TA	Age/sex: 15-19 Male	53		Redacted
HTC_TST_TA	Age/sex: 20-24 Male	44		Redacted
HTC_TST_TA	Age/sex: 25-49 Male	116		Redacted
HTC_TST_TA	Age/sex: 50+ Male	4		Redacted
HTC_TST_TA	Age/sex: 5-9 Female	114		Redacted
HTC_TST_TA	Age/sex: 10-14 Female	86		Redacted

HTC_TST_TA	Age/sex: 15-19 Female	1,641		Redacted
HTC_TST_TA	Age/sex: 20-24 Female	1,436		Redacted
HTC_TST_TA	Age/sex: 25-49 Female	3,760		Redacted
HTC_TST_TA	Age/sex: 50+ Female	5		Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	7,423		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	164		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	217		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	200		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	6,842		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	364		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	7,059		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	7,423		Redacted
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	257		Redacted
OVC_ACC_DSD	Sex: Male	117		Redacted
OVC_ACC_DSD	Sex: Female	140		Redacted
OVC_ACC_DSD	Sum of Sex disaggregates	257		Redacted
OVC_ACC_DSD	Age: <1	11		Redacted
OVC_ACC_DSD	Age: 1-4	41		Redacted
OVC_ACC_DSD	Age: 5-9	72		Redacted
OVC_ACC_DSD	Age: 10-14	74		Redacted
OVC_ACC_DSD	Age: 15-17	47		Redacted
OVC_ACC_DSD	Age: 18+	12		Redacted
OVC_ACC_DSD	Sum of Age disaggregates	257		Redacted
OVC_ACC_TA	Sum of Sex disaggregates	257		Redacted
OVC_ACC_TA	Sum of Age disaggregates	257		Redacted
OVC_SERV_DSD	Number of active beneficiaries served	1,335		Redacted



	by PEPFAR OVC programs for children and families affected by HIV/AIDS			
OVC_SERV_DSD	Sex: Male	606		Redacted
OVC_SERV_DSD	Sex: Female	729		Redacted
OVC_SERV_DSD	Sum of Sex disaggregates	1,335		Redacted
OVC_SERV_DSD	Age: <1	56		Redacted
OVC_SERV_DSD	Age: 1-4	211		Redacted
OVC_SERV_DSD	Age: 5-9	374		Redacted
OVC_SERV_DSD	Age: 10-14	382		Redacted
OVC_SERV_DSD	Age: 15-17	246		Redacted
OVC_SERV_DSD	Age: 18+	67		Redacted
OVC_SERV_DSD	Sum of Age disaggregates	1,336		Redacted
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	70		Redacted
OVC_SERV_TA	Sex: Male	32		Redacted
OVC_SERV_TA	Sex: Female	38		Redacted
OVC_SERV_TA	Sum of Sex disaggregates	70		Redacted
OVC_SERV_TA	Age: <1	3		Redacted
OVC_SERV_TA	Age: 1-4	11		Redacted
OVC_SERV_TA	Age: 5-9	20		Redacted
OVC_SERV_TA	Age: 10-14	20		Redacted
OVC_SERV_TA	Age: 15-17	13		Redacted
OVC_SERV_TA	Age: 18+	4		Redacted
OVC_SERV_TA	Sum of Age disaggregates	71		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	30,221	36,322	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	997	1,162	Redacted
CARE_CURR_DS	Aggregated Age/sex - USE WITH HQ	9,640	1,380	Redacted

D	PERMISSION ONLY: 15+ Male			
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,360	11,442	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	18,224	22,338	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	30,221	36,322	Redacted
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	935		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	31		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	298		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	42		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	564		Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	935		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	3,391	10,386	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	149	322	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	1,041	3,417	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	139	364	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	2,062	6,283	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	3,391	10,386	Redacted

CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	3,391	10,386	Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	804	872	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	10,054	10,897	Redacted
FN_THER_DSD	Aggregated Age: <18	460	336	Redacted
FN_THER_DSD	Aggregated Age: 18+	288	536	Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	748	872	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	740	170	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	925	213	Redacted
TB_ART_DSD	Age: 0-4	2		Redacted
TB_ART_DSD	Age: 5-14	21		Redacted
TB_ART_DSD	Age: 15+	902		Redacted
TB_ART_DSD	Male	601	60	Redacted
TB_ART_DSD	Female	324	110	Redacted
TB_ART_DSD	Sum of Sex disaggregates	925	170	Redacted
TB_ART_DSD	Aggregated Age: <15	23	12	Redacted
TB_ART_DSD	Aggregated Age: 15+	902	158	Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	925	170	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,102	2,638	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant	2,627		Redacted

	women identified during the reporting period (include known HIV-positive women at entry into PMTCT)			
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	2,102	266	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,102	2,638	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	131		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	29,072	34,112	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,076		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	9,012	21,641	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,163		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	17,821	9,960	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,239		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	26,833	31,601	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	29,072	31,601	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4,733	8,690	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	160		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,231	5,654	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	185		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	3,157	2,676	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	4,733	8,330	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	6,308	4,285	Redacted

TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	6,932	5,041	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	460		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,847		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	506		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,426		Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	0		Redacted
LAB_ACC_DSD	By site support type: Direct Service	0		Redacted

	Delivery (DSD)			
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	0		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	0		Redacted
LAB_ACC_TA	Sum of Support Type disaggregates	0		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	10		Redacted
LAB_CAP_DSD	By clinical laboratories	9		Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	9		Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	1		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	10		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	10		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	28,040	36,322	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	30,221	36,322	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	3,757	2,543	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	24,283	33,779	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	28,040	36,322	Redacted
TB_SCREEN_DSD	Sex: Male	9,758	12,604	Redacted
TB_SCREEN_DSD	Sex: Female	18,282	23,718	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	28,040	36,322	Redacted



TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	935		Redacted
--------------	---	-----	--	----------

Implementing Mechanism Details

Mechanism ID: 13138	Mechanism Name: Informatics Development and Support
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Public Health Informatics Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)



Budget Code Information

Mechanism ID:	13138		
Mechanism Name:	Informatics Development and Support		
Prime Partner Name:	Public Health Informatics Institute		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13161	Mechanism Name: Enhanced Prevention
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Uganda Virus Research Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 581,688	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	581,688

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Gender: GBV	50,000
-------------	--------



Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	30,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Key Populations: FSW	80,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 13161			
Mechanism Name: Enhanced Prevention			
Prime Partner Name: Uganda Virus Research Institute			
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Care	HBHC	8,666	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	1,246	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	1,086	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	17,409	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	442,110	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	10,384	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	787	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PP_PREV_DSD	Number of the target population who	3,004		Redacted

	completed a standardized HIV prevention intervention including the minimum components during the reporting period.			
PP_PREV_DSD	Age/sex: 10-14 Male	97		Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	232		Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	194		Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	513		Redacted
PP_PREV_DSD	Age/sex: 50+ Male	21		Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	133		Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	426		Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	373		Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	977		Redacted
PP_PREV_DSD	Age/sex: 50+ Female	38		Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	3,004		Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	2,127	2,688	Redacted
PP_PREV_TA	Total number of people in the target population	0	6,721	Redacted
PP_PREV_TA	Age/sex: 10-14 Male	5	135	Redacted
PP_PREV_TA	Age/sex: 15-19 Male	341	238	Redacted
PP_PREV_TA	Age/sex: 20-24 Male	286	257	Redacted
PP_PREV_TA	Age/sex: 25-49 Male	754	456	Redacted
PP_PREV_TA	Age/sex: 50+ Male	28	40	Redacted
PP_PREV_TA	Age/sex: 10-14 Female	6	181	Redacted
PP_PREV_TA	Age/sex: 15-19 Female	166	291	Redacted
PP_PREV_TA	Age/sex: 20-24 Female	145	428	Redacted
PP_PREV_TA	Age/sex: 25-49 Female	380	621	Redacted
PP_PREV_TA	Age/sex: 50+ Female	14	41	Redacted
PP_PREV_TA	Sum of Age/Sex disaggregates	2,125	2,688	Redacted

HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	5,356	6,696	Redacted
HTC_TST_DSD	By Test Result: Negative	4,010	6,428	Redacted
HTC_TST_DSD	By Test Result: Positive	1,346	268	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	5,356	6,696	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	0		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	17		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	13		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	853		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	715		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	1,886		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	70		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	0		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	21		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	16		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	415		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	363		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	952		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	35		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	5,356		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	30	339	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,524	2,474	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	37	449	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,765	3,434	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	67	788	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	5,289	5,908	Redacted

HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	5,356	6,696	Redacted
GEND_GBV_DSD	Number of people receiving post-GBV care	4,852	100	Redacted
GEND_GBV_DSD	Age: 0-9	0		Redacted
GEND_GBV_DSD	Age: 10-14	1,227		Redacted
GEND_GBV_DSD	Age: 15-17	1,630		Redacted
GEND_GBV_DSD	Age: 18-24	1,389		Redacted
GEND_GBV_DSD	Age: 25+	606		Redacted
GEND_GBV_DSD	Sum of Age disaggregates	4,852		Redacted
GEND_GBV_DSD	Sex: Male	2,286		Redacted
GEND_GBV_DSD	Sex: Female	2,566		Redacted
GEND_GBV_DSD	Sum of Sex disaggregates	4,852		Redacted
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	0	41	Redacted
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	0	47	Redacted
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	0		Redacted
GEND_GBV_TA	Sum of Age disaggregates	4,852		Redacted
GEND_GBV_TA	Sum of Sex disaggregates	4,852		Redacted
GEND_NORM_DS D	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	512		Redacted
GEND_NORM_DS D	By Age: 25+	512		Redacted
GEND_NORM_DS D	Sum of Age disaggregates	512		Redacted
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	229		Redacted
OVC_ACC_DSD	Sex: Male	104		Redacted

OVC_ACC_DSD	Sex: Female	125		Redacted
OVC_ACC_DSD	Sum of Sex disaggregates	229		Redacted
OVC_ACC_DSD	Age: <1	10		Redacted
OVC_ACC_DSD	Age: 1-4	36		Redacted
OVC_ACC_DSD	Age: 5-9	64		Redacted
OVC_ACC_DSD	Age: 10-14	65		Redacted
OVC_ACC_DSD	Age: 15-17	42		Redacted
OVC_ACC_DSD	Age: 18+	11		Redacted
OVC_ACC_DSD	Sum of Age disaggregates	228		Redacted
OVC_ACC_TA	Sum of Sex disaggregates	229		Redacted
OVC_ACC_TA	Sum of Age disaggregates	228		Redacted
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	1,188		Redacted
OVC_SERV_DSD	Sex: Male	539		Redacted
OVC_SERV_DSD	Sex: Female	648		Redacted
OVC_SERV_DSD	Sum of Sex disaggregates	1,187		Redacted
OVC_SERV_DSD	Age: <1	50		Redacted
OVC_SERV_DSD	Age: 1-4	188		Redacted
OVC_SERV_DSD	Age: 5-9	333		Redacted
OVC_SERV_DSD	Age: 10-14	340		Redacted
OVC_SERV_DSD	Age: 15-17	219		Redacted
OVC_SERV_DSD	Age: 18+	59		Redacted
OVC_SERV_DSD	Sum of Age disaggregates	1,189		Redacted
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	64		Redacted
OVC_SERV_TA	Sex: Male	28		Redacted
OVC_SERV_TA	Sex: Female	34		Redacted
OVC_SERV_TA	Sum of Sex disaggregates	62		Redacted
OVC_SERV_TA	Age: <1	3		Redacted
OVC_SERV_TA	Age: 1-4	10		Redacted

OVC_SERV_TA	Age: 5-9	18		Redacted
OVC_SERV_TA	Age: 10-14	18		Redacted
OVC_SERV_TA	Age: 15-17	12		Redacted
OVC_SERV_TA	Age: 18+	3		Redacted
OVC_SERV_TA	Sum of Age disaggregates	64		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	2,669	410	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	88	13	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	851	16	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	120	129	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,610	252	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	2,669	410	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	26		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	50		Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	83		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at	1,393	385	Redacted

	enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load			
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	61	12	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	428	127	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	57	13	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	847	233	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	1,393	385	Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	1,393	385	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	65	4	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	82	5	Redacted
TB_ART_DSD	Age: 0-4	0		Redacted
TB_ART_DSD	Age: 5-14	2		Redacted
TB_ART_DSD	Age: 15+	80		Redacted
TB_ART_DSD	Male	53	1	Redacted
TB_ART_DSD	Female	29	3	Redacted
TB_ART_DSD	Sum of Sex disaggregates	82	4	Redacted
TB_ART_DSD	Aggregated Age: <15	2		Redacted
TB_ART_DSD	Aggregated Age: 15+	80	4	Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	82	4	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	6,809		Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive	7,566		Redacted

	women at entry into PMTCT)			
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	6,809		Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	6,809		Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	378		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,998	385	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	74		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	619	245	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	80		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	1,225	112	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	154		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	1,844	357	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	1,998	357	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,212	332	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	41		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	315	217	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	47		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	809	102	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,212	319	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	885	164	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months	972	192	Redacted

	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up			
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	65		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	820		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	71		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	901		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	2,477	410	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	2,669	410	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ	332	29	Redacted



	PERMISSION ONLY: <15			
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	2,145	381	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	2,477	410	Redacted
TB_SCREEN_DSD	Sex: Male	862	142	Redacted
TB_SCREEN_DSD	Sex: Female	1,615	268	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	2,477	410	Redacted

Implementing Mechanism Details

Mechanism ID: 13170	Mechanism Name: Surveillance - Epi
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Makerere University School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 393,729	
Applied Pipeline Amount: 706,271	
Funding Source	Funding Amount
GHP-State	393,729

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)



Budget Code Information

Mechanism ID: 13170			
Mechanism Name: Surveillance - Epi			
Prime Partner Name: Makerere University School of Public Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	393,729	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13226	Mechanism Name: Procurement and Logistics Management of Health-related Commodities for HHS/CDC funded HIV/AIDS Programs
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Medical Access Uganda Limited (MAUL)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 59,464,568	
Applied Pipeline Amount: 0	



Funding Source	Funding Amount
GHP-State	59,464,568

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13226		
Mechanism Name:	Procurement and Logistics Management of Health-related Commodities		
Prime Partner Name:	for HHS/CDC funded HIV/AIDS Programs Medical Access Uganda Limited (MAUL)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	10,510,759	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	57,374	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	1,181,182	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	4,158,464	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HMBL	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,465,768	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	2,243,132	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	32,941,342	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	6,667,528	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	239,019	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13317	Mechanism Name: Targeted HIV/AIDS and Laboratory Services (THALAS)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Joint Clinical Research Center, Uganda	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,424,623	
Applied Pipeline Amount: 0	



Funding Source	Funding Amount
GHP-State	1,424,623

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	400,000
Key Populations: FSW	40,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13317
Mechanism Name:	Targeted HIV/AIDS and Laboratory Services (THALAS)
Prime Partner Name:	Joint Clinical Research Center, Uganda

Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	382,605	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	70,726	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	47,748	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	23,158	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	612,997	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	37,389	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	5,208	
PP_PREV_DSD	Age/sex: 10-14 Male	169	
PP_PREV_DSD	Age/sex: 15-19 Male	402	
PP_PREV_DSD	Age/sex: 20-24 Male	337	

PP_PREV_DSD	Age/sex: 25-49 Male	889	
PP_PREV_DSD	Age/sex: 50+ Male	36	
PP_PREV_DSD	Age/sex: 10-14 Female	230	
PP_PREV_DSD	Age/sex: 15-19 Female	739	
PP_PREV_DSD	Age/sex: 20-24 Female	647	
PP_PREV_DSD	Age/sex: 25-49 Female	1,693	
PP_PREV_DSD	Age/sex: 50+ Female	66	
PP_PREV_DSD	Sum of Age/Sex disaggregates	5,208	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	11,824	21,979
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	390	703
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,772	835
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	532	6,923
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	7,130	13,518
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	11,824	21,979
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	182	1,428
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	8	44
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	56	470
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	7	50
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	111	864
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	182	1,428
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	182	1,428

FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	284	527
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	3,830	6,594
FN_THER_DSD	Aggregated Age: <18	175	203
FN_THER_DSD	Aggregated Age: 18+	109	324
FN_THER_DSD	Sum of Aggregated Age disaggregates	284	527
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	281	26
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	351	32
TB_ART_DSD	Age: 0-4	1	
TB_ART_DSD	Age: 5-14	8	
TB_ART_DSD	Age: 15+	342	
TB_ART_DSD	Male	228	9
TB_ART_DSD	Female	123	17
TB_ART_DSD	Sum of Sex disaggregates	351	26
TB_ART_DSD	Aggregated Age: <15	9	2
TB_ART_DSD	Aggregated Age: 15+	342	24
TB_ART_DSD	Sum of Aggregated Age disaggregates	351	26
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	11,550	20,707
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	427	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	3,581	13,137
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	462	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	7,080	6,046
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	889	

TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	10,661	19,183
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	11,550	19,183
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	247	956
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	8	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	64	623
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	10	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	165	294
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	247	917
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	161	495
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	177	582
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11	
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	150	
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	13	
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have	164	

	died, those who have stopped ART, and those lost to follow-up)		
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	0	1
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	0	
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	0	
LAB_ACC_DSD	Sum of Support Type disaggregates	0	
LAB_ACC_TA	Sum of Support Type disaggregates	0	
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	6	1
LAB_CAP_DSD	By clinical laboratories	6	1
LAB_CAP_DSD	By Point-of-care testing sites	0	4
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	6	
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	0	
LAB_CAP_DSD	Sum of Site Support Type disaggregates	6	
LAB_CAP_TA	Sum of Site Support Type disaggregates	6	
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	10,641	21,979
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	11,824	21,979
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ	1,426	1,539



	PERMISSION ONLY: <15		
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	9,215	20,440
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	10,641	21,979
TB_SCREEN_DSD	Sex: Male	3,703	7,627
TB_SCREEN_DSD	Sex: Female	6,938	14,352
TB_SCREEN_DSD	Sum of Sex disaggregates	10,641	21,979

Implementing Mechanism Details

Mechanism ID: 13325	Mechanism Name: Provision of comprehensive, community-based HIV/AIDS services and Capacity Building of Indigenous Organizations in the Republic Of Uganda
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Reach Out Mbuya	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 965,884	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	965,884

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	100
Gender: GBV	80,000
Focus Area:	Post GBV Care



Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Key Populations: FSW	100,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Gender: Gender Equality	50,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13325
Mechanism Name:	Provision of comprehensive, community-based HIV/AIDS services and
Prime Partner Name:	Capacity Building of Indigenous Organizations in the Republic Of



Uganda Reach Out Mbuya			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	163,799	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	172,607	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	29,981	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	22,425	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	47,739	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	246,522	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	2,347	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	265,220	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	15,244	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	38	50	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	42	50	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	38		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	25	16	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	13	34	Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0		Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	38		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	38	50	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	598	489	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	629	515	Redacted

PMTCT_STAT_DS D	By: Known positives at entry	16	34	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	26	16	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	42	50	Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	3,757		Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	122		Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	290		Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	243		Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	642		Redacted
PP_PREV_DSD	Age/sex: 50+ Male	26		Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	166		Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	533		Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	466		Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	1,222		Redacted
PP_PREV_DSD	Age/sex: 50+ Female	48		Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	3,758		Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	4,282	9,829	Redacted
PP_PREV_TA	Total number of people in the target population	0	24,575	Redacted
PP_PREV_TA	Age/sex: 10-14 Male	88	451	Redacted
PP_PREV_TA	Age/sex: 15-19 Male	594	836	Redacted
PP_PREV_TA	Age/sex: 20-24 Male	498	907	Redacted
PP_PREV_TA	Age/sex: 25-49 Male	1,313	1,624	Redacted



PP_PREV_TA	Age/sex: 50+ Male	49	139	Redacted
PP_PREV_TA	Age/sex: 10-14 Female	108	588	Redacted
PP_PREV_TA	Age/sex: 15-19 Female	385	1,111	Redacted
PP_PREV_TA	Age/sex: 20-24 Female	337	1,643	Redacted
PP_PREV_TA	Age/sex: 25-49 Female	883	2,371	Redacted
PP_PREV_TA	Age/sex: 50+ Female	28	159	Redacted
PP_PREV_TA	Sum of Age/Sex disaggregates	4,283	9,829	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	11,357	18,856	Redacted
HTC_TST_DSD	By Test Result: Negative	9,168	18,103	Redacted
HTC_TST_DSD	By Test Result: Positive	2,189	753	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	11,357	18,856	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	0		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	293		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	221		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	1,484		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	1,244		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	3,281		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	123		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	0		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	358		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	270		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	963		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	843		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	2,207		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	70		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	11,357		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	514	954	Redacted

HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	6,133	6,966	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	628	1,265	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	4,082	9,671	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,142	2,219	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	10,215	16,637	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	11,357	18,856	Redacted
GEND_GBV_DSD	Number of people receiving post-GBV care	7,038	150	Redacted
GEND_GBV_DSD	Age: 0-9	0		Redacted
GEND_GBV_DSD	Age: 10-14	2,911		Redacted
GEND_GBV_DSD	Age: 15-17	460		Redacted
GEND_GBV_DSD	Age: 18-24	392		Redacted
GEND_GBV_DSD	Age: 25+	3,275		Redacted
GEND_GBV_DSD	Sum of Age disaggregates	7,038		Redacted
GEND_GBV_DSD	Sex: Male	2,460		Redacted
GEND_GBV_DSD	Sex: Female	4,578		Redacted
GEND_GBV_DSD	Sum of Sex disaggregates	7,038		Redacted
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	0	120	Redacted
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	0	45	Redacted
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	0		Redacted
GEND_GBV_TA	Sum of Age disaggregates	7,038		Redacted
GEND_GBV_TA	Sum of Sex disaggregates	7,038		Redacted
GEND_NORM_DS D	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	3,952		Redacted



GEND_NORM_DS D	By Age: 0-9	0		Redacted
GEND_NORM_DS D	By Age: 10-14	2,882		Redacted
GEND_NORM_DS D	By Age: 15-19	342		Redacted
GEND_NORM_DS D	By Age: 20-24	291		Redacted
GEND_NORM_DS D	By Age: 25+	437		Redacted
GEND_NORM_DS D	Sum of Age disaggregates	3,952		Redacted
GEND_NORM_DS D	By Sex: Male	2,019		Redacted
GEND_NORM_DS D	By Sex: Female	1,933		Redacted
GEND_NORM_DS D	Sum of Sex disaggregates	3,952		Redacted
GEND_NORM_DS D	By type of activity: Individual	0		Redacted
GEND_NORM_DS D	By type of activity: Small Group	0		Redacted
GEND_NORM_DS D	By type of activity: Community-level	0		Redacted
GEND_NORM_TA	Sum of Sex disaggregates	3,952		Redacted
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	1,900	2,444	Redacted
OVC_ACC_DSD	Sex: Male	863		Redacted
OVC_ACC_DSD	Sex: Female	1,038		Redacted
OVC_ACC_DSD	Sum of Sex disaggregates	1,901		Redacted
OVC_ACC_DSD	Age: <1	80		Redacted
OVC_ACC_DSD	Age: 1-4	300		Redacted
OVC_ACC_DSD	Age: 5-9	532		Redacted



OVC_ACC_DSD	Age: 10-14	543		Redacted
OVC_ACC_DSD	Age: 15-17	350		Redacted
OVC_ACC_DSD	Age: 18+	95		Redacted
OVC_ACC_DSD	Sum of Age disaggregates	1,900		Redacted
OVC_ACC_TA	Sum of Sex disaggregates	1,901		Redacted
OVC_ACC_TA	Sum of Age disaggregates	1,900		Redacted
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	10,151	4,755	Redacted
OVC_SERV_DSD	Sex: Male	4,480		Redacted
OVC_SERV_DSD	Sex: Female	5,388		Redacted
OVC_SERV_DSD	Sum of Sex disaggregates	9,868		Redacted
OVC_SERV_DSD	Age: <1	414		Redacted
OVC_SERV_DSD	Age: 1-4	1,559		Redacted
OVC_SERV_DSD	Age: 5-9	2,763		Redacted
OVC_SERV_DSD	Age: 10-14	2,822		Redacted
OVC_SERV_DSD	Age: 15-17	1,816		Redacted
OVC_SERV_DSD	Age: 18+	493		Redacted
OVC_SERV_DSD	Sum of Age disaggregates	9,867		Redacted
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	519		Redacted
OVC_SERV_TA	Sex: Male	236		Redacted
OVC_SERV_TA	Sex: Female	284		Redacted
OVC_SERV_TA	Sum of Sex disaggregates	520		Redacted
OVC_SERV_TA	Age: <1	22		Redacted
OVC_SERV_TA	Age: 1-4	82		Redacted
OVC_SERV_TA	Age: 5-9	145		Redacted
OVC_SERV_TA	Age: 10-14	149		Redacted
OVC_SERV_TA	Age: 15-17	96		Redacted
OVC_SERV_TA	Age: 18+	26		Redacted
OVC_SERV_TA	Sum of Age disaggregates	520		Redacted

CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	8,322	7,351	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	275	235	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,655	280	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	374	2,316	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	5,018	4,520	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	8,322	7,351	Redacted
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	257		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	8		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	82		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	12		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	155		Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	257		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO	2,308	1,137	Redacted

	staging) OR CD4 count OR viral load			
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	102	36	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	708	374	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	95	40	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	1,403	687	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	2,308	1,137	Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	2,308	1,137	Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	166	176	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	2,763	2,205	Redacted
FN_THER_DSD	Aggregated Age: <18	127	68	Redacted
FN_THER_DSD	Aggregated Age: 18+	79	108	Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	206	176	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	204	49	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	254	61	Redacted
TB_ART_DSD	Age: 0-4	1		Redacted
TB_ART_DSD	Age: 5-14	6		Redacted
TB_ART_DSD	Age: 15+	248		Redacted
TB_ART_DSD	Male	166	18	Redacted
TB_ART_DSD	Female	89	31	Redacted
TB_ART_DSD	Sum of Sex disaggregates	255	49	Redacted

TB_ART_DSD	Aggregated Age: <15	6	3	Redacted
TB_ART_DSD	Aggregated Age: 15+	248	46	Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	254	49	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	33	40	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	42		Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	42	4	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	42	40	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	2		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	7,228	6,913	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	267		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	2,241	4,385	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	289		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	4,431	2,019	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	556		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	6,672	6,404	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	7,228	6,404	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,154	1,860	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	73		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	560	1,210	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	84		Redacted

TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,437	573	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	2,154	1,783	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,840	1,034	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,023	1,216	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	134		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,706		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	148		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,875		Redacted

LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	1	1	Redacted
LAB_CAP_DSD	By clinical laboratories	1	1	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	1		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	1		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	1		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	7,721	7,351	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	8,322	7,351	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	1,035	515	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	6,686	6,836	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	7,721	7,351	Redacted
TB_SCREEN_DSD	Sex: Male	2,687	2,551	Redacted
TB_SCREEN_DSD	Sex: Female	5,034	4,800	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	7,721	7,351	Redacted
TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	257		Redacted

Implementing Mechanism Details

Mechanism ID: 13383	Mechanism Name: Supporting the Scale-up of
----------------------------	---



Comprehensive HIV/AIDS Prevention Services in the Republic of Uganda under the Presidents Emergency Plan for AIDS Relief	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Medical and Research Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,148,689	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	1,148,689

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13383
Mechanism Name:	Supporting the Scale-up of Comprehensive HIV/AIDS Prevention Services in the Republic of Uganda under the Presidents Emergency Plan for AIDS Relief
Prime Partner Name:	African Medical and Research Foundation

Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	1,148,689	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	119	107	Redacted
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	3		Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	3		Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	3		Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	111		Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative	101		Redacted

	AE(s)			
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	10		Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	16		Redacted
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)	16		Redacted
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	3		Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	35,993	37,909	Redacted
VMMC_CIRC_DS D	By Age: 10-14	6,479		Redacted
VMMC_CIRC_DS D	By Age: 15-19	7,112		Redacted
VMMC_CIRC_DS D	By Age: 20-24	5,960		Redacted
VMMC_CIRC_DS D	By Age: 25-49	15,722		Redacted
VMMC_CIRC_DS D	By Age: 50+	720		Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	35,993		Redacted

VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	842	620	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	27,232	25,050	Redacted
VMMC_CIRC_DS D	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	7,918	7,239	Redacted
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	33,759	32,909	Redacted
VMMC_CIRC_DS D	By circumcision technique: Device-based VMMC	2,234		Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	33,759	32,909	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0		Redacted
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0		Redacted
VMMC_CIRC_TA	By Age: <1	0		Redacted
VMMC_CIRC_TA	By Age: 1-9	0		Redacted
VMMC_CIRC_TA	By Age: 10-14	0		Redacted
VMMC_CIRC_TA	By Age: 15-19	0		Redacted
VMMC_CIRC_TA	By Age: 20-24	0		Redacted
VMMC_CIRC_TA	By Age: 25-49	0		Redacted
VMMC_CIRC_TA	By Age: 50+	0		Redacted
VMMC_CIRC_TA	Sum of Age disaggregations	0		Redacted

VMMC_CIRC_TA	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	0		Redacted
VMMC_CIRC_TA	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	0		Redacted
VMMC_CIRC_TA	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0		Redacted
VMMC_CIRC_TA	By circumcision technique: Surgical VMMC	0		Redacted
VMMC_CIRC_TA	By circumcision technique: Device-based VMMC	0		Redacted
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	0		Redacted
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0		Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	13,878		Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	2,498		Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	2,742		Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	2,298		Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	6,062		Redacted
PP_PREV_DSD	Age/sex: 50+ Male	278		Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	0		Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	0		Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	0		Redacted



PP_PREV_DSD	Age/sex: 25-49 Female	0		Redacted
PP_PREV_DSD	Age/sex: 50+ Female	0		Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	13,878		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	34,697	29,619	Redacted
HTC_TST_DSD	By Test Result: Negative	33,656	29,028	Redacted
HTC_TST_DSD	By Test Result: Positive	1,041	591	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	34,697	29,619	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	6,245		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	6,856		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	5,746		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	15,156		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	694		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	34,697		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	6,245	1,513	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	28,452	10,945	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	6,245	3,519	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	28,452	26,100	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	34,697	29,619	Redacted

Implementing Mechanism Details

Mechanism ID: 13416	Mechanism Name: Scaling up comprehensive HIV/AIDS services including PICT,TB/HIV,OVC,ART (including pregnant women)&children through public university teaching hospitals, regional referral hospitals& public& private-not-for-profit health facilities in Uganda under PEPFAR.
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Mildmay International	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 9,755,670	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	9,755,670

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13416		
Mechanism Name:	Scaling up comprehensive HIV/AIDS services including PICT,TB/HIV,OVC,ART (including pregnant women)&children through public university teaching hospitals, regional referral hospitals& public& private-not-for-profit health facilities in Uganda under PEPFAR.		
Prime Partner Name:	Mildmay International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	3,373,927	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HKID	602,508	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	395,925	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	973,439	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	396,736	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	300,668	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	187,793	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	763,209	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,512,999	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	248,466	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	2,263	6,634	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	2,514	6,634	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	2,263		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	1,516	1,032	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	747	5,602	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	2,263		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	2,263	6,634	Redacted
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	3,125	5,955	Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	3,472	5,955	Redacted

PMTCT_ARV_TA	Life-long ART (including Option B+)	3,125		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	2,094	748	Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,031	5,207	Redacted
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0		Redacted
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	3,125		Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	3,125	5,955	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	35,918	52,193	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	37,808	54,958	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	955	5,602	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	1,559	1,032	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	2,514	6,634	Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	49,600	43,877	Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	52,211	46,169	Redacted

PMTCT_STAT_TA	By: Known positives at entry	1,319	5,208	Redacted
PMTCT_STAT_TA	By: Number of new positives identified	2,153	747	Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	3,472	5,955	Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	111,893	50,238	Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	8,956	1,132	Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	6,992	7,286	Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	6,005	7,991	Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	15,479	14,024	Redacted
PP_PREV_DSD	Age/sex: 50+ Male	270	1,205	Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	9,416	490	Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	17,187	3,795	Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	14,846	5,654	Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	32,245	8,137	Redacted
PP_PREV_DSD	Age/sex: 50+ Female	497	523	Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	111,893	50,237	Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0	208,459	Redacted
PP_PREV_TA	Age/sex: 10-14 Male	0	9,968	Redacted
PP_PREV_TA	Age/sex: 15-19 Male	0	18,027	Redacted
PP_PREV_TA	Age/sex: 20-24 Male	0	19,548	Redacted
PP_PREV_TA	Age/sex: 25-49 Male	0	34,740	Redacted
PP_PREV_TA	Age/sex: 10-14 Female	0	13,086	Redacted
PP_PREV_TA	Age/sex: 15-19 Female	0	23,151	Redacted
PP_PREV_TA	Age/sex: 20-24 Female	0	34,210	Redacted
PP_PREV_TA	Age/sex: 25-49 Female	0	49,429	Redacted
PP_PREV_TA	Sum of Age/Sex disaggregates	0	208,459	Redacted

KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	5,692	9,900	Redacted
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	5,692	9,241	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	83,243	280,586	Redacted
HTC_TST_DSD	By Test Result: Negative	80,746	270,205	Redacted
HTC_TST_DSD	By Test Result: Positive	2,497	10,381	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	83,243	280,586	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	0		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	4,241		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	0		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	0		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	0		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	0		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	0		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	0		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	5,183		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	3,910		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	19,978		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	17,481		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	45,784		Redacted

HTC_TST_DSD	Age/sex: 50+ Female	327		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	96,904		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	14,206	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0	103,674	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	9,093	18,842	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	83,243	143,864	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	9,093	33,048	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	83,243	247,538	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	92,336	280,586	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	121,849	256,502	Redacted
HTC_TST_TA	By Test Result: Negative	108,691	246,914	Redacted
HTC_TST_TA	By Test Result: Positive	13,158	9,588	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	121,849	256,502	Redacted
HTC_TST_TA	Age/sex: <1 Male	0		Redacted
HTC_TST_TA	Age/sex: 1-4 Male	0		Redacted
HTC_TST_TA	Age/sex: 5-9 Male	9,862		Redacted
HTC_TST_TA	Age/sex: 10-14 Male	7,440		Redacted
HTC_TST_TA	Age/sex: 15-19 Male	10,979		Redacted
HTC_TST_TA	Age/sex: 20-24 Male	9,201		Redacted
HTC_TST_TA	Age/sex: 25-49 Male	24,270		Redacted
HTC_TST_TA	Age/sex: 50+ Male	907		Redacted
HTC_TST_TA	Age/sex: <1 Female	0		Redacted
HTC_TST_TA	Age/sex: 1-4 Female	0		Redacted
HTC_TST_TA	Age/sex: 5-9 Female	12,054		Redacted
HTC_TST_TA	Age/sex: 10-14 Female	9,093		Redacted
HTC_TST_TA	Age/sex: 15-19 Female	8,948		Redacted

HTC_TST_TA	Age/sex: 20-24 Female	7,829		Redacted
HTC_TST_TA	Age/sex: 25-49 Female	20,505		Redacted
HTC_TST_TA	Age/sex: 50+ Female	761		Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	121,849		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	17,302	12,989	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	45,357	94,775	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	21,147	17,222	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	38,043	131,516	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	38,449	30,211	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	83,400	226,291	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	121,849	256,502	Redacted
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	1,852	587	Redacted
OVC_ACC_DSD	Sex: Male	841		Redacted
OVC_ACC_DSD	Sex: Female	1,011		Redacted
OVC_ACC_DSD	Sum of Sex disaggregates	1,852		Redacted
OVC_ACC_DSD	Age: <1	78		Redacted
OVC_ACC_DSD	Age: 1-4	293		Redacted
OVC_ACC_DSD	Age: 5-9	519		Redacted
OVC_ACC_DSD	Age: 10-14	530		Redacted
OVC_ACC_DSD	Age: 15-17	341		Redacted
OVC_ACC_DSD	Age: 18+	93		Redacted
OVC_ACC_DSD	Sum of Age disaggregates	1,854		Redacted
OVC_ACC_TA	Sum of Sex disaggregates	1,852		Redacted
OVC_ACC_TA	Sum of Age disaggregates	1,854		Redacted
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children	9,112	16,598	Redacted

	and families affected by HIV/AIDS			
OVC_SERV_DSD	Sex: Male	4,137		Redacted
OVC_SERV_DSD	Sex: Female	4,975		Redacted
OVC_SERV_DSD	Sum of Sex disaggregates	9,112		Redacted
OVC_SERV_DSD	Age: <1	383		Redacted
OVC_SERV_DSD	Age: 1-4	1,440		Redacted
OVC_SERV_DSD	Age: 5-9	2,552		Redacted
OVC_SERV_DSD	Age: 10-14	2,606		Redacted
OVC_SERV_DSD	Age: 15-17	1,677		Redacted
OVC_SERV_DSD	Age: 18+	456		Redacted
OVC_SERV_DSD	Sum of Age disaggregates	9,114		Redacted
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	1,013		Redacted
OVC_SERV_TA	Sex: Male	460		Redacted
OVC_SERV_TA	Sex: Female	553		Redacted
OVC_SERV_TA	Sum of Sex disaggregates	1,013		Redacted
OVC_SERV_TA	Age: <1	43		Redacted
OVC_SERV_TA	Age: 1-4	160		Redacted
OVC_SERV_TA	Age: 5-9	284		Redacted
OVC_SERV_TA	Age: 10-14	290		Redacted
OVC_SERV_TA	Age: 15-17	186		Redacted
OVC_SERV_TA	Age: 18+	51		Redacted
OVC_SERV_TA	Sum of Age disaggregates	1,014		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	39,000	57,143	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,287	1,831	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	12,441	2,172	Redacted

CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,755	17,990	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	23,517	35,150	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	39,000	57,143	Redacted
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	53,857	52,825	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,777	1,686	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	17,180	2,007	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,424	16,650	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	32,476	32,482	Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	53,857	52,825	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	23,859	14,782	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	1,050	456	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	7,325	4,869	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	978	514	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	14,506	8,943	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	23,859	14,782	Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex	23,859	14,782	Redacted

	disaggregates			
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	2,397	1,371	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	29,967	17,146	Redacted
FN_THER_DSD	Aggregated Age: <18	1,371	527	Redacted
FN_THER_DSD	Aggregated Age: 18+	858	844	Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	2,229	1,371	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2,758	867	Redacted
TB_ART_DSD	Age: 0-4	6		Redacted
TB_ART_DSD	Age: 5-14	63		Redacted
TB_ART_DSD	Age: 15+	2,689		Redacted
TB_ART_DSD	Male	1,793	312	Redacted
TB_ART_DSD	Female	965	555	Redacted
TB_ART_DSD	Sum of Sex disaggregates	2,758	867	Redacted
TB_ART_DSD	Aggregated Age: <15	69	64	Redacted
TB_ART_DSD	Aggregated Age: 15+	2,689	803	Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	2,758	867	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	4,789	5,312	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	5,986		Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12	4,789	534	Redacted

	months of age			
PMTCT_EID_DSD	Sum of Infant Age disaggregates	4,789	5,312	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	299		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	35,564	53,484	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,316		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	11,025	33,931	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,423		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	21,800	15,621	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,739		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	32,825	49,552	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	35,564	49,552	Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	47,142	49,255	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	1,744		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	14,614	31,247	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	1,886		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	28,898	14,378	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	3,630		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	43,512	45,625	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	47,142	45,625	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	25,136	19,875	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	855		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	6,535	12,928	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	980		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+	16,766	6,123	Redacted

	Female			
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	25,136	19,051	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	25,645	12,376	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	28,181	14,563	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,872		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	23,772		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,057		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	26,124		Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing	9	77	Redacted

	facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation			
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	9		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	9		Redacted
LAB_ACC_TA	Sum of Support Type disaggregates	9		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	223	63	Redacted
LAB_CAP_DSD	By clinical laboratories	223	63	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	223		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	223		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	223		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	83,571	57,143	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	39,000	57,143	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	11,199	4,000	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	72,373	53,143	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	83,572	57,143	Redacted



TB_SCREEN_DSD	Sex: Male	29,083	19,833	Redacted
TB_SCREEN_DSD	Sex: Female	54,488	37,310	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	83,571	57,143	Redacted
TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	53,857	52,825	Redacted

Implementing Mechanism Details

Mechanism ID: 13466	Mechanism Name: Provision of Comprehensive HIV/AIDS Care, Treatment and Prevention services in Track 1.0 Health Facilities in Uganda
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Uganda Protestant Medical Board	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,402,688	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	1,402,688

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)



Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13466		
Mechanism Name:	Provision of Comprehensive HIV/AIDS Care, Treatment and Prevention services in Track 1.0 Health Facilities in Uganda		
Prime Partner Name:	Uganda Protestant Medical Board		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	333,215	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	92,238	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	63,829	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	106,965	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	45,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	114,763	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	88,807	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	524,278	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	33,593	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	316	1,190	Redacted

PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	352	1,190	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	316		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	212	493	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	104	697	Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0		Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	316		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	316	1,190	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	5,023	18,406	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	5,288	19,375	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	134	697	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	218	493	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	352	1,190	Redacted

VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	17		Redacted
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	53		Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	53		Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	15		Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	17		Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	16		Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	2		Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	0		Redacted
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category:	0		Redacted

	Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)			
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	15		Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	5,281		Redacted
VMMC_CIRC_DS D	By Age: 10-14	951		Redacted
VMMC_CIRC_DS D	By Age: 15-19	1,044		Redacted
VMMC_CIRC_DS D	By Age: 20-24	875		Redacted
VMMC_CIRC_DS D	By Age: 25-49	2,307		Redacted
VMMC_CIRC_DS D	By Age: 50+	106		Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	5,283		Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	124		Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	3,996		Redacted
VMMC_CIRC_DS D	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	1,162		Redacted
VMMC_CIRC_DS	By circumcision technique: Surgical	5,281		Redacted

D	VMMC			
VMMC_CIRC_DS D	By circumcision technique: Device-based VMMC	0		Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	5,281		Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0		Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	10,934		Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	1,056		Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	1,070		Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	908		Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	2,383		Redacted
PP_PREV_DSD	Age/sex: 50+ Male	86		Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	660		Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	1,350		Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	1,177		Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	2,179		Redacted
PP_PREV_DSD	Age/sex: 50+ Female	65		Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	10,934		Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0	25,129	Redacted
PP_PREV_TA	Age/sex: 10-14 Male	0	1,181	Redacted
PP_PREV_TA	Age/sex: 15-19 Male	0	2,159	Redacted

PP_PREV_TA	Age/sex: 20-24 Male	0	2,339	Redacted
PP_PREV_TA	Age/sex: 25-49 Male	0	4,168	Redacted
PP_PREV_TA	Age/sex: 50+ Male	0	360	Redacted
PP_PREV_TA	Age/sex: 10-14 Female	0	1,541	Redacted
PP_PREV_TA	Age/sex: 15-19 Female	0	2,817	Redacted
PP_PREV_TA	Age/sex: 20-24 Female	0	4,159	Redacted
PP_PREV_TA	Age/sex: 25-49 Female	0	6,004	Redacted
PP_PREV_TA	Age/sex: 50+ Female	0	401	Redacted
PP_PREV_TA	Sum of Age/Sex disaggregates	0	25,129	Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	206		Redacted
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	206		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	16,134	67,865	Redacted
HTC_TST_DSD	By Test Result: Negative	15,263	65,357	Redacted
HTC_TST_DSD	By Test Result: Positive	870	2,508	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	16,133	67,865	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	0		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	558		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	1,338		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	1,507		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	1,263		Redacted

HTC_TST_DSD	Age/sex: 25-49 Male	3,332		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	143		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	0		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	683		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	515		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	1,621		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	1,419		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	3,717		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	38		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	16,134		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,896	3,435	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	6,246	25,077	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,197	4,557	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	6,794	34,796	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	3,093	7,992	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	13,040	59,873	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	16,133	67,865	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0		Redacted
GEND_GBV_DSD	Number of people receiving post-GBV care	1,200		Redacted
GEND_GBV_DSD	Age: 10-14	5		Redacted
GEND_GBV_DSD	Age: 15-17	114		Redacted
GEND_GBV_DSD	Age: 18-24	97		Redacted
GEND_GBV_DSD	Age: 25+	984		Redacted
GEND_GBV_DSD	Sum of Age disaggregates	1,200		Redacted

GEND_GBVDSD	Sex: Male	602		Redacted
GEND_GBVDSD	Sex: Female	598		Redacted
GEND_GBVDSD	Sum of Sex disaggregates	1,200		Redacted
GEND_GBVTAD	Sum of Age disaggregates	1,200		Redacted
GEND_GBVTAD	Sum of Sex disaggregates	1,200		Redacted
GEND_NORM_DS D	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	2,530		Redacted
GEND_NORM_DS D	By Age: 10-14	26		Redacted
GEND_NORM_DS D	By Age: 15-19	186		Redacted
GEND_NORM_DS D	By Age: 20-24	158		Redacted
GEND_NORM_DS D	By Age: 25+	2,160		Redacted
GEND_NORM_DS D	Sum of Age disaggregates	2,530		Redacted
GEND_NORM_DS D	By Sex: Male	1,051		Redacted
GEND_NORM_DS D	By Sex: Female	1,479		Redacted
GEND_NORM_DS D	Sum of Sex disaggregates	2,530		Redacted
GEND_NORM_TAD	Sum of Sex disaggregates	2,530		Redacted
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	834	1,306	Redacted
OVC_ACC_DSD	Sex: Male	378		Redacted
OVC_ACC_DSD	Sex: Female	455		Redacted
OVC_ACC_DSD	Sum of Sex disaggregates	833		Redacted
OVC_ACC_DSD	Age: <1	35		Redacted
OVC_ACC_DSD	Age: 1-4	132		Redacted



OVC_ACC_DSD	Age: 5-9	233		Redacted
OVC_ACC_DSD	Age: 10-14	238		Redacted
OVC_ACC_DSD	Age: 15-17	153		Redacted
OVC_ACC_DSD	Age: 18+	42		Redacted
OVC_ACC_DSD	Sum of Age disaggregates	833		Redacted
OVC_ACC_TA	Sum of Sex disaggregates	833		Redacted
OVC_ACC_TA	Sum of Age disaggregates	833		Redacted
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	4,329	2,541	Redacted
OVC_SERV_DSD	Sex: Male	1,965		Redacted
OVC_SERV_DSD	Sex: Female	2,364		Redacted
OVC_SERV_DSD	Sum of Sex disaggregates	4,329		Redacted
OVC_SERV_DSD	Age: <1	182		Redacted
OVC_SERV_DSD	Age: 1-4	684		Redacted
OVC_SERV_DSD	Age: 5-9	1,212		Redacted
OVC_SERV_DSD	Age: 10-14	1,238		Redacted
OVC_SERV_DSD	Age: 15-17	797		Redacted
OVC_SERV_DSD	Age: 18+	216		Redacted
OVC_SERV_DSD	Sum of Age disaggregates	4,329		Redacted
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	228		Redacted
OVC_SERV_TA	Sex: Male	103		Redacted
OVC_SERV_TA	Sex: Female	124		Redacted
OVC_SERV_TA	Sum of Sex disaggregates	227		Redacted
OVC_SERV_TA	Age: <1	10		Redacted
OVC_SERV_TA	Age: 1-4	36		Redacted
OVC_SERV_TA	Age: 5-9	64		Redacted
OVC_SERV_TA	Age: 10-14	65		Redacted
OVC_SERV_TA	Age: 15-17	42		Redacted
OVC_SERV_TA	Age: 18+	11		Redacted

OVC_SERV_TA	Sum of Age disaggregates	228		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	6,280	15,153	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	207	486	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,003	576	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	283	4,774	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,787	9,317	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	6,280	15,153	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	2,722	2,627	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	120	83	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	835	864	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	112	93	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	1,655	1,587	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	2,722	2,627	Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	2,722	2,627	Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	24,079	363	Redacted

FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	309,773	4,546	Redacted
FN_THER_DSD	Aggregated Age: <18	93	139	Redacted
FN_THER_DSD	Aggregated Age: 18+	58	224	Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	151	363	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	149	318	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	186	396	Redacted
TB_ART_DSD	Age: 0-4	0		Redacted
TB_ART_DSD	Age: 5-14	4		Redacted
TB_ART_DSD	Age: 15+	182		Redacted
TB_ART_DSD	Male	121	113	Redacted
TB_ART_DSD	Female	65	205	Redacted
TB_ART_DSD	Sum of Sex disaggregates	186	318	Redacted
TB_ART_DSD	Aggregated Age: <15	4	23	Redacted
TB_ART_DSD	Aggregated Age: 15+	182	295	Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	186	318	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	281	952	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	352		Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	281	94	Redacted

PMTCT_EID_DSD	Sum of Infant Age disaggregates	281	952	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	18		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	5,626	14,115	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	208		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,744	8,952	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	225		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	3,449	4,122	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	433		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	5,193	13,074	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	5,626	13,074	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,273	3,570	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	77		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	591	2,320	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	89		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,516	1,101	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	2,273	3,421	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,443	3,212	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,685	3,779	Redacted

TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	178		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,265		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	196		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,489		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	5,652	15,153	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	6,280	15,153	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	757	1,061	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	4,895	14,092	Redacted



TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	5,652	15,153	Redacted
TB_SCREEN_DSD	Sex: Male	1,967	5,258	Redacted
TB_SCREEN_DSD	Sex: Female	3,685	9,895	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	5,652	15,153	Redacted

Implementing Mechanism Details

Mechanism ID: 13486	Mechanism Name: Scaling Up Integrated, Effective and Sustainable Services for the Prevention of Mother to Child Transmission of HIV (PMTCT) in Uganda
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Protecting Families from AIDS, Uganda	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 2,458,270	
Applied Pipeline Amount: 445,884	
Funding Source	Funding Amount
GHP-State	2,458,270

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13486		
Mechanism Name:	Scaling Up Integrated, Effective and Sustainable Services for the		
Prime Partner Name:	Prevention of Mother to Child Transmission of HIV (PMTCT) in Uganda		
	Protecting Families from AIDS, Uganda		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	508,427	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	143,804	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	752,063	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	764,147	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	289,829	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT)	5,883	5,322	Redacted

	during pregnancy and delivery			
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	6,536	5,322	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	5,883		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	3,942	1,240	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,941	4,082	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	5,883		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	5,883	5,322	Redacted
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,858	9,282	Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	2,064	9,282	Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	1,858		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	1,245	1,532	Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	613	7,750	Redacted
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_TA	Maternal AZT (prophylaxis component)	0		Redacted

	of WHO Option A during pregnancy and delivery)			
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	1,858		Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	1,858	9,282	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	93,376	52,256	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	98,290	55,005	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	2,484	4,055	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	4,053	1,267	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	6,537	5,322	Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	29,487	92,080	Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	31,039	96,927	Redacted
PMTCT_STAT_TA	By: Known positives at entry	784	7,777	Redacted
PMTCT_STAT_TA	By: Number of new positives identified	1,280	1,505	Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	2,064	9,282	Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0		Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the	47,837		Redacted

	minimum components during the reporting period.			
PP_PREV_TA	Age/sex: 10-14 Male	0		Redacted
PP_PREV_TA	Age/sex: 15-19 Male	0		Redacted
PP_PREV_TA	Age/sex: 20-24 Male	0		Redacted
PP_PREV_TA	Age/sex: 25-49 Male	0		Redacted
PP_PREV_TA	Age/sex: 50+ Male	0		Redacted
PP_PREV_TA	Age/sex: 10-14 Female	0		Redacted
PP_PREV_TA	Age/sex: 15-19 Female	11,481		Redacted
PP_PREV_TA	Age/sex: 20-24 Female	10,046		Redacted
PP_PREV_TA	Age/sex: 25-49 Female	26,310		Redacted
PP_PREV_TA	Age/sex: 50+ Female	0		Redacted
PP_PREV_TA	Sum of Age/Sex disaggregates	47,837		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	119,595	67,258	Redacted
HTC_TST_DSD	By Test Result: Negative	116,007	65,580	Redacted
HTC_TST_DSD	By Test Result: Positive	3,588	1,678	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	119,595	67,258	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	0		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	0		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	0		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	0		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	0		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	0		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	0		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	0		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	0		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	0		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	28,703		Redacted

HTC_TST_DSD	Age/sex: 20-24 Female	25,115		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	65,777		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	0		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	119,595		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	3,426	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0	24,853	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	4,538	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	119,595	34,441	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	0	7,964	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	119,595	59,294	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	119,595	67,258	Redacted
GEND_GBV_DSD	Number of people receiving post-GBV care	7,427		Redacted
GEND_GBV_DSD	Age: 0-9	0		Redacted
GEND_GBV_DSD	Age: 10-14	984		Redacted
GEND_GBV_DSD	Age: 15-17	1,313		Redacted
GEND_GBV_DSD	Age: 18-24	1,118		Redacted
GEND_GBV_DSD	Age: 25+	4,012		Redacted
GEND_GBV_DSD	Sum of Age disaggregates	7,427		Redacted
GEND_GBV_DSD	Sex: Male	2,840		Redacted
GEND_GBV_DSD	Sex: Female	4,587		Redacted
GEND_GBV_DSD	Sum of Sex disaggregates	7,427		Redacted
GEND_GBV_TA	Sum of Age disaggregates	7,427		Redacted
GEND_GBV_TA	Sum of Sex disaggregates	7,427		Redacted
GEND_NORM_DS D	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	8,996		Redacted
GEND_NORM_DS	By Age: 0-9	0		Redacted

D				
GEND_NORM_DS D	By Age: 10-14	1,102		Redacted
GEND_NORM_DS D	By Age: 15-19	1,564		Redacted
GEND_NORM_DS D	By Age: 20-24	1,332		Redacted
GEND_NORM_DS D	By Age: 25+	4,998		Redacted
GEND_NORM_DS D	Sum of Age disaggregates	8,996		Redacted
GEND_NORM_DS D	By Sex: Male	5,859		Redacted
GEND_NORM_DS D	By Sex: Female	3,137		Redacted
GEND_NORM_DS D	Sum of Sex disaggregates	8,996		Redacted
GEND_NORM_TA	Sum of Sex disaggregates	8,996		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	6,880	4,127	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	8,600		Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	6,880	411	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	6,880	4,129	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	430		Redacted

Implementing Mechanism Details

Mechanism ID: 13717	Mechanism Name: Provision of Comprehensive CARE, Treatment and Prevention Services in
----------------------------	--



	Indigenous Health Facilities - AIDS Care and Treatment
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Registered Trustees for the Uganda Episcopal Conference	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 6,635,263	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	6,635,263

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Renovation	70,000
Gender: GBV	700,000
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	350,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education



Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Key Populations: FSW	400,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13717		
Mechanism Name:	Provision of Comprehensive CARE, Treatment and Prevention Services in Indigenous Health Facilities - AIDS Care and Treatment		
Prime Partner Name:	Registered Trustees for the Uganda Episcopal Conference		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,810,176	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	157,506	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	341,821	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Care	PDCS	410,631	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	279,275	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	50,606	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	266,882	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	82,900	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	232,935	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,828,633	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	173,898	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS	Number of HIV-positive pregnant	2,081	3,542	Redacted

D	women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery			
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	2,313	3,542	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	2,081		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	1,394	674	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	687	2,868	Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0		Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	2,081		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	2,081	3,542	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	33,037	32,354	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	34,776	34,057	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	879	2,868	Redacted

PMTCT_STAT_DS D	By: Number of new positives identified	1,434	674	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	2,313	3,542	Redacted
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	21	27	Redacted
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	1		Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	1		Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	13		Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	21		Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	19		Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	2		Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients	0		Redacted

	with one or more moderate or severe medical device-related AE(s)			
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)	0		Redacted
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	13		Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	5,050	8,001	Redacted
VMMC_CIRC_DS D	By Age: 10-14	909		Redacted
VMMC_CIRC_DS D	By Age: 15-19	998		Redacted
VMMC_CIRC_DS D	By Age: 20-24	836		Redacted
VMMC_CIRC_DS D	By Age: 25-49	2,206		Redacted
VMMC_CIRC_DS D	By Age: 50+	101		Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	5,050		Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	118	144	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	3,821	7,857	Redacted

VMMC_CIRC_DS D	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	1,111		Redacted
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	5,050	8,001	Redacted
VMMC_CIRC_DS D	By circumcision technique: Device-based VMMC	0		Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	5,050	8,001	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0		Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	33,790	14,057	Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	3,746	2,609	Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	2,317	3,150	Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	1,940		Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	4,955		Redacted
PP_PREV_DSD	Age/sex: 50+ Male	387		Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	3,987	3,991	Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	3,915	4,307	Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	3,294		Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	8,539		Redacted
PP_PREV_DSD	Age/sex: 50+ Female	711		Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	33,791	14,057	Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the	8,868	78,585	Redacted

	minimum components during the reporting period.			
PP_PREV_TA	Age/sex: 10-14 Male	1,515	3,350	Redacted
PP_PREV_TA	Age/sex: 15-19 Male	721	7,002	Redacted
PP_PREV_TA	Age/sex: 20-24 Male	597	8,022	Redacted
PP_PREV_TA	Age/sex: 25-49 Male	1,553	13,466	Redacted
PP_PREV_TA	Age/sex: 10-14 Female	1,515	4,329	Redacted
PP_PREV_TA	Age/sex: 15-19 Female	721	8,712	Redacted
PP_PREV_TA	Age/sex: 20-24 Female	612	12,863	Redacted
PP_PREV_TA	Age/sex: 25-49 Female	1,634	18,506	Redacted
PP_PREV_TA	Sum of Age/Sex disaggregates	8,868	78,585	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	59,199	164,209	Redacted
HTC_TST_DSD	By Test Result: Negative	55,922	158,263	Redacted
HTC_TST_DSD	By Test Result: Positive	3,277	5,946	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	59,199	164,209	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	0		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	1,944		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	2,342		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	2,834		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	2,375		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	6,264		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	252		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	0		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	2,376		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	1,792		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	9,332		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	8,166		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	21,385		Redacted

HTC_TST_DSD	Age/sex: 50+ Female	137		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	59,199		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	4,286	8,320	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	11,724	60,674	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,166	11,031	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	39,023	84,184	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	8,452	19,351	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	50,747	144,858	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	59,199	164,209	Redacted
GEND_GBV_DSD	Number of people receiving post-GBV care	2,777		Redacted
GEND_GBV_DSD	Age: 0-9	0		Redacted
GEND_GBV_DSD	Age: 10-14	817		Redacted
GEND_GBV_DSD	Age: 15-17	860		Redacted
GEND_GBV_DSD	Age: 18-24	732		Redacted
GEND_GBV_DSD	Age: 25+	368		Redacted
GEND_GBV_DSD	Sum of Age disaggregates	2,777		Redacted
GEND_GBV_DSD	Sex: Male	1,016		Redacted
GEND_GBV_DSD	Sex: Female	1,761		Redacted
GEND_GBV_DSD	Sum of Sex disaggregates	2,777		Redacted
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	0		Redacted
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	0		Redacted
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	0		Redacted
GEND_GBV_TA	Sum of Age disaggregates	2,777		Redacted

GEND_GBV_TA	Sum of Sex disaggregates	2,777		Redacted
GEND_NORM_DS D	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	2,907		Redacted
GEND_NORM_DS D	By Age: 0-9	0		Redacted
GEND_NORM_DS D	By Age: 10-14	833		Redacted
GEND_NORM_DS D	By Age: 15-19	887		Redacted
GEND_NORM_DS D	By Age: 20-24	756		Redacted
GEND_NORM_DS D	By Age: 25+	431		Redacted
GEND_NORM_DS D	Sum of Age disaggregates	2,907		Redacted
GEND_NORM_DS D	By Sex: Male	1,074		Redacted
GEND_NORM_DS D	By Sex: Female	1,833		Redacted
GEND_NORM_DS D	Sum of Sex disaggregates	2,907		Redacted
GEND_NORM_DS D	By type of activity: Individual	0		Redacted
GEND_NORM_DS D	By type of activity: Small Group	0		Redacted
GEND_NORM_DS D	By type of activity: Community-level	0		Redacted
GEND_NORM_TA	Sum of Sex disaggregates	2,907		Redacted
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	1,286	2,230	Redacted
OVC_ACC_DSD	Sex: Male	584		Redacted
OVC_ACC_DSD	Sex: Female	702		Redacted



OVC_ACC_DSD	Sum of Sex disaggregates	1,286		Redacted
OVC_ACC_DSD	Age: <1	54		Redacted
OVC_ACC_DSD	Age: 1-4	203		Redacted
OVC_ACC_DSD	Age: 5-9	360		Redacted
OVC_ACC_DSD	Age: 10-14	368		Redacted
OVC_ACC_DSD	Age: 15-17	237		Redacted
OVC_ACC_DSD	Age: 18+	64		Redacted
OVC_ACC_DSD	Sum of Age disaggregates	1,286		Redacted
OVC_ACC_TA	Sum of Sex disaggregates	1,286		Redacted
OVC_ACC_TA	Sum of Age disaggregates	1,286		Redacted
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	6,679	4,339	Redacted
OVC_SERV_DSD	Sex: Male	3,032		Redacted
OVC_SERV_DSD	Sex: Female	3,647		Redacted
OVC_SERV_DSD	Sum of Sex disaggregates	6,679		Redacted
OVC_SERV_DSD	Age: <1	281		Redacted
OVC_SERV_DSD	Age: 1-4	1,055		Redacted
OVC_SERV_DSD	Age: 5-9	1,870		Redacted
OVC_SERV_DSD	Age: 10-14	1,910		Redacted
OVC_SERV_DSD	Age: 15-17	1,229		Redacted
OVC_SERV_DSD	Age: 18+	334		Redacted
OVC_SERV_DSD	Sum of Age disaggregates	6,679		Redacted
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	352		Redacted
OVC_SERV_TA	Sex: Male	160		Redacted
OVC_SERV_TA	Sex: Female	192		Redacted
OVC_SERV_TA	Sum of Sex disaggregates	352		Redacted
OVC_SERV_TA	Age: <1	15		Redacted
OVC_SERV_TA	Age: 1-4	56		Redacted
OVC_SERV_TA	Age: 5-9	98		Redacted

OVC_SERV_TA	Age: 10-14	101		Redacted
OVC_SERV_TA	Age: 15-17	65		Redacted
OVC_SERV_TA	Age: 18+	18		Redacted
OVC_SERV_TA	Sum of Age disaggregates	353		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	49,418	71,216	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,631	2,279	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	15,764	2,707	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,224	22,433	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	29,799	43,797	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	49,418	71,216	Redacted
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	1,529		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	50		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	488		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	69		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	922		Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	1,529		Redacted

CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	4,558	6,643	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	201	206	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	1,399	2,186	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	187	233	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	2,771	4,018	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	4,558	6,643	Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	4,558	6,643	Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	1,223	1,709	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	16,448	21,365	Redacted
FN_THER_DSD	Aggregated Age: <18	752	658	Redacted
FN_THER_DSD	Aggregated Age: 18+	471	1,051	Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	1,223	1,709	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,513	941	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,628	1,177	Redacted
TB_ART_DSD	Age: 0-4	3		Redacted

TB_ART_DSD	Age: 5-14	35		Redacted
TB_ART_DSD	Age: 15+	1,475		Redacted
TB_ART_DSD	Male	984	334	Redacted
TB_ART_DSD	Female	530	607	Redacted
TB_ART_DSD	Sum of Sex disaggregates	1,514	941	Redacted
TB_ART_DSD	Aggregated Age: <15	38	65	Redacted
TB_ART_DSD	Aggregated Age: 15+	1,475	876	Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	1,513	941	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,850	2,834	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	2,313		Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1,850	282	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,850	2,834	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	116		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	47,245	66,530	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,748		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	14,646	42,210	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,890		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	28,961	19,425	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	3,638		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	43,607	61,635	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	47,245	61,635	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	6,912	13,149	Redacted

TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	235		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,797	8,549	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	270		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	4,610	4,050	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	6,912	12,599	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	10,270	8,481	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	11,286	9,977	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	750		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9,520		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	824		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	10,462		Redacted

	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	2	1	Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	2		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	2		Redacted
LAB_ACC_TA	Sum of Support Type disaggregates	2		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	19	18	Redacted
LAB_CAP_DSD	By clinical laboratories	19	18	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	19		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	19		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	19		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	19		Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	19		Redacted
FPINT_SITE_DSD	By site support type: Direct Service	19		Redacted

	Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services			
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	19		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	19		Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	19		Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	19		Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	19		Redacted
FPINT_SITE_TA	Sum of Denominator Site Support Type disaggregates	19		Redacted
FPINT_SITE_TA	Sum of Numerator Site Support Type disaggregates	19		Redacted
FPINT_SITE_TA	Sum of Service Delivery Type disaggregates	19		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	45,851	71,216	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	49,418	71,216	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	6,144	4,983	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	39,708	66,233	Redacted



TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	45,852	71,216	Redacted
TB_SCREEN_DSD	Sex: Male	15,956	24,712	Redacted
TB_SCREEN_DSD	Sex: Female	29,895	46,504	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	45,851	71,216	Redacted
TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	1,529		Redacted

Implementing Mechanism Details

Mechanism ID: 13833	Mechanism Name: TRACK TB
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,255,760	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	1,255,760

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues



(No data provided.)

Budget Code Information

Mechanism ID:	13833		
Mechanism Name:	TRACK TB		
Prime Partner Name:	Management Sciences for Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	1,255,760	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13835	Mechanism Name: Strengthening National Pediatric HIV/AIDS and Scaling up Comprehensive HIV/AIDS Services in the Republic of Uganda under The President's Emergency Plan For AIDS Relief
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Baylor College of Medicine Children's Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 9,543,755	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	9,543,755



Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Gender: GBV	500,000
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	250,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Key Populations: FSW	500,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention

Key Issues



(No data provided.)

Budget Code Information

Mechanism ID:		13835	
Mechanism Name:		Strengthening National Pediatric HIV/AIDS and Scaling up	
Prime Partner Name:		Comprehensive HIV/AIDS Services in the Republic of Uganda under The President's Emergency Plan For AIDS Relief	
		Baylor College of Medicine Children's Foundation	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,589,739	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,131,726	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	295,599	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	728,503	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	946,483	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	306,172	0

Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	543,255	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	3,382,501	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	569,777	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	5,756	4,271	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	6,396	4,271	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	5,756		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	3,857	635	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,900	3,636	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	5,756		Redacted
PMTCT_ARV_DS	Sum of New and Current disaggregates	5,757	4,271	Redacted

D				
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,096	1,868	Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,218	1,868	Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	1,096		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	735	234	Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	362	1,634	Redacted
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0		Redacted
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	1,096		Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	1,097	1,868	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	91,368	72,941	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	96,177	76,944	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	2,430	3,626	Redacted

PMTCT_STAT_DS D	By: Number of new positives identified	3,965	645	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	6,395	4,271	Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	17,403	29,067	Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	18,319	30,637	Redacted
PMTCT_STAT_TA	By: Known positives at entry	463	1,598	Redacted
PMTCT_STAT_TA	By: Number of new positives identified	755	270	Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	1,218	1,868	Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	4,239	7,547	Redacted
PP_PREV_DSD	Total number of people in the target population	5,791	21,811	Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	843		Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	2,013	908	Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	1,687	982	Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	4,449	1,734	Redacted
PP_PREV_DSD	Age/sex: 50+ Male	180	150	Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	1,150		Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	3,697	790	Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	3,235	1,170	Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	8,472	1,663	Redacted
PP_PREV_DSD	Age/sex: 50+ Female	331	150	Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	26,057	7,547	Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the	73,595	139,366	Redacted

	reporting period.			
PP_PREV_TA	Total number of people in the target population	0	348,403	Redacted
PP_PREV_TA	Age/sex: 10-14 Male	3,396	6,401	Redacted
PP_PREV_TA	Age/sex: 15-19 Male	3,778	12,819	Redacted
PP_PREV_TA	Age/sex: 20-24 Male	3,167	14,744	Redacted
PP_PREV_TA	Age/sex: 25-49 Male	8,352	24,474	Redacted
PP_PREV_TA	Age/sex: 50+ Male	337	1,984	Redacted
PP_PREV_TA	Age/sex: 10-14 Female	2,669	8,401	Redacted
PP_PREV_TA	Age/sex: 15-19 Female	12,409	14,841	Redacted
PP_PREV_TA	Age/sex: 20-24 Female	10,858	21,909	Redacted
PP_PREV_TA	Age/sex: 25-49 Female	28,438	31,683	Redacted
PP_PREV_TA	Age/sex: 50+ Female	191	2,110	Redacted
PP_PREV_TA	Sum of Age/Sex disaggregates	73,595	139,366	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	122,707	301,759	Redacted
HTC_TST_DSD	By Test Result: Negative	119,026	292,058	Redacted
HTC_TST_DSD	By Test Result: Positive	3,681	9,701	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	122,707	301,759	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	3,029		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	3,325		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	2,787		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	7,351		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	337		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	25,411		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	22,234		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	58,233		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	122,707		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,029	15,320	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ	13,800	111,505	Redacted

	PERMISSION ONLY: 15+ Male			
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	20,310	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	105,878	154,624	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	3,029	35,630	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	119,678	266,129	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	122,707	301,759	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	77,363	98,873	Redacted
HTC_TST_TA	By Test Result: Negative	70,524	95,736	Redacted
HTC_TST_TA	By Test Result: Positive	6,839	3,137	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	77,363	98,873	Redacted
HTC_TST_TA	Age/sex: <1 Male	0		Redacted
HTC_TST_TA	Age/sex: 1-4 Male	0		Redacted
HTC_TST_TA	Age/sex: 5-9 Male	7,237		Redacted
HTC_TST_TA	Age/sex: 10-14 Male	5,460		Redacted
HTC_TST_TA	Age/sex: 15-19 Male	6,121		Redacted
HTC_TST_TA	Age/sex: 20-24 Male	5,129		Redacted
HTC_TST_TA	Age/sex: 25-49 Male	13,530		Redacted
HTC_TST_TA	Age/sex: 50+ Male	506		Redacted
HTC_TST_TA	Age/sex: 5-9 Female	8,846		Redacted
HTC_TST_TA	Age/sex: 10-14 Female	6,673		Redacted
HTC_TST_TA	Age/sex: 15-19 Female	5,612		Redacted
HTC_TST_TA	Age/sex: 20-24 Female	4,911		Redacted
HTC_TST_TA	Age/sex: 25-49 Female	12,861		Redacted
HTC_TST_TA	Age/sex: 50+ Female	477		Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	77,363		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	12,697	5,024	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ	25,286	36,531	Redacted

	PERMISSION ONLY: 15+ Male			
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	15,519	6,654	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	23,861	50,664	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	28,216	11,678	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	49,147	87,195	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	77,363	98,873	Redacted
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	1,331	18,193	Redacted
OVC_ACC_DSD	Sex: Male	604		Redacted
OVC_ACC_DSD	Sex: Female	727		Redacted
OVC_ACC_DSD	Sum of Sex disaggregates	1,331		Redacted
OVC_ACC_DSD	Age: <1	56		Redacted
OVC_ACC_DSD	Age: 1-4	210		Redacted
OVC_ACC_DSD	Age: 5-9	373		Redacted
OVC_ACC_DSD	Age: 10-14	381		Redacted
OVC_ACC_DSD	Age: 15-17	245		Redacted
OVC_ACC_DSD	Age: 18+	67		Redacted
OVC_ACC_DSD	Sum of Age disaggregates	1,332		Redacted
OVC_ACC_TA	Sum of Sex disaggregates	1,331		Redacted
OVC_ACC_TA	Sum of Age disaggregates	1,332		Redacted
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	6,912	34,334	Redacted
OVC_SERV_DSD	Sex: Male	3,138		Redacted
OVC_SERV_DSD	Sex: Female	3,774		Redacted
OVC_SERV_DSD	Sum of Sex disaggregates	6,912		Redacted
OVC_SERV_DSD	Age: <1	290		Redacted
OVC_SERV_DSD	Age: 1-4	1,092		Redacted
OVC_SERV_DSD	Age: 5-9	1,935		Redacted



OVC_SERV_DSD	Age: 10-14	1,977		Redacted
OVC_SERV_DSD	Age: 15-17	1,272		Redacted
OVC_SERV_DSD	Age: 18+	346		Redacted
OVC_SERV_DSD	Sum of Age disaggregates	6,912		Redacted
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	364		Redacted
OVC_SERV_TA	Sex: Male	165		Redacted
OVC_SERV_TA	Sex: Female	199		Redacted
OVC_SERV_TA	Sum of Sex disaggregates	364		Redacted
OVC_SERV_TA	Age: <1	15		Redacted
OVC_SERV_TA	Age: 1-4	57		Redacted
OVC_SERV_TA	Age: 5-9	102		Redacted
OVC_SERV_TA	Age: 10-14	104		Redacted
OVC_SERV_TA	Age: 15-17	67		Redacted
OVC_SERV_TA	Age: 18+	18		Redacted
OVC_SERV_TA	Sum of Age disaggregates	363		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	54,400	50,699	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,795	1,622	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	17,354	1,927	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,448	15,978	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	32,803	31,172	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	54,400	50,699	Redacted
CARE_CURR_TA	Number of HIV positive adults and	4,730	9,188	Redacted

	children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load			
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	156	295	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,509	348	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	213	2,886	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,852	5,659	Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	4,730	9,188	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	13,268	8,830	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	584	274	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	4,073	2,900	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	544	314	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	8,067	5,342	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	13,268	8,830	Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	13,268	8,830	Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	1,419	1,216	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be	19,159	15,211	Redacted

	clinically undernourished.			
FN_THER_DSD	Aggregated Age: <18	873	472	Redacted
FN_THER_DSD	Aggregated Age: 18+	546	744	Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	1,419	1,216	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,405	602	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,756	752	Redacted
TB_ART_DSD	Age: 0-4	4		Redacted
TB_ART_DSD	Age: 5-14	40		Redacted
TB_ART_DSD	Age: 15+	1,712		Redacted
TB_ART_DSD	Male	1,141	217	Redacted
TB_ART_DSD	Female	615	385	Redacted
TB_ART_DSD	Sum of Sex disaggregates	1,756	602	Redacted
TB_ART_DSD	Newly tested	37		Redacted
TB_ART_DSD	Known HIV-positive	1,479	275	Redacted
TB_ART_DSD	Sum of Test Status disaggregates	1,516	275	Redacted
TB_ART_DSD	Aggregated Age: <15	44	49	Redacted
TB_ART_DSD	Aggregated Age: 15+	1,712	553	Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	1,756	602	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	6,091	3,416	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	7,614		Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12	6,091	342	Redacted

	months of age			
PMTCT_EID_DSD	Sum of Infant Age disaggregates	6,091	3,416	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	381		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	48,640	48,036	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,800		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	15,078	30,484	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,946		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	29,816	14,015	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	3,746		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	44,894	44,499	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	48,640	44,499	Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	4,229	8,476	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	156		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	1,311	5,368	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	169		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	2,593	2,485	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	325		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	3,904	7,853	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	4,229	7,853	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	15,289	12,229	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	520		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	3,975	7,938	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	596		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+	10,198	3,774	Redacted

	Female			
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	15,289	11,712	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	17,421	8,548	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	19,143	10,061	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,272		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	16,149		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,397		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	17,746		Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing	6	1	Redacted

	facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation			
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	6		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	6		Redacted
LAB_ACC_TA	Sum of Support Type disaggregates	6		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	170	24	Redacted
LAB_CAP_DSD	By clinical laboratories	170	24	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	170		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	170		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	170		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	53,217	50,699	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	54,400	50,699	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	7,131	3,544	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	46,086	47,155	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	53,217	50,699	Redacted

TB_SCREEN_DSD	Sex: Male	18,520	17,593	Redacted
TB_SCREEN_DSD	Sex: Female	34,697	33,106	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	53,217	50,699	Redacted
TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	4,730	9,188	Redacted

Implementing Mechanism Details

Mechanism ID: 13837	Mechanism Name: Monitoring, Evaluation and Learning Program
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: QED Group, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,460,247	
Applied Pipeline Amount: 326,661	
Funding Source	Funding Amount
GHP-State	1,460,247

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues



(No data provided.)

Budget Code Information

Mechanism ID: 13837			
Mechanism Name: Monitoring, Evaluation and Learning Program			
Prime Partner Name: QED Group, LLC			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	986,247	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	24,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13841	Mechanism Name: CDC-WHO collaboration
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: World Health Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 280,000	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	280,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 13841			
Mechanism Name: CDC-WHO collaboration			
Prime Partner Name: World Health Organization			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	80,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	200,000	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 13864	Mechanism Name: Ministry of Health, Uganda
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health, Uganda	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 1,780,000	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	1,780,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13864		
Mechanism Name:	Ministry of Health, Uganda		
Prime Partner Name:	Ministry of Health, Uganda		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HBHC	45,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	30,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	730,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	130,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	160,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	75,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	75,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	105,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	30,000	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13874	Mechanism Name: Health Advocacy Program
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Program for Appropriate Technology in Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 253,251	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	253,251

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13874
----------------------	--------------



Mechanism Name: Health Advocacy Program			
Prime Partner Name: Program for Appropriate Technology in Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	53,251	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13877	Mechanism Name: New Hope Project – Provision of Comprehensive HIV/AIDS Care, Treatment and Prevention services in Track 1.0 Health Facilities in Uganda
----------------------------	--



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Children's AIDS Fund	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,860,007	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	1,860,007

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Gender: GBV	180,000
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	80,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation



Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13877		
Mechanism Name:	New Hope Project – Provision of Comprehensive HIV/AIDS Care, Treatment and Prevention services in Track 1.0 Health Facilities in		
Prime Partner Name:	Uganda Children's AIDS Fund		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	413,617	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	519,235	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	74,806	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	58,794	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	93,761	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Prevention	MTCT	804	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	659,776	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	39,214	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	55	148	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	62	148	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	55		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	37	19	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	18	129	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	55		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	55	148	Redacted

PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	879	1,729	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	925	1,818	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	23	130	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	38	18	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	61	148	Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	10,044		Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	325		Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	776		Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	650		Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	1,715		Redacted
PP_PREV_DSD	Age/sex: 50+ Male	69		Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	443		Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	1,425		Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	1,247		Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	3,266		Redacted
PP_PREV_DSD	Age/sex: 50+ Female	128		Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	10,044		Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	1,619	26,730	Redacted
PP_PREV_TA	Total number of people in the target	0	66,824	Redacted

	population			
PP_PREV_TA	Age/sex: 10-14 Male	113	1,162	Redacted
PP_PREV_TA	Age/sex: 15-19 Male	130	2,231	Redacted
PP_PREV_TA	Age/sex: 20-24 Male	109	2,421	Redacted
PP_PREV_TA	Age/sex: 25-49 Male	286	4,349	Redacted
PP_PREV_TA	Age/sex: 50+ Male	11	373	Redacted
PP_PREV_TA	Age/sex: 10-14 Female	138	1,499	Redacted
PP_PREV_TA	Age/sex: 15-19 Female	197	3,099	Redacted
PP_PREV_TA	Age/sex: 20-24 Female	173	4,576	Redacted
PP_PREV_TA	Age/sex: 25-49 Female	452	6,579	Redacted
PP_PREV_TA	Age/sex: 50+ Female	10	441	Redacted
PP_PREV_TA	Sum of Age/Sex disaggregates	1,619	26,730	Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	134		Redacted
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	134		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	855	24,747	Redacted
HTC_TST_DSD	By Test Result: Negative	830	23,799	Redacted
HTC_TST_DSD	By Test Result: Positive	25	948	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	855	24,747	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	0		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	0		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	0		Redacted

HTC_TST_DSD	Age/sex: 25-49 Male	0		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	0		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	205		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	180		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	470		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	855		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	1,254	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0	9,144	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	855	12,690	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	0	2,913	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	855	21,834	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	855	24,747	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	4,027	18,385	Redacted
HTC_TST_TA	By Test Result: Negative	3,590	17,651	Redacted
HTC_TST_TA	By Test Result: Positive	437	734	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	4,027	18,385	Redacted
HTC_TST_TA	Age/sex: 5-9 Male	375		Redacted
HTC_TST_TA	Age/sex: 10-14 Male	283		Redacted
HTC_TST_TA	Age/sex: 15-19 Male	324		Redacted
HTC_TST_TA	Age/sex: 20-24 Male	271		Redacted
HTC_TST_TA	Age/sex: 25-49 Male	716		Redacted
HTC_TST_TA	Age/sex: 50+ Male	27		Redacted
HTC_TST_TA	Age/sex: 5-9 Female	459		Redacted
HTC_TST_TA	Age/sex: 10-14 Female	346		Redacted
HTC_TST_TA	Age/sex: 15-19 Female	288		Redacted
HTC_TST_TA	Age/sex: 20-24 Female	252		Redacted
HTC_TST_TA	Age/sex: 25-49 Female	660		Redacted

HTC_TST_TA	Age/sex: 50+ Female	25		Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	4,026		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	659	930	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,338	6,793	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	805	1,232	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,225	9,430	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	1,464	2,162	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	2,563	16,223	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	4,027	18,385	Redacted
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	100	7,351	Redacted
OVC_ACC_DSD	Sex: Male	45		Redacted
OVC_ACC_DSD	Sex: Female	55		Redacted
OVC_ACC_DSD	Sum of Sex disaggregates	100		Redacted
OVC_ACC_DSD	Age: <1	4		Redacted
OVC_ACC_DSD	Age: 1-4	16		Redacted
OVC_ACC_DSD	Age: 5-9	28		Redacted
OVC_ACC_DSD	Age: 10-14	29		Redacted
OVC_ACC_DSD	Age: 15-17	18		Redacted
OVC_ACC_DSD	Age: 18+	5		Redacted
OVC_ACC_DSD	Sum of Age disaggregates	100		Redacted
OVC_ACC_TA	Sum of Sex disaggregates	100		Redacted
OVC_ACC_TA	Sum of Age disaggregates	100		Redacted
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	520	14,304	Redacted
OVC_SERV_DSD	Sex: Male	236		Redacted

OVC_SERV_DSD	Sex: Female	284		Redacted
OVC_SERV_DSD	Sum of Sex disaggregates	520		Redacted
OVC_SERV_DSD	Age: <1	22		Redacted
OVC_SERV_DSD	Age: 1-4	82		Redacted
OVC_SERV_DSD	Age: 5-9	146		Redacted
OVC_SERV_DSD	Age: 10-14	149		Redacted
OVC_SERV_DSD	Age: 15-17	96		Redacted
OVC_SERV_DSD	Age: 18+	26		Redacted
OVC_SERV_DSD	Sum of Age disaggregates	521		Redacted
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	27		Redacted
OVC_SERV_TA	Sex: Male	12		Redacted
OVC_SERV_TA	Sex: Female	15		Redacted
OVC_SERV_TA	Sum of Sex disaggregates	27		Redacted
OVC_SERV_TA	Age: <1	1		Redacted
OVC_SERV_TA	Age: 1-4	4		Redacted
OVC_SERV_TA	Age: 5-9	8		Redacted
OVC_SERV_TA	Age: 10-14	8		Redacted
OVC_SERV_TA	Age: 15-17	5		Redacted
OVC_SERV_TA	Age: 18+	1		Redacted
OVC_SERV_TA	Sum of Age disaggregates	27		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	16,699	19,257	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	551	617	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	5,327	732	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	752	6,066	Redacted

CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	10,069	11,842	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	16,699	19,257	Redacted
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	6,176	8,746	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	204	280	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,970	332	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	278	2,755	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,724	5,379	Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	6,176	8,746	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	651	1,668	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	29	51	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	200	548	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	27	59	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	395	1,010	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	651	1,668	Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	651	1,668	Redacted
FN_THER_DSD	Number of clinically malnourished	443	462	Redacted

	PLHIV who received therapeutic and/or supplementary food during the reporting period.			
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	7,385	5,776	Redacted
FN_THER_DSD	Aggregated Age: <18	338	178	Redacted
FN_THER_DSD	Aggregated Age: 18+	211	284	Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	549	462	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	544	241	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	679	300	Redacted
TB_ART_DSD	Age: 0-4	1		Redacted
TB_ART_DSD	Age: 5-14	16		Redacted
TB_ART_DSD	Age: 15+	662		Redacted
TB_ART_DSD	Male	441	86	Redacted
TB_ART_DSD	Female	238	155	Redacted
TB_ART_DSD	Sum of Sex disaggregates	679	241	Redacted
TB_ART_DSD	Aggregated Age: <15	17	17	Redacted
TB_ART_DSD	Aggregated Age: 15+	662	224	Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	679	241	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	49	119	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	62		Redacted

PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	49	12	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	49	119	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	3		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	15,957	18,117	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	590		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	4,947	11,493	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	638		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	9,782	5,290	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,228		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	14,729	16,783	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	15,957	16,783	Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	5,319	8,214	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	197		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	1,649	5,211	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	212		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	3,261	2,398	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	409		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	4,910	7,609	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	5,319	7,609	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,385	3,181	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	81		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	620	2,070	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15	93		Redacted

	Female			
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,591	979	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	2,385	3,049	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	4,776	2,230	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	5,249	2,622	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	348		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,428		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	383		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,866		Redacted

	those lost to follow-up)			
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	20,587	19,257	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	16,699	19,257	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	2,759	1,349	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	17,828	17,908	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	20,587	19,257	Redacted
TB_SCREEN_DSD	Sex: Male	7,164	6,682	Redacted
TB_SCREEN_DSD	Sex: Female	13,423	12,575	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	20,587	19,257	Redacted
TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	6,176	8,746	Redacted

Implementing Mechanism Details

Mechanism ID: 13880	Mechanism Name: Provision of Comprehensive HIV/AIDS Services and Health Work Force Development for Managing Health Programs in the Republic of Uganda under the President's Plan for AIDS Relief
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Makerere University School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: Yes	Managing Agency: HHS/CDC
----------	--------------------------

Total All Funding Sources: 4,170,833	
Applied Pipeline Amount: 768,170	
Funding Source	Funding Amount
GHP-State	4,170,833

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Renovation	90,000
Motor Vehicles: Purchased	215,000
Gender: GBV	250,000
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	125,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic



	Information
Sub Area:	Monitoring and Evaluation
Key Populations: FSW	150,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13880		
Mechanism Name:	Provision of Comprehensive HIV/AIDS Services and Health Work Force Development for Managing Health Programs in the Republic of Uganda		
Prime Partner Name:	under the President's Plan for AIDS Relief Makerere University School of Public Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	529,385	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	108,215	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	236,460	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and	HVSI	0	0

Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	907,071	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	93,226	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	1,458,792	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	782,968	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	54,716	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,454	329	Redacted

PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,615	329	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	1,454		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	974	33	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	480	296	Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0		Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	1,454		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	1,454	329	Redacted
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,096	3,172	Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,218	3,172	Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	1,096		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	735	317	Redacted

PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	362	2,855	Redacted
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0		Redacted
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	1,096		Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	1,097	3,172	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	23,071	2,161	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	24,286	2,274	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	614	296	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	1,001	33	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	1,615	329	Redacted
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	16		Redacted
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	27		Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more	27		Redacted

	moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)			
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	11		Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	9		Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	8		Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	81		Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	16		Redacted
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)	16		Redacted
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	11		Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male	4,947		Redacted

	circumcision (VMMC) for HIV prevention program within the reporting period			
VMMC_CIRC_DS D	By Age: 10-14	890		Redacted
VMMC_CIRC_DS D	By Age: 15-19	978		Redacted
VMMC_CIRC_DS D	By Age: 20-24	819		Redacted
VMMC_CIRC_DS D	By Age: 25-49	2,161		Redacted
VMMC_CIRC_DS D	By Age: 50+	99		Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	4,947		Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	116		Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	3,743		Redacted
VMMC_CIRC_DS D	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	1,088		Redacted
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	2,713		Redacted
VMMC_CIRC_DS D	By circumcision technique: Device-based VMMC	2,234		Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	2,713		Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14	0		Redacted

	days of circumcision surgery			
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0		Redacted
VMMC_CIRC_TA	By Age: <1	0		Redacted
VMMC_CIRC_TA	By Age: 1-9	0		Redacted
VMMC_CIRC_TA	By Age: 10-14	0		Redacted
VMMC_CIRC_TA	By Age: 15-19	0		Redacted
VMMC_CIRC_TA	By Age: 20-24	0		Redacted
VMMC_CIRC_TA	By Age: 25-49	0		Redacted
VMMC_CIRC_TA	By Age: 50+	0		Redacted
VMMC_CIRC_TA	Sum of Age disaggregations	0		Redacted
VMMC_CIRC_TA	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	0		Redacted
VMMC_CIRC_TA	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	0		Redacted
VMMC_CIRC_TA	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0		Redacted
VMMC_CIRC_TA	By circumcision technique: Surgical VMMC	0		Redacted
VMMC_CIRC_TA	By circumcision technique: Device-based VMMC	0		Redacted
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	0		Redacted
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14	0		Redacted

	days of circumcision surgery			
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	11,759	1,755	Redacted
PP_PREV_DSD	Total number of people in the target population	23,517	1,755	Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	629		Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	1,204	191	Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	1,010	212	Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	2,666	327	Redacted
PP_PREV_DSD	Age/sex: 50+ Male	148	91	Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	378		Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	1,346	213	Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	1,128	268	Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	2,976	339	Redacted
PP_PREV_DSD	Age/sex: 50+ Female	273	114	Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	11,758	1,755	Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	13,846	26,051	Redacted
PP_PREV_TA	Age/sex: 10-14 Male	845	818	Redacted
PP_PREV_TA	Age/sex: 15-19 Male	392	3,165	Redacted
PP_PREV_TA	Age/sex: 20-24 Male	324	4,538	Redacted
PP_PREV_TA	Age/sex: 25-49 Male	843	5,829	Redacted
PP_PREV_TA	Age/sex: 10-14 Female	845	1,046	Redacted
PP_PREV_TA	Age/sex: 15-19 Female	2,548	2,180	Redacted
PP_PREV_TA	Age/sex: 20-24 Female	2,219	3,215	Redacted
PP_PREV_TA	Age/sex: 25-49 Female	5,830	4,622	Redacted
PP_PREV_TA	Age/sex: 50+ Female	0	308	Redacted

PP_PREV_TA	Sum of Age/Sex disaggregates	13,846	26,051	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	27,227	25,403	Redacted
HTC_TST_DSD	By Test Result: Negative	26,410	24,675	Redacted
HTC_TST_DSD	By Test Result: Positive	817	728	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	27,227	25,403	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	858		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	942		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	790		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	2,083		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	95		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	5,390		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	4,716		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	12,352		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	27,226		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	858	1,291	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,911	9,386	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	22,458	13,014	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	858	3,003	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	26,369	22,400	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	27,227	25,403	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	7,169	44,178	Redacted
HTC_TST_TA	By Test Result: Negative	10,927	42,900	Redacted
HTC_TST_TA	By Test Result: Positive	1,224	1,278	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	12,151	44,178	Redacted
HTC_TST_TA	Age/sex: 5-9 Male	0		Redacted

HTC_TST_TA	Age/sex: 10-14 Male	0		Redacted
HTC_TST_TA	Age/sex: 15-19 Male	0		Redacted
HTC_TST_TA	Age/sex: 20-24 Male	0		Redacted
HTC_TST_TA	Age/sex: 25-49 Male	0		Redacted
HTC_TST_TA	Age/sex: 50+ Male	0		Redacted
HTC_TST_TA	Age/sex: 5-9 Female	1,324		Redacted
HTC_TST_TA	Age/sex: 10-14 Female	999		Redacted
HTC_TST_TA	Age/sex: 15-19 Female	0		Redacted
HTC_TST_TA	Age/sex: 20-24 Female	0		Redacted
HTC_TST_TA	Age/sex: 25-49 Female	0		Redacted
HTC_TST_TA	Age/sex: 50+ Female	0		Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	2,323		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	2,249	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0	16,324	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,323	2,977	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0	22,628	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	2,323	5,226	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	0	38,952	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	2,323	44,178	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	8,417	4,131	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	278	137	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,685	156	Redacted

CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	379	1,295	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	5,075	2,543	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	8,417	4,131	Redacted
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	11,156	16,765	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	368	532	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,559	638	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	502	5,287	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	6,727	10,308	Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	11,156	16,765	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	2,470	562	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	109	20	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	758	176	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	101	21	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	1,502	345	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	2,470	562	Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex	2,470	562	Redacted

	disaggregates			
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	505	97	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	6,308	1,238	Redacted
FN_THER_DSD	Aggregated Age: <18	289	40	Redacted
FN_THER_DSD	Aggregated Age: 18+	181	57	Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	470	97	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	465	25	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	581	35	Redacted
TB_ART_DSD	Age: 0-4	1		Redacted
TB_ART_DSD	Age: 5-14	13		Redacted
TB_ART_DSD	Age: 15+	567		Redacted
TB_ART_DSD	Male	378	8	Redacted
TB_ART_DSD	Female	203	17	Redacted
TB_ART_DSD	Sum of Sex disaggregates	581	25	Redacted
TB_ART_DSD	Aggregated Age: <15	14	2	Redacted
TB_ART_DSD	Aggregated Age: 15+	567	23	Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	581	25	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,292	264	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting	1,615		Redacted

	period (include known HIV-positive women at entry into PMTCT)			
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1,292	27	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,292	264	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	81		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	7,966	3,822	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	295		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	2,469	2,428	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	319		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	4,883	1,114	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	614		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	7,352	3,542	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	7,966	3,542	Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	10,633	15,959	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	375		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	3,143	10,121	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	405		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	6,214	4,661	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	780		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	9,357	14,782	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	10,137	14,782	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,221	920	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	110		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+	837	597	Redacted

	Male			
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	126		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,148	283	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	3,221	880	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,994	526	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	4,389	615	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	292		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,702		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	320		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting	4,069		Redacted

	period, including those who have died, those who have stopped ART, and those lost to follow-up)			
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	1		Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	0		Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	1		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	1		Redacted
LAB_ACC_TA	Sum of Support Type disaggregates	1		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	20	1	Redacted
LAB_CAP_DSD	By clinical laboratories	20	1	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	20		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	20		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	20		Redacted
HRH_PRE	By Graduates: Other	43	59	Redacted
HRH_PRE	Sum of Graduates disaggreagtes	43	59	Redacted
HRH_PRE	By new graduates who are licensed and registered: Other (where applicable)	43		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility	17,615	4,131	Redacted



	during the reporting period			
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	8,417	4,131	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	2,360	291	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	15,254	3,840	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	17,614	4,131	Redacted
TB_SCREEN_DSD	Sex: Male	6,130	1,435	Redacted
TB_SCREEN_DSD	Sex: Female	11,485	2,696	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	17,615	4,131	Redacted
TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	11,156	16,765	Redacted

Implementing Mechanism Details

Mechanism ID: 13885	Mechanism Name: Spring
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: John Snow Inc (JSI)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0



Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 13885			
Mechanism Name: Spring			
Prime Partner Name: John Snow Inc (JSI)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
------------------	-------	------	------

FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	2,086	
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	26,081	
FN_THER_DSD	Aggregated Age: <18	792	
FN_THER_DSD	Aggregated Age: 18+	495	
FN_THER_DSD	Sum of Aggregated Age disaggregates	1,287	

Implementing Mechanism Details

Mechanism ID: 13892	Mechanism Name: School Health and Reading Program (SHRP)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Research Triangle International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 840,894	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	840,894

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	100,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms



Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Operation Research
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 13892			
Mechanism Name: School Health and Reading Program (SHRP)			
Prime Partner Name: Research Triangle International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	840,894	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	350,000	199,999



PP_PREV_DSD	Age/sex: 10-14 Male	36,475	91,470
PP_PREV_DSD	Age/sex: 15-19 Male	93,539	7,549
PP_PREV_DSD	Age/sex: 20-24 Male	0	
PP_PREV_DSD	Age/sex: 25-49 Male	0	
PP_PREV_DSD	Age/sex: 50+ Male	0	
PP_PREV_DSD	Age/sex: 10-14 Female	48,276	94,411
PP_PREV_DSD	Age/sex: 15-19 Female	171,710	6,569
PP_PREV_DSD	Age/sex: 20-24 Female	0	
PP_PREV_DSD	Age/sex: 25-49 Female	0	
PP_PREV_DSD	Age/sex: 50+ Female	0	
PP_PREV_DSD	Sum of Age/Sex disaggregates	350,000	199,999

Implementing Mechanism Details

Mechanism ID: 13897	Mechanism Name: Public Health Workforce and Systems
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Field Epidemiology Network	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 473,777	
Applied Pipeline Amount: 126,223	
Funding Source	Funding Amount
GHP-State	473,777

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)



Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 13897			
Mechanism Name: Public Health Workforce and Systems			
Prime Partner Name: African Field Epidemiology Network			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	473,777	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13900	Mechanism Name: Northern Uganda Health Integration to Enhance Services (NU-HITES)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: PLAN International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0



Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 13900			
Mechanism Name: Northern Uganda Health Integration to Enhance Services (NU-HITES)			
Prime Partner Name: PLAN International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0

Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	9,643	
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	10,714	

PMTCT_ARV_DSD	Life-long ART (including Option B+)	9,643	
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	6,461	
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	3,182	
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	9,643	
PMTCT_ARV_DSD	Sum of New and Current disaggregates	9,643	
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	153,060	
PMTCT_STAT_DSD	Number of new ANC and L&D clients	161,116	
PMTCT_STAT_DSD	By: Known positives at entry	4,071	
PMTCT_STAT_DSD	By: Number of new positives identified	6,643	
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	10,714	
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	128	
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	4	
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	4	
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	41	
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	120	
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s)	109	

	by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)		
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	11	
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	16	
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)	16	
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	41	
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	38,737	
VMMC_CIRC_DSD	By Age: 10-14	6,973	
VMMC_CIRC_DSD	By Age: 15-19	7,654	
VMMC_CIRC_DSD	By Age: 20-24	6,415	
VMMC_CIRC_DSD	By Age: 25-49	16,920	
VMMC_CIRC_DSD	By Age: 50+	775	
VMMC_CIRC_DSD	Sum of age disaggregates	38,737	
VMMC_CIRC_DSD	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	906	
VMMC_CIRC_DSD	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	29,308	

VMMC_CIRC_DSD	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	8,552	
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	36,503	
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	2,234	
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	36,503	
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	51,556	
PP_PREV_DSD	Age/sex: 10-14 Male	3,628	
PP_PREV_DSD	Age/sex: 15-19 Male	4,281	
PP_PREV_DSD	Age/sex: 20-24 Male	4,188	
PP_PREV_DSD	Age/sex: 25-49 Male	7,856	
PP_PREV_DSD	Age/sex: 50+ Male	262	
PP_PREV_DSD	Age/sex: 10-14 Female	3,824	
PP_PREV_DSD	Age/sex: 15-19 Female	6,734	
PP_PREV_DSD	Age/sex: 20-24 Female	6,473	
PP_PREV_DSD	Age/sex: 25-49 Female	13,828	
PP_PREV_DSD	Age/sex: 50+ Female	482	
PP_PREV_DSD	Sum of Age/Sex disaggregates	51,556	
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	100,808	
PP_PREV_TA	Age/sex: 10-14 Male	3,527	

PP_PREV_TA	Age/sex: 15-19 Male	4,487	
PP_PREV_TA	Age/sex: 20-24 Male	3,761	
PP_PREV_TA	Age/sex: 25-49 Male	9,919	
PP_PREV_TA	Age/sex: 50+ Male	377	
PP_PREV_TA	Age/sex: 10-14 Female	4,003	
PP_PREV_TA	Age/sex: 15-19 Female	17,863	
PP_PREV_TA	Age/sex: 20-24 Female	15,631	
PP_PREV_TA	Age/sex: 25-49 Female	40,937	
PP_PREV_TA	Age/sex: 50+ Female	303	
PP_PREV_TA	Sum of Age/Sex disaggregates	100,808	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	152,494	
HTC_TST_DSD	By Test Result: Negative	147,919	
HTC_TST_DSD	By Test Result: Positive	4,575	
HTC_TST_DSD	Sum of Test Result disaggregates	152,494	
HTC_TST_DSD	Age/sex: 10-14 Male	631	
HTC_TST_DSD	Age/sex: 15-19 Male	693	
HTC_TST_DSD	Age/sex: 20-24 Male	580	
HTC_TST_DSD	Age/sex: 25-49 Male	1,531	
HTC_TST_DSD	Age/sex: 50+ Male	71	
HTC_TST_DSD	Age/sex: 15-19 Female	35,757	
HTC_TST_DSD	Age/sex: 20-24 Female	31,288	
HTC_TST_DSD	Age/sex: 25-49 Female	81,943	
HTC_TST_DSD	Sum of Age/Sex disaggregates	152,494	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	631	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,874	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	148,989	
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	631	

HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	151,863	
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	152,494	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	123,643	
HTC_TST_TA	By Test Result: Negative	111,826	
HTC_TST_TA	By Test Result: Positive	11,817	
HTC_TST_TA	Sum of Test Result disaggregates	123,643	
HTC_TST_TA	Age/sex: 1-4 Male	0	
HTC_TST_TA	Age/sex: 5-9 Male	10,853	
HTC_TST_TA	Age/sex: 10-14 Male	8,187	
HTC_TST_TA	Age/sex: 15-19 Male	10,526	
HTC_TST_TA	Age/sex: 20-24 Male	8,820	
HTC_TST_TA	Age/sex: 25-49 Male	23,267	
HTC_TST_TA	Age/sex: 50+ Male	870	
HTC_TST_TA	Age/sex: 5-9 Female	13,265	
HTC_TST_TA	Age/sex: 10-14 Female	10,007	
HTC_TST_TA	Age/sex: 15-19 Female	8,902	
HTC_TST_TA	Age/sex: 20-24 Female	7,789	
HTC_TST_TA	Age/sex: 25-49 Female	20,400	
HTC_TST_TA	Age/sex: 50+ Female	757	
HTC_TST_TA	Sum of Age/Sex disaggregates	123,643	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	19,041	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	43,483	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	23,272	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	37,847	
HTC_TST_TA	Sum of Aggregated Age/Sex <15	42,313	
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	81,330	
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	123,643	

GEND_GBVDSD	Number of people receiving post-GBV care	1,165	
GEND_GBVDSD	Age: 0-9	0	
GEND_GBVDSD	Age: 10-14	59	
GEND_GBVDSD	Age: 15-17	112	
GEND_GBVDSD	Age: 18-24	96	
GEND_GBVDSD	Age: 25+	898	
GEND_GBVDSD	Sum of Age disaggregates	1,165	
GEND_GBVDSD	Sex: Male	367	
GEND_GBVDSD	Sex: Female	798	
GEND_GBVDSD	Sum of Sex disaggregates	1,165	
GEND_GBVTATA	Sum of Age disaggregates	1,165	
GEND_GBVTATA	Sum of Sex disaggregates	1,165	
GEND_NORMDSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	3,118	
GEND_NORMDSD	By Age: 0-9	0	
GEND_NORMDSD	By Age: 10-14	88	
GEND_NORMDSD	By Age: 15-19	276	
GEND_NORMDSD	By Age: 20-24	235	
GEND_NORMDSD	By Age: 25+	2,519	
GEND_NORMDSD	Sum of Age disaggregates	3,118	
GEND_NORMDSD	By Sex: Male	1,026	
GEND_NORMDSD	By Sex: Female	2,092	
GEND_NORMDSD	Sum of Sex disaggregates	3,118	
GEND_NORMTATA	Sum of Sex disaggregates	3,118	
CARE_CURRDSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	86,406	
CARE_CURRDSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,851	
CARE_CURRDSD	Aggregated Age/sex - USE WITH HQ	27,564	

	PERMISSION ONLY: 15+ Male		
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,888	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	52,103	
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	86,406	
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	20,109	
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	885	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	6,174	
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	824	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	12,226	
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	20,109	
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	20,109	
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	2,073	
FN_THER_DSD	Aggregated Age: <18	1,275	
FN_THER_DSD	Aggregated Age: 18+	798	
FN_THER_DSD	Sum of Aggregated Age disaggregates	2,073	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2,053	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	2,566	
TB_ART_DSD	Age: 0-4	5	
TB_ART_DSD	Age: 5-14	59	

TB_ART_DSD	Age: 15+	2,502	
TB_ART_DSD	Male	1,668	
TB_ART_DSD	Female	898	
TB_ART_DSD	Sum of Sex disaggregates	2,566	
TB_ART_DSD	Aggregated Age: <15	64	
TB_ART_DSD	Aggregated Age: 15+	502	
TB_ART_DSD	Sum of Aggregated Age disaggregates	566	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	8,571	
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	10,714	
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	8,571	
PMTCT_EID_DSD	Sum of Infant Age disaggregates	8,571	
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	536	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	74,705	
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2,764	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	23,158	
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	2,988	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	45,794	
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	5,752	
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	68,952	
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	74,704	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	25,785	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	877	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	6,704	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15	1,006	

	Female		
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	17,198	
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	25,785	
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	33,925	
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	37,281	
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,477	
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	31,449	
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,721	
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	34,559	
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such	6	

	accreditation		
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	6	
LAB_ACC_DSD	Sum of Support Type disaggregates	6	
LAB_ACC_TA	Sum of Support Type disaggregates	6	
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	119	
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	119	
LAB_CAP_DSD	Sum of Site Support Type disaggregates	119	
LAB_CAP_TA	Sum of Site Support Type disaggregates	119	
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	125	
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	132	
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	125	
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	125	
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	132	

FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0	
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	132	
FPINT_SITE_DSD	Service delivery type: Community	0	
FPINT_SITE_DSD	Service delivery type: Clinical	125	
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	125	
FPINT_SITE_TA	Sum of Denominator Site Support Type disaggregates	132	
FPINT_SITE_TA	Sum of Numerator Site Support Type disaggregates	125	
FPINT_SITE_TA	Sum of Service Delivery Type disaggregates	125	
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	77,765	
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	86,406	
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	10,420	
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	67,345	
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	77,765	
TB_SCREEN_DSD	Sex: Male	27,062	
TB_SCREEN_DSD	Sex: Female	50,703	
TB_SCREEN_DSD	Sum of Sex disaggregates	77,765	

Implementing Mechanism Details

Mechanism ID: 13901	Mechanism Name: Communication for Healthy Communities
----------------------------	--



Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,468,804	
Applied Pipeline Amount: 934,196	
Funding Source	Funding Amount
GHP-State	1,468,804

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Gender: GBV	30,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Gender: Gender Equality	25,000
Focus Area:	Changing harmful gender norms and promoting



	positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Key Populations: MSM and TG	30,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	30,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs



	and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13901		
Mechanism Name:	Communication for Healthy Communities		
Prime Partner Name:	FHI 360		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	435,510	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	11,166	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	489,371	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	258,778	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	173,979	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13924	Mechanism Name: Production for Improved Nutrition (PIN) Project
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: RECO Industries	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 2,046,338	
Applied Pipeline Amount: 548,672	
Funding Source	Funding Amount
GHP-State	2,046,338

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 13924			
Mechanism Name: Production for Improved Nutrition (PIN) Project			
Prime Partner Name: RECO Industries			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,977,530	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	68,808	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	386	1,727
OVC_ACC_DSD	Age: <1	17	
OVC_ACC_DSD	Age: 1-4	61	



OVC_ACC_DSD	Age: 5-9	108	
OVC_ACC_DSD	Age: 10-14	110	
OVC_ACC_DSD	Age: 15-17	71	
OVC_ACC_DSD	Age: 18+	19	
OVC_ACC_DSD	Sum of Age disaggregates	386	
OVC_ACC_TA	Sum of Age disaggregates	386	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	2,109	3,361
OVC_SERV_DSD	Sex: Male	957	
OVC_SERV_DSD	Sex: Female	1,152	
OVC_SERV_DSD	Sum of Sex disaggregates	2,109	
OVC_SERV_DSD	Age: <1	89	
OVC_SERV_DSD	Age: 1-4	333	
OVC_SERV_DSD	Age: 5-9	591	
OVC_SERV_DSD	Age: 10-14	603	
OVC_SERV_DSD	Age: 15-17	388	
OVC_SERV_DSD	Age: 18+	105	
OVC_SERV_DSD	Sum of Age disaggregates	2,109	

Implementing Mechanism Details

Mechanism ID: 13944	Mechanism Name: USAID/Uganda Good Life HIV Integrated Counseling and Testing Kampala
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Uganda Health Marketing Group	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	



Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13944		
Mechanism Name:	USAID/Uganda Good Life HIV Integrated Counseling and Testing		
Prime Partner Name:	Kampala Uganda Health Marketing Group		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum	0	

	components during the reporting period.		
PP_PREV_DSD	Total number of people in the target population	0	
PP_PREV_DSD	Age/sex: 10-14 Male	0	
PP_PREV_DSD	Age/sex: 15-19 Male	0	
PP_PREV_DSD	Age/sex: 20-24 Male	0	
PP_PREV_DSD	Age/sex: 25-49 Male	0	
PP_PREV_DSD	Age/sex: 50+ Male	0	
PP_PREV_DSD	Age/sex: 10-14 Female	0	
PP_PREV_DSD	Age/sex: 15-19 Female	0	
PP_PREV_DSD	Age/sex: 20-24 Female	0	
PP_PREV_DSD	Age/sex: 25-49 Female	0	
PP_PREV_DSD	Age/sex: 50+ Female	0	
PP_PREV_DSD	Sum of Age/Sex disaggregates	0	
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	14,834	23,097
PP_PREV_TA	Age/sex: 10-14 Male	936	1,167
PP_PREV_TA	Age/sex: 15-19 Male	1,035	2,048
PP_PREV_TA	Age/sex: 20-24 Male	868	2,222
PP_PREV_TA	Age/sex: 25-49 Male	2,288	3,923
PP_PREV_TA	Age/sex: 50+ Male	86	341
PP_PREV_TA	Age/sex: 10-14 Female	1,144	1,550
PP_PREV_TA	Age/sex: 15-19 Female	2,014	2,489
PP_PREV_TA	Age/sex: 20-24 Female	1,763	3,670
PP_PREV_TA	Age/sex: 25-49 Female	4,615	5,333
PP_PREV_TA	Age/sex: 50+ Female	85	354
PP_PREV_TA	Sum of Age/Sex disaggregates	14,834	23,097
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards	2,600	

	required		
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,300	
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,300	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	43,978	33,952
HTC_TST_DSD	By Test Result: Negative	43,658	32,602
HTC_TST_DSD	By Test Result: Positive	320	1,350
HTC_TST_DSD	Sum of Test Result disaggregates	43,978	33,952
HTC_TST_DSD	Age/sex: <1 Male	0	
HTC_TST_DSD	Age/sex: 1-4 Male	0	
HTC_TST_DSD	Age/sex: 5-9 Male	3,102	
HTC_TST_DSD	Age/sex: 10-14 Male	2,340	
HTC_TST_DSD	Age/sex: 15-19 Male	2,588	
HTC_TST_DSD	Age/sex: 20-24 Male	2,169	
HTC_TST_DSD	Age/sex: 25-49 Male	5,721	
HTC_TST_DSD	Age/sex: 50+ Male	214	
HTC_TST_DSD	Age/sex: <1 Female	0	
HTC_TST_DSD	Age/sex: 1-4 Female	0	
HTC_TST_DSD	Age/sex: 5-9 Female	3,791	
HTC_TST_DSD	Age/sex: 10-14 Female	2,860	
HTC_TST_DSD	Age/sex: 15-19 Female	5,036	
HTC_TST_DSD	Age/sex: 20-24 Female	4,406	



HTC_TST_DSD	Age/sex: 25-49 Female	11,541	
HTC_TST_DSD	Age/sex: 50+ Female	210	
HTC_TST_DSD	Sum of Age/Sex disaggregates	43,978	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5,442	1,716
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	10,691	12,546
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	6,652	2,278
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	21,193	17,412
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	12,094	3,994
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	31,884	29,958
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	43,978	33,952
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	30,160
HTC_TST_TA	By Test Result: Negative	0	29,089
HTC_TST_TA	By Test Result: Positive	0	1,071
HTC_TST_TA	Sum of Test Result disaggregates	0	30,160
HTC_TST_TA	Age/sex: 1-4 Male	0	
HTC_TST_TA	Age/sex: 5-9 Male	0	
HTC_TST_TA	Age/sex: 10-14 Male	0	
HTC_TST_TA	Age/sex: 15-19 Male	0	
HTC_TST_TA	Age/sex: 20-24 Male	0	
HTC_TST_TA	Age/sex: 25-49 Male	0	
HTC_TST_TA	Age/sex: 50+ Male	0	
HTC_TST_TA	Age/sex: <1 Female	0	
HTC_TST_TA	Age/sex: 1-4 Female	0	
HTC_TST_TA	Age/sex: 5-9 Female	0	
HTC_TST_TA	Age/sex: 10-14 Female	0	
HTC_TST_TA	Age/sex: 15-19 Female	0	
HTC_TST_TA	Age/sex: 20-24 Female	0	



HTC_TST_TA	Age/sex: 25-49 Female	0	
HTC_TST_TA	Age/sex: 50+ Female	0	
HTC_TST_TA	Sum of Age/Sex disaggregates	0	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	1,525
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0	11,143
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	2,025
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0	15,467
HTC_TST_TA	Sum of Aggregated Age/Sex <15	0	3,550
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	0	26,610
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	0	30,160

Implementing Mechanism Details

Mechanism ID: 16594	Mechanism Name: Measure Evaluation IV
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: University of North Carolina at Chapel Hill, Carolina Population Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 231,624	
Applied Pipeline Amount: 518,376	
Funding Source	Funding Amount
GHP-State	231,624

Sub Partner Name(s)

(No data provided.)



Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 16594			
Mechanism Name: Measure Evaluation IV			
Prime Partner Name: University of North Carolina at Chapel Hill, Carolina Population Center			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	231,624	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16606	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 16626	Mechanism Name: Uganda Private Health Support Program
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Cardno Emerging Markets	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 6,639,080	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	6,639,080

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 16626			
Mechanism Name: Uganda Private Health Support Program			
Prime Partner Name: Cardno Emerging Markets			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,268,476	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,659,164	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	262,395	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	255,010	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	436,313	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	282,448	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	175,626	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,197,455	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	102,193	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,363	1,362
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,514	1,362
PMTCT_ARV_DSD	Life-long ART (including Option B+)	1,363	

PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	913	249
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	450	1,113
PMTCT_ARV_DSD	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
PMTCT_ARV_DSD	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	
PMTCT_ARV_DSD	Single-dose nevirapine (with or without tail)	0	
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	1,363	
PMTCT_ARV_DSD	Sum of New and Current disaggregates	1,363	1,362
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	21,631	15,945
PMTCT_STAT_DSD	Number of new ANC and L&D clients	22,770	16,740
PMTCT_STAT_DSD	By: Known positives at entry	575	1,110
PMTCT_STAT_DSD	By: Number of new positives identified	939	252
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	1,514	1,362
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	21	41
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	1	
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	1	
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients	31	

	with one or more severe surgical intra-operative AE(s)		
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	21	
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	19	
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	2	
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	0	
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)	0	
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	31	
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	6,416	12,500
VMMC_CIRC_DSD	By Age: 10-14	1,155	
VMMC_CIRC_DSD	By Age: 15-19	1,268	
VMMC_CIRC_DSD	By Age: 20-24	1,062	
VMMC_CIRC_DSD	By Age: 25-49	2,803	
VMMC_CIRC_DSD	By Age: 50+	128	

VMMC_CIRC_DSD	Sum of age disaggregates	6,416	
VMMC_CIRC_DSD	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	150	227
VMMC_CIRC_DSD	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	4,854	9,524
VMMC_CIRC_DSD	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	1,412	2,750
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	6,416	12,500
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	0	
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	6,416	12,500
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	43	71,335
PP_PREV_TA	Age/sex: 10-14 Male	3	2,940
PP_PREV_TA	Age/sex: 15-19 Male	5	6,600
PP_PREV_TA	Age/sex: 20-24 Male	4	7,830
PP_PREV_TA	Age/sex: 25-49 Male	11	12,627
PP_PREV_TA	Age/sex: 50+ Male	0	970
PP_PREV_TA	Age/sex: 10-14 Female	4	3,801
PP_PREV_TA	Age/sex: 15-19 Female	4	7,709
PP_PREV_TA	Age/sex: 20-24 Female	3	11,380
PP_PREV_TA	Age/sex: 25-49 Female	9	16,382
PP_PREV_TA	Age/sex: 50+ Female	0	1,096
PP_PREV_TA	Sum of Age/Sex disaggregates	43	71,335

HTC_TST_DSD	By Test Result: Negative	26,423	110,093
HTC_TST_DSD	By Test Result: Positive	817	3,977
HTC_TST_DSD	Sum of Test Result disaggregates	27,240	114,070
HTC_TST_DSD	Age/sex: 10-14 Male	1,113	
HTC_TST_DSD	Age/sex: 15-19 Male	1,222	
HTC_TST_DSD	Age/sex: 20-24 Male	1,024	
HTC_TST_DSD	Age/sex: 25-49 Male	2,701	
HTC_TST_DSD	Age/sex: 50+ Male	124	
HTC_TST_DSD	Age/sex: 15-19 Female	50,536	
HTC_TST_DSD	Age/sex: 20-24 Female	4,422	
HTC_TST_DSD	Age/sex: 25-49 Female	11,581	
HTC_TST_DSD	Sum of Age/Sex disaggregates	72,723	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,113	5,782
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	5,071	42,149
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	48,107	58,471
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,113	13,450
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	53,178	100,620
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	54,291	114,070
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	14,399	34,744
HTC_TST_TA	By Test Result: Negative	13,083	33,589
HTC_TST_TA	By Test Result: Positive	1,316	1,155
HTC_TST_TA	Sum of Test Result disaggregates	14,399	34,744
HTC_TST_TA	Age/sex: 5-9 Male	1,322	
HTC_TST_TA	Age/sex: 10-14 Male	997	
HTC_TST_TA	Age/sex: 15-19 Male	1,160	
HTC_TST_TA	Age/sex: 20-24 Male	972	
HTC_TST_TA	Age/sex: 25-49 Male	2,563	

HTC_TST_TA	Age/sex: 50+ Male	96	
HTC_TST_TA	Age/sex: 5-9 Female	1,615	
HTC_TST_TA	Age/sex: 10-14 Female	1,219	
HTC_TST_TA	Age/sex: 15-19 Female	1,048	
HTC_TST_TA	Age/sex: 20-24 Female	917	
HTC_TST_TA	Age/sex: 25-49 Female	2,402	
HTC_TST_TA	Age/sex: 50+ Female	89	
HTC_TST_TA	Sum of Age/Sex disaggregates	14,400	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,319	1,760
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	4,790	12,840
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,834	2,337
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	4,456	17,807
HTC_TST_TA	Sum of Aggregated Age/Sex <15	5,153	4,097
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	9,246	30,647
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	14,399	34,744
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	772	23,490
OVC_ACC_DSD	Sex: Male	350	
OVC_ACC_DSD	Sex: Female	422	
OVC_ACC_DSD	Sum of Sex disaggregates	772	
OVC_ACC_DSD	Age: <1	32	
OVC_ACC_DSD	Age: 1-4	122	
OVC_ACC_DSD	Age: 5-9	216	
OVC_ACC_DSD	Age: 10-14	221	
OVC_ACC_DSD	Age: 15-17	142	
OVC_ACC_DSD	Age: 18+	39	
OVC_ACC_DSD	Sum of Age disaggregates	772	
OVC_ACC_TA	Sum of Sex disaggregates	772	

OVC_ACC_TA	Sum of Age disaggregates	772	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	4,219	45,707
OVC_SERV_DSD	Sex: Male	1,915	
OVC_SERV_DSD	Sex: Female	2,304	
OVC_SERV_DSD	Sum of Sex disaggregates	4,219	
OVC_SERV_DSD	Age: <1	177	
OVC_SERV_DSD	Age: 1-4	667	
OVC_SERV_DSD	Age: 5-9	1,181	
OVC_SERV_DSD	Age: 10-14	1,207	
OVC_SERV_DSD	Age: 15-17	776	
OVC_SERV_DSD	Age: 18+	211	
OVC_SERV_DSD	Sum of Age disaggregates	4,219	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	37,334	53,941
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,232	1,724
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	11,910	2,047
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,680	16,993
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	22,513	33,177
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	37,335	53,941
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	6,411	4,048

CARE_NEW_DSD	Aggregated Age/sex: <15 Male	282	129
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	1,968	1,332
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	263	145
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	3,898	2,442
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	6,411	4,048
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	6,411	4,048
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	202	1,295
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	3,373	16,182
FN_THER_DSD	Aggregated Age: <18	653	500
FN_THER_DSD	Aggregated Age: 18+	409	795
FN_THER_DSD	Sum of Aggregated Age disaggregates	1,062	1,295
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,051	519
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,314	646
TB_ART_DSD	Age: 0-4	3	
TB_ART_DSD	Age: 5-14	30	
TB_ART_DSD	Age: 15+	1,281	
TB_ART_DSD	Male	854	187
TB_ART_DSD	Female	460	332
TB_ART_DSD	Sum of Sex disaggregates	1,314	519
TB_ART_DSD	Newly tested	0	
TB_ART_DSD	Known HIV-positive	0	234
TB_ART_DSD	Sum of Test Status disaggregates	0	234
TB_ART_DSD	Aggregated Age: <15	33	37

TB_ART_DSD	Aggregated Age: 15+	1,281	482
TB_ART_DSD	Sum of Aggregated Age disaggregates	1,314	519
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,211	1,109
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	1,514	
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	2,768	115
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,768	1,109
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	76	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	39,881	50,392
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,476	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	12,363	31,970
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,595	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	24,447	14,713
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	3,071	
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	36,810	46,683
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	39,881	46,683
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	9,063	6,000
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	308	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	2,356	3,895
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	354	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	6,045	1,850
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	9,063	5,745
TX_RET_DSD	Number of adults and children who are still	2,677	4,622

	alive and on treatment at 12 months after initiating ART		
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,942	5,442
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	183	
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	195	
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,318	
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,481	
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	37,334	53,941
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	5,336	3,774
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	34,484	50,167
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	39,820	53,941



TB_SCREEN_DSD	Sex: Male	13,857	18,733
TB_SCREEN_DSD	Sex: Female	25,963	35,208
TB_SCREEN_DSD	Sum of Sex disaggregates	39,820	53,941

Implementing Mechanism Details

Mechanism ID: 17061	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17062	Mechanism Name: Palliative Care
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: HOSPICE AFRICA, Uganda	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues



(No data provided.)

Budget Code Information

Mechanism ID: 17062			
Mechanism Name: Palliative Care			
Prime Partner Name: HOSPICE AFRICA, Uganda			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	500	
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	22	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	153	
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	21	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	304	
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	500	
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	500	

Implementing Mechanism Details

Mechanism ID: 17063	TBD: Yes
REDACTED	

Implementing Mechanism Details



Mechanism ID: 17064	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17065	Mechanism Name: Sustainable Outcomes for Children and Youth Central and Western Uganda
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 5,468,164	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	5,468,164

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Food and Nutrition: Policy, Tools, and Service Delivery	150,000
Economic Strengthening	180,000
Education	40,000
Water	30,000
Gender: GBV	40,000
Focus Area:	GBV Prevention
Sub Area:	Implementation



Focus Area:	Post GBV Care
Gender: Gender Equality	40,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Capacity building
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Operation Research

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	17065		
Mechanism Name:	Sustainable Outcomes for Children and Youth Central and Western		
Prime Partner Name:	Uganda		
	Catholic Relief Services		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	5,468,164	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
OVC_ACC_DSD	Sex: Male	4,760	
OVC_ACC_DSD	Sex: Female	5,724	
OVC_ACC_DSD	Sum of Sex disaggregates	10,484	
OVC_ACC_DSD	Age: <1	440	
OVC_ACC_DSD	Age: 1-4	1,657	
OVC_ACC_DSD	Age: 5-9	2,936	
OVC_ACC_DSD	Age: 10-14	2,999	
OVC_ACC_DSD	Age: 15-17	1,929	
OVC_ACC_DSD	Age: 18+	523	
OVC_ACC_DSD	Sum of Age disaggregates	10,484	
OVC_ACC_TA	Sum of Sex disaggregates	10,484	
OVC_ACC_TA	Sum of Age disaggregates	10,484	
OVC_SERV_DSD	Sex: Male	22,360	
OVC_SERV_DSD	Sex: Female	26,891	
OVC_SERV_DSD	Sum of Sex disaggregates	49,251	
OVC_SERV_DSD	Age: <1	2,069	
OVC_SERV_DSD	Age: 1-4	7,782	
OVC_SERV_DSD	Age: 5-9	13,790	
OVC_SERV_DSD	Age: 10-14	14,086	
OVC_SERV_DSD	Age: 15-17	9,062	
OVC_SERV_DSD	Age: 18+	2,462	
OVC_SERV_DSD	Sum of Age disaggregates	49,251	
OVC_SERV_TA	Sex: Male	5,590	
OVC_SERV_TA	Sex: Female	6,723	
OVC_SERV_TA	Sum of Sex disaggregates	12,313	
OVC_SERV_TA	Age: <1	517	
OVC_SERV_TA	Age: 1-4	1,945	
OVC_SERV_TA	Age: 5-9	3,448	



OVC_SERV_TA	Age: 10-14	3,521	
OVC_SERV_TA	Age: 15-17	2,266	
OVC_SERV_TA	Age: 18+	616	
OVC_SERV_TA	Sum of Age disaggregates	12,313	

Implementing Mechanism Details

Mechanism ID: 17066	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17078	Mechanism Name: Applying Science to Strengthen and Improve Systems (ASSIST) Project
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Council	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 6,696,212	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	6,696,212

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	25,000
Focus Area:	Equity in HIV prevention, care, treatment and



	support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Condom programming	50,000
Key Populations: FSW	25,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Motor Vehicles: Purchased	100,000

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	17078		
Mechanism Name:	Applying Science to Strengthen and Improve Systems (ASSIST) Project		
Prime Partner Name:	University Research Council		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,394,624	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HVTB	260,553	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	853,974	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	244,179	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	458,178	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	407,238	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,198,409	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	479,057	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17079	Mechanism Name: Strengthening National Health Laboratory Services in Uganda under the President's Emergency Plan for AIDS Relief (PEPFAR)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health, Uganda	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	17079		
Mechanism Name:	Strengthening National Health Laboratory Services in Uganda under the		
Prime Partner Name:	President's Emergency Plan for AIDS Relief (PEPFAR)		
	Ministry of Health, Uganda		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and	HLAB	0	0



Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17089	Mechanism Name: DELIVER II
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: John Snow Inc (JSI)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 2,000,000	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	2,000,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)



Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 17089			
Mechanism Name: DELIVER II			
Prime Partner Name: John Snow Inc (JSI)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	2,000,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17090	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17094	Mechanism Name: Uganda Health Supply Chain
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 3,200,000	
Applied Pipeline Amount: 0	



Funding Source	Funding Amount
GHP-State	3,200,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 17094			
Mechanism Name: Uganda Health Supply Chain			
Prime Partner Name: Management Sciences for Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	3,200,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17649	TBD: Yes
REDACTED	



Implementing Mechanism Details

Mechanism ID: 17651	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17654	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17682	Mechanism Name: Blanket Purchase Agreement (BPA) for Studies and Evaluations - DSWA
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: New Partner	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 100,000	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	100,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)



Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	17682		
Mechanism Name:	Blanket Purchase Agreement (BPA) for Studied and Evaluations -		
Prime Partner Name:	DSWSA New Partner		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	100,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17686	Mechanism Name: Blanket Purchase Agreement (BPA) for Studied and Evaluations - SGIL
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: New Partner	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 100,000	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	100,000



Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	17686		
Mechanism Name:	Blanket Purchase Agreement (BPA) for Studied and Evaluations - SGIL		
Prime Partner Name:	New Partner		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	100,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17688	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17690	Mechanism Name: Strengthening HRH
Funding Agency: USAID	Procurement Type: Cooperative Agreement



Prime Partner Name: IntraHealth International, Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 2,648,876	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	2,648,876

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	17690		
Mechanism Name:	Strengthening HRH		
Prime Partner Name:	IntraHealth International, Inc		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	2,648,876	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	330	585
HRH_PRE	By Graduates: Midwives	200	477
HRH_PRE	By Graduates: Other	130	98
HRH_PRE	Sum of Graduates disaggregated	330	585
HRH_PRE	By new graduates who are licensed and registered: Midwives	200	
HRH_PRE	By new graduates who are licensed and registered: Other (where applicable)	130	

Implementing Mechanism Details

Mechanism ID: 17695	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17696	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17698	Mechanism Name: Provision of comprehensive HIV/AIDS and TB services including prevention, care, support and treatment to prisoners and staff of the prisons service in the Republic of Uganda under PEPFAR
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Uganda Prisons Services	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 247,146	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	247,146

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Gender: GBV	30,000
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	20,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support



Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	17698		
Mechanism Name:	Provision of comprehensive HIV/AIDS and TB services including prevention, care, support and treatment to prisoners and staff of the		
Prime Partner Name:	prisons service in the Republic of Uganda under PEPFAR Uganda Prisons Services		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVCT	97,146	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17703	Mechanism Name: Monitoring and Evaluation Technical Support (METS)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Makerere University School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 5,358,000	
Applied Pipeline Amount: 124,900	
Funding Source	Funding Amount
GHP-State	5,358,000



Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 17703			
Mechanism Name: Monitoring and Evaluation Technical Support (METS)			
Prime Partner Name: Makerere University School of Public Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	3,300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	1,058,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	450,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	HTXS	0	0
-----------	------	---	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17704	Mechanism Name: African Society for Laboratory Medicine - LIMS Support for hubs
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Society for Laboratory Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 145,223	
Applied Pipeline Amount: 254,777	
Funding Source	Funding Amount
GHP-State	145,223

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)



Budget Code Information

Mechanism ID: 17704			
Mechanism Name: African Society for Laboratory Medicine - LIMS Support for hubs			
Prime Partner Name: African Society for Laboratory Medicine			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	145,223	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17705	Mechanism Name: Implementation science-Birth Defects surveillance study
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Makerere University John Hopkins University Collaboration	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 100	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)



(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 17705			
Mechanism Name: Implementation science-Birth Defects surveillance study			
Prime Partner Name: Makerere University John Hopkins University Collaboration			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17706	Mechanism Name: Scaling up HIV services in Western and West Nile Regions of Uganda
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Infectious Disease Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 9,422,086	
Applied Pipeline Amount: 0	



Funding Source	Funding Amount
GHP-State	9,422,086

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Renovation	197,879
Motor Vehicles: Purchased	280,000
Gender: GBV	100,000
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	50,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Key Populations: FSW	100,000



Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
-------------	--

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	17706		
Mechanism Name:	Scaling up HIV services in Western and West Nile Regions of Uganda		
Prime Partner Name:	Infectious Disease Institute		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	2,394,513	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	283,816	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	449,529	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	893,882	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVCT	673,763	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	456,055	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	990,260	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	3,179,950	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	318	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17779	Mechanism Name: Population-based HIV Impact Assessment in Resource-Constrained Settings under the President's Emergency Plan for AIDS Relief
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: International Center for AIDS Care and Treatment Programs, Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount



GHP-State	0
-----------	---

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 17779 Mechanism Name: Population-based HIV Impact Assessment in Resource-Constrained Settings under the President's Emergency Plan for AIDS Relief Prime Partner Name: International Center for AIDS Care and Treatment Programs, Columbia University			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17855	Mechanism Name: RTI (International)
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Research Triangle International	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 1,503,370	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	1,503,370

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	17855		
Mechanism Name:	RTI (International)		
Prime Partner Name:	Research Triangle International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	465,313	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	221,633	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HVTB	127,758	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	86,514	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	174,525	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	14,169	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	102,265	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	224,283	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	31,540	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	55,370	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17874	Mechanism Name: NAMERU
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: National Medical Research Unit	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:
---------	------------------

Total All Funding Sources: 1,303,845	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	1,303,845

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Gender: GBV	10,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Condom programming	15,000
Economic Strengthening	10,000
Gender: Gender Equality	10,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 17874			
Mechanism Name: NAMERU			
Prime Partner Name: National Medical Research Unit			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	80,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,023,845	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17976	Mechanism Name: Supporting Laboratory Strengthening Activities in Resource-Limited Countries Under the President's Emergency Plan for AIDS Relief
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Association of Public Health Laboratories	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:
---------	------------------

Total All Funding Sources: 400,000	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	400,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	17976		
Mechanism Name:	Supporting Laboratory Strengthening Activities in Resource-Limited Countries Under the President's Emergency Plan for AIDS Relief		
Prime Partner Name:	Association of Public Health Laboratories		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	400,000	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 17977	Mechanism Name: Biomedical Engineering Support for Equipment Maintenance and Training in Clinical Laboratory Sites Providing HIV/AIDS Care and Treatment
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: American International Health Alliance Twinning Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 450,000	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	450,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	17977
Mechanism Name:	Biomedical Engineering Support for Equipment Maintenance and
Prime Partner Name:	Training in Clinical Laboratory Sites Providing HIV/AIDS Care and



Treatment American International Health Alliance Twinning Center			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	450,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17978	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17979	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18003	Mechanism Name: Technical assistance for strengthening national laboratory systems in Uganda under the President's Emergency Plan for AIDS Relief
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Global Healthcare Public Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 2,000,000	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	2,000,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	350,000
---------------------------	---------

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	18003		
Mechanism Name:	Technical assistance for strengthening national laboratory systems in		
Prime Partner Name:	Uganda under the President's Emergency Plan for AIDS Relief		
	Global Healthcare Public Foundation		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	2,000,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details



Mechanism ID: 18017	Mechanism Name: EGPAF: HQ Technical Assistance CoAg
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 74,998	
Applied Pipeline Amount: 375,000	
Funding Source	Funding Amount
GHP-State	74,998

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 18017			
Mechanism Name: EGPAF: HQ Technical Assistance CoAg			
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	74,998	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18029	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18030	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18031	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18032	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18033	TBD: Yes
REDACTED	

Implementing Mechanism Details



Mechanism ID: 18034	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18041	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18042	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18077	Mechanism Name: Better Outcomes for Children and Youth Eastern and Northern Regions
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: World Education	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 4,473,953	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	4,473,953

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Food and Nutrition: Policy, Tools, and Service Delivery	120,000
Economic Strengthening	168,000
Education	20,000
Water	15,000
Gender: GBV	20,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Focus Area:	Post GBV Care
Gender: Gender Equality	20,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Capacity building
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Motor Vehicles: Purchased	184,400

Key Issues

(No data provided.)



Budget Code Information

Mechanism ID: 18077			
Mechanism Name: Better Outcomes for Children and Youth Eastern and Northern Regions			
Prime Partner Name: World Education			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	4,473,953	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18085	TBD: Yes
REDACTED	



Agency Information - Costs of Doing Business
U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Computers/IT Services		700,619		700,619	0
ICASS		2,269,486		2,269,486	0
Institutional Contractors		641,455		641,455	0
Management Meetings/Professional Development		237,462		237,462	0
Non-ICASS Administrative Costs		235,784		235,784	0
Staff Program Travel		1,241,408		1,241,408	0
USG Staff Salaries and Benefits		4,296,996		4,296,996	0
Total	0	9,623,210	0	9,623,210	0

U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
ICASS		114,999		114,999	0
Management Meetings/Professional Development		42,517		42,517	0



Non-ICASS Administrative Costs		176,403		176,403	0
Staff Program Travel		63,817		63,817	0
USG Staff Salaries and Benefits		248,997		248,997	0
Total	0	646,733	0	646,733	0

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Capital Security Cost Sharing		350,000		350,000	0
Computers/IT Services		762,953		762,953	0
ICASS		2,270,561		2,270,561	0
Institutional Contractors				0	0
Management Meetings/Professional Development		561,889		561,889	0
Non-ICASS Administrative Costs		958,267		958,267	0
Non-ICASS Motor Vehicles		373,081		373,081	0
Staff Program Travel	0	1,072,790		1,072,790	0
USG Staff Salaries	3,212,500	4,954,062		8,166,562	0



and Benefits					
Total	3,212,500	11,303,603	0	14,516,103	0

U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
ICASS		54,624		54,624	0
Management Meetings/Professional Development		20,405		20,405	0
Non-ICASS Administrative Costs		17,203		17,203	0
Staff Program Travel		33,200		33,200	0
USG Staff Salaries and Benefits		287,138		287,138	272,623
Total	0	412,570	0	412,570	272,623

U.S. Peace Corps

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Non-ICASS Administrative Costs		149,732		149,732	32,977
Peace Corps Volunteer Costs		882,335		882,335	126,708
Staff Program		56,306		56,306	74,111



Travel					
USG Staff Salaries and Benefits		176,328		176,328	40,984
Total	0	1,264,701	0	1,264,701	274,780